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 Role of Neurokinin 1 Receptor in Modulating the Immune-Stimulatory Function of         
                                                            Dendritic Cells 
Brian Mark Janelsins, Ph.D. 
University of Pittsburgh, 2010
 
There is a growing body of evidence indicating that the nervous and immune systems cross-talk 
during inflammatory and immune responses.  Secretion of pro-inflammatory neuropeptides from 
the tachykinin family, including substance P (SP) and hemokinin-1 (HK-1), favors cellular 
immunity by binding the neurokinin 1 receptor (NK1R) to promote immune cell survival and 
activation.  Dendritic cells (DCs) are essential for the stimulation of cellular immunity; however, 
the ability of pro-inflammatory tachykinins to affect the immune-stimulatory function of DCs 
remains elusive.  Since DCs home strategically to peripheral and lymphoid tissues where 
tachykinins are secreted, we hypothesized that signaling via the NK1R enhances DC longevity 
and their T cell-stimulatory function, including the induction of type-1 CD4+ T cell helper (Th1) 
and CD8+ cytotoxic T cell (CTL/Tc1) responses.   
Using DCs generated from murine bone marrow precursors (BMDCs), I describe that 
BMDCs express functional NK1R, and agonistic signaling via the receptor rescues BMDCs from 
apoptosis.  The immunological relevance of these findings were validated in vivo, as I 
demonstrate that adoptive transfer of NK1R-signaled BMDCs loaded with antigen (Ag) migrate 
efficiently to tissue-draining lymph nodes (DLNs) where they survive longer and induce superior 
type-1 DTH responses compared to adoptive transfer of control Ag-loaded BMDCs.   
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Secondly, I investigated the mechanisms by which NK1R-signaled BMDCs favor cellular 
immunity, including their ability to generate Th1 and CTL/Tc1 responses.  I show that agonistic 
signaling via the NK1R promotes the maturation of BMDCs and inhibits their secretion of IL-10, 
and adoptive transfer of NK1R-signaled BMDCs elicits enhanced Ag-specific Th1 and CTL/Tc1 
responses.  The individual roles of adoptively transferred NK1R-signaled BMDCs and 
endogenous DCs were further addressed by comparing the development of type-1 immunity in 
wild-type, IL-12 knockout (IL-12p35-/-) and Diphtheria Toxin Recetor (DTR) transgenic 
(inducible depletion of CD11c+ DCs) mice.  With these models, I demonstrate that generation of 
robust Ag-specific Th1 and CTL/Tc1 responses requires secretion of IL-12p70 by endogenous 
DCs and inhibition of IL-10 production by transferred BMDCs.  Collectively, our data strongly 
suggest that adoptive transfer of NK1R-signaled BMDCs promotes enhanced type-1 immunity 
by mechanisms involving both exogenous and endogenous DC populations.  
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1.0  CHAPTER ONE: INTRODUCTION 
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1.1 DENDRITIC CELLS  
Dendritic cells (DCs) are potent ‘professional’ antigen (Ag)-presenting cells (APCs) that serve as 
central conductors in bridging innate and adaptive immune responses.  Strategically located in 
areas of pathogen exposure, DCs are specialized to recognize pathogens and internalize foreign 
antigenic material, ultimately leading to DC maturation and migration into secondary lymphoid 
tissues where they generate and polarize T cell immunity.1,2,3,4  It is now appreciated that DCs 
migrating from peripheral tissues can transfer Ag to lymphoid-resident DCs, allowing for 
efficient induction of T cell responses.5  Due to their unique ability to stimulate biased naïve and 
memory T cell responses, DCs are currently being investigated for their capability to serve as 
adjuvants in immunotherapy to promote robust cellular immunity against tumors and 
intracellular infections, including the polarization of type-1 T cell responses.6 
1.1.1 Plasticity of DCs  
DCs are defined by their phenotype, morphology and function.  In mice, DCs are phenotypically 
identified by expression of the CD11c integrin molecule, while the phenotype of human DCs is 
not entirely defined.  Despite ambiguity in phenotype, all DCs at some point in their life-span 
exhibit dendritic morphology and undergo functional conversion from an Ag-capturing mode to 
an immune-stimulatory Ag-presenting capability; a process termed ‘maturation’.7  According to 
their maturation state, DCs can be classified as immature or mature cells.  In the steady-state, 
DCs reside in peripheral and secondary lymphoid tissues as immature DCs where they promote 
immunological tolerance.  In the presence of a pro-inflammatory environment, immature DCs 
undergo maturation to become mature DCs, which are fully activated and acquire potent T cell 
stimulatory function.  Alternatively, DCs are capable of encountering activation signals that only 
induce partial stimulation, rendering them as semi-mature.  Similarly to immature DCs, semi-
mature DCs induce immunological tolerance8 and are receptive to full activation by pro-
inflammatory signaling to become potent stimulators of T cell function (Figure 1).9,10    
 
Figure 1:  Immature, semi-mature and mature DCs differentially regulate immunity. 
Three stages of DC activation during steady-state and danger-state.  DCs exist as (i) immature 
(low levels of cell-surface MHC class II and co-stimulatory molecules), (ii) semi-mature 
(intermediate to high levels of cell-surface MHC class II and co-stimulatory molecules with low 
secretion of pro-inflammatory cytokines) or (iii) mature (high levels of MHC class II and co-
stimulatory molecules and secretion of pro-inflammatory cytokines) cells.   
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1.1.1.1 DC maturation 
Serving as sentinels for danger signals in peripheral and lymphoid tissues, immature DCs are 
quiescent and exhibit a high endocytic capacity to continuously sample foreign Ag via a variety 
of uptake mechanisms, including receptor-mediated endocytosis, phagocytosis and 
macropincytosis.  Indeed, immature DCs express high levels of C-type lectins and other 
endocytic receptors specific for Fc, complement, scavenger and heat-shock proteins.10,11  Due to 
the fact that immature DCs do not secrete pro-inflammatory cytokines and express low levels of 
co-stimulatory molecules and DLN-specific chemokine receptors on their cell-suface,2 immature 
DCs are poor stimulators of T cell responses.  Thus, it has been postulated that immature DCs 
derived from the periphery and resident in lymphoid tissues collectively induce and reinforce 
tolerance to T cells specific to harmless Ag (i.e., tissue-derived self Ag). 
When peripheral tissues become inflamed or penetrated by microbes, haptens or 
allergens, DCs sense danger by encountering exogenous (pathogen-associated molecular 
patterns, PAMPs) and endogenous (e.g., alarmins) activation signals that promote their 
maturation from immature Ag-capturing DCs to mature immune-stimulatory DCs.  PAMPs 
represent a diverse set of microbial molecules, which share a number of different recognizable 
biochemical features that inform DCs of invading pathogens.  Such PAMPs are recognized by 
pattern recognition receptors (PRRs), including the well-described Toll-like receptor (TLR) 
family.  TLRs have been demonstrated to recognize and respond to specific microbial products:  
lipoteichoic acid, peptidoglycan and zymosan are recognized by TLR-2; double-stranded RNA, 
viral RNA and polyinosinic:polytidylic acid (polyI:C) by TLR-3; lipopolysaccharide (LPS) by 
TLR-4; flagellin by TLR-5 and cytosine-phosphate-guanine (CpG) motifs of bacterial DNA by 
TLR-9.12  Ligation of most TLR agonists induces DC maturation and secretion of pro-
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inflammatory cytokines (i.e., IL-6, IL-1β and IL-12p70).13,14  In addition to invading microbes, 
endogenous factors including neuropeptides,15,16 anti-microbial peptides17 and ATP18 are often 
released during infection and damage to tissues, resulting in further activation of DCs. 
DCs undergoing maturation down-regulate most of their endocytic receptors while up-
regulating cell-surface MHC class I and II molecules, co-stimulatory molecules including 
members of the B7 (CD80, CD86 and ICOSL) and TNF (RANK, CD40L, 4-1BBL, OX40L and 
CD70) families, chemokine receptors (CCR5 and CCR7) and adhesion molecules (ICAM-1,-2 
and LFA-1,-3), as well as enhancing the production of pro-inflammatory cytokines (IL-12p70, 
IL-6, IL-1β and TNF-α).2  Upon the up-regulation of CCR7, maturing DCs respond to 
chemokines CCL19 and CCL21,19 leading to lymph-trafficking into T cell-rich areas of 
lymphoid tissues.  Mature DCs are then capable of presenting Ag in the context of MHC class I 
and II molecules for the activation of Ag-specific naïve T cells into effector and memory CD8+ 
and CD4+ T cells, respectively (Section 1.1.1.2).  
Interestingly, some DCs resembling the mature phenotype have been described to 
promote T cell tolerance.20-22  These DCs were classically distinguished as mature DCs due to 
intermediate to high levels of CCR7, MHC class II and co-stimulatory molecules on their cell 
surface.  However, these DCs do not produce pro-inflammatory cytokines (IL-6, IL-1β and IL-
12p70) but enhance the secretion of anti-inflammatory cytokine IL-10, ultimately leading to the 
induction of Ag-specific T regulatory cells (T regs).  Thus, these partially activated DCs are 
called semi-mature DCs, and recent studies suggest that interaction with gut flora, apoptotic cells 
and TNF-α induces partial activation of DCs.9,10  Interestingly, semi-mature DCs become fully 
immunogenic when challenged with typical pro-inflammatory stimuli, including LPS and 
agonistic CD40 ligation.  Thus, it is likely that semi-mature DCs represent an intermediate bridge 
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to migrate into secondary lymphoid organs for the purpose of tolerizing self during the steady-
state, while becoming fully mature to promote immunity against invading pathogens during 
infection.9 
1.1.1.2  T cell activation 
Mature DCs egress via the lymph into T cell-rich areas of DLNs, then induce CD4+ and CD8+ T 
cell activation by communicating a series of signals through the ‘immunological synapse’; a 
network of collaborative membrane-bound and secreted signaling events between the Ag-
presenting DC and the engaging T cell.23,24  In the center of the synapse, DCs present Ag in the 
context of MHC class I and II molecules, which is recognized by an Ag-specific TCR (signal 1) 
expressed on naïve CD8+ and CD4+ T cells, respectively.  In addition to adhesion interactions 
mediated by ICAM-1, ligation of co-stimulatory molecules CD86 and CD80 with the molecule 
CD28, expressed on the cell-surface of T cells, allows for efficient activation of CD4+ and CD8+ 
T cells to prevent tolerance against the presented Ag.  Additionally, engagement of co-
stimulatory molecule CD40 with CD40L expressed on CD4+ T cells further activates DCs to 
induce potent CD8+ T cell responses.  Excessive T cell stimulation is avoided by co-stimulatory 
(CD80 and CD86) and inhibitory (PDL-1/-2) molecule interaction with CTLA-4 and PD-1/-2, 
respectively, on activated CD4+ and CD8+ T cells.  As shown in Figure 2, DCs emit a 3rd signal 
to T cells that serves to polarize the type of Ag-specific T cell response generated, via secretion 
of cytokines or ligation of membrane-bound molecules (IL-12p70, Th1; IL-4 and OX40L, Th2; 
IL-6 and TGF-β1, Th17; and TGF-β1 and IL-10, T regs).  Recently, Kalinski and colleagues 
proposed   that  a  4th  signal  transmitted  through  the  immunological   synapse  determines  the  
efficiency of activated CD4+ and CD8+ T cells to migrate into peripheral tissues and elicit Ag-
specific effector functions.24  In contrast to naive T cells, effector and memory T cells require 
signal 1 with only little co-stimulation for re-activation.    
 
Figure 2:  DC polarization of Ag-specific T cell responses. 
Intracellular pathogens signal DCs to exhibit a type-1 biasing phenotype (DC1), which polarizes 
Th1/Tc1 responses via IL-12p70 production.  Alternatively, DCs employ a DC2 phenotype when 
signaled with extracellular pathogens (e.g., helminths), ultimately leading to the generation of 
Th2/Tc2 responses associated with robust signaling via OX40/L and IL-4 with minimal 
production of IL-12p70.  ATP and certain neuropeptides have been proposed to play roles in 
inducing DCs to bias Th17/Tc17 responses (DC17) by favoring IL-6 and TGF-β1 secretion.  In 
contrast, DCs interact with factors that prevent their full maturation, ultimately leading to 
secretion of anti-inflammatory cytokines IL-10 and TGF-β1 and interaction with programmed 
death ligands (PDLs).  Such immature DCs inhibit Ag-specific effector populations (anergy and 
apoptosis) and promote Ag-specific T reg populations.  
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1.1.2 Induction of type-1 T cell responses  
DCs have been shown to elicit robust CD4+ Th1 and CD8+ CTL/Tc1 responses, which are 
necessary for the generation of potent cellular immunity targeting intracellular infections and 
tumors.25-27  Current research is focused on stimulating DCs with adjuvants that polarize DC1s to 
preferentially elicit Th1/Tc1 responses.  In addition to DC1 bias, the longevity of DCs serves as 
another crucial parameter for the ability of DCs to induce long-lasting robust Th1/Tc1 responses 
in vivo. 
1.1.2.1 Bias of type-1 DCs 
The molecules produced by DC1s that drive Th1/Tc1 polarization, and the factors that induce 
their long-lasting expression, are the center of investigation for studies utilizing DCs for 
generation of cellular immunity.  Twenty years after its discovery, IL-12p70 is now appreciated 
as the major cytokine produced by DCs that polarizes Th1 responses in CD4+ T cells and 
contributes to the generation of potent CD8+ CTL/Tc1 responses.28-31  Additional studies indicate 
that DCs employ other mechanisms to promote type-1 T cell responses, including the secretion 
of IL-23,32 IL-27,33 IL-1834 and IFN-α/β35 and membrane-bound ligation of CD70,36 ICAM-137 
and notch ligand, delta-like 4.38  Most reports suggest that these factors act in concert with IL-
12p70 to enhance Th1/Tc1 induction, but further investigation is warranted to determine if they 
promote Th1/Tc1 responses via IL-12p70-independent mechanisms. 
TLRs are the most well studied PRRs that instruct DCs to secrete high levels of IL-12p70 
for the generation of Th1/Tc1 responses.  Indeed, agonistic signaling via TLR-3, -4 and -9 
promotes IL-12p70 production in most human and mouse DC subtypes.39-43  However, DCs 
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become exhausted in their ability to produce high levels of IL-12p70 unless maintained by other 
factors, such as those provided in the DC-CD4+ T cell synapse.44  Likewise, as TLR-signaled 
DCs mature and travel to DLNs, DCs interact with CD4+ T cells via CD40 ligation to optimize 
IL-12p70 production for extended periods of time.43  Enhanced secretion of IL-12p70 in the DC-
CD4+ T cell synapse potently stimulates IFN-γ production via induction of the transcription 
factor T-bet in naïve CD4+ and CD8+ T cells, leading to generation of potent Th1 and CTL/Tc1 
responses.  Furthermore, DC populations in lymphoid tissues have been observed to be critical 
for cross-priming and inducing high levels of IL-12p70 after systemic delivery of Ag.45  These 
results suggest that in additional to instructional factors in peripheral tissues, conditions in 
secondary lymphoid tissues also drive and optimize IL-12p70 signaling to favor Th1/Tc1 
immunity.  
Interestingly, most TLR agonists such as LPS and CpG not only generate potent levels of 
IL-12p70 in DCs, but also promote abundant secretion of the anti-inflammatory cytokine IL-
10.46-48  IL-10 signaling serves to abrogate Th1/Tc1 responses by inhibiting the immune-
stimulatory function of DCs, including their maturation and secretion of IL-12p70, while also 
inhibiting T cell responsiveness of IL-12p70 and secretion of IFN-γ and IL-2.49,50  Thus, 
investigators are searching for other DC adjuvants that promote secretion of IL-12p70 without 
favoring the production of anti-inflammatory cytokines that would circumvent the optimal 
induction of Th1/Tc1 responses.   
Emerging data from the last decade demonstrate that inflammatory mediators IL-1β, IFN-
γ and polyI:C, in conjunction with interactions from immune cell populations, including memory 
CD8+ T cells and properly activated NK cells, promote DCs to secrete higher levels of IL-12p70 
in comparison to signaling DCs with TLR agonists alone, ultimately leading to robust Th1/Tc1 
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immune responses.25,51,52  It is unknown whether these DC1s lead to better Th1/Tc1 responses by 
producing higher levels of IL-12p70 coupled with reduced secretion of IL-10 or via other 
mechanisms, such as enhanced chemotaxis and longevity.   
1.1.2.2 Survival of DCs 
The longevity of DCs in vivo is another critical parameter in generating robust Th1/Tc1 immune 
responses.  DCs in peripheral and lymphoid tissues encounter a variety of pro-apoptotic signals, 
including tissue-derived factors and immune cell populations.53  Indeed, upon adoptive transfer 
into mice, activated DCs loaded with Ag are short-lived in tissue-DLNs, and phagocytosis of 
dying DCs leads to tolerance towards the immunizing Ag.54,55  
Due to these observations, investigators have aimed to identify ligands and their 
intracellular signaling pathways that promote enhanced DC survival, while still preferentially 
inducing Th1/Tc1 responses.  It is well-established that granulocyte-macrophage colony 
stimulating factor (GM-CSF) and prostaglandin E2 (PG-E2) serve as growth factors that favor 
the survival of DCs.  However, GM-CSF and PG-E2 also promote high levels of IL-10, which 
inhibits Th1/Tc1 responses.56-59  In contrast, stimulation of DCs via membrane-bound molecules 
(CD40, TRANCE and CCR7) or secreted peptides (leptin) enhances DC survival and immune-
stimulatory function to favor Th1/Tc1 responses.60-62   
Pharmacological studies utilizing such pro-survival factors have implicated certain 
intracellular signaling pathways that preferentially regulate DC longevity.  Utilizing murine D1 
cells (splenic DC cell-line), it was initially reported that LPS activates nuclear factor- kappa B 
(NF-κB) to promote DC maturation, while signaling via extracellular signal-regulated kinase 
(Erk), from the mitogen-activated protein kinase (MAPK) family, to favor cell survival.63  
  
11
Studies utilizing more physiologically relevant DCs suggest versatility of intracellular pathways 
involved in favoring DC longevity.  Ardeshna et al. demonstrated that human monocyte-derived 
DCs cultured with LPS utilize PI3K (phosphoinositide-3-kinase)-Akt (protein kinase B; referred 
as Akt) pathways to promote survival.64  Other studies have observed that TNF family ligands 
CD40 and TRANCE activate NF-κB to sustain cell longevity in bone marrow-derived DCs 
(BMDCs) and splenic DCs.65  It is becoming increasingly evident that PI3K-Akt and NF-κB 
intracellular signaling pathways are related; activation of PI3K-Akt signaling enhances the 
degradation of IκB, allowing for full activation of NF-κB to synergistically inhibit pro-apoptotic 
molecules (BAD, BID and caspases).  Indeed, activated DCs derived from human peripheral 
blood mononuclear cells (PBMCs) utilize both PI3K/Akt and NF-κB intracellular signaling 
pathways to up-regulate anti-apoptotic machinery and promote DC survival.66-68  Similar to NF-
κB, PI3K-Akt signaling has recently been shown to activate pathways that are responsible for 
DC activation [i.e., c-Jun-N-terminal kinase (MAPK/Jnk)], leading to elevated production of IL-
12p70.69  Further studies illustrate that the balance of pro-survival and pro-activation pathways 
ultimately dictate the fate of DC longevity.  These studies demonstrate that pro-activation 
signaling pathways (MAPK/Jnk) leads to apoptosis of DCs when pro-survival pathways are 
compromised.70  
Given the importance of PI3K-Akt activation in enhancing DC survival and immune-
stimulatory function, Spencer and colleagues have demonstrated that sustained activation of Akt 
enhances the immune-stimulatory function and longevity of DCs in DLNs after adoptive 
transfer,  augmenting  their  ability to promote  robust  CTL  responses  against  tumor-associated  
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Ag.54  Thus, signaling DCs with agonists that mediate PI3K-Akt activation might enhance the 
longevity and bias of adoptively transferred DCs for the purpose of generating robust Th1/Tc1 
responses in vivo. 
1.1.3 Adoptively transferred DCs and induction of Th1/Tc1 responses 
As stated above, immune-stimulatory function and longevity are important parameters of 
adoptively transferred DCs to elicit Th1/Tc1 responses in vivo;52,71-73 however, the mechanisms 
by which adoptively transferred DCs induce such responses in vivo are not entirely known.    
Emerging data support crucial roles for both adoptively transferred DCs and endogenous DC 
populations to promote robust Th1/Tc1 immunity.  Indeed, it has recently been shown that 
endogenous DCs are required to induce Ag-specific T cell responses mediated by subcutaneous 
delivery of adoptively transferred DCs,74   while respiratory mucosal delivery elicits Ag-specific 
T cell responses independent of endogenous DCs.75  Generation of acquired Th1/Tc1 responses 
in vivo could be due to the enhanced longevity and immune-stimulatory function of adoptively 
transferred DCs to directly activate and polarize Ag-specific Th1/Tc1 cells,76 or indirectly, by 
spreading Ag in an immune-stimulatory manner to activate endogenous DC populations in 
peripheral and/or lymphoid tissues.77  While there are few reports investigating how adoptively 
transferred DCs utilize endogenous DCs to promote Th1/Tc1 responses, various endogenous DC 
populations, including subtypes located in peripheral and lymphoid tissues, have been described 
to play essential roles in promoting Th1/Tc1 responses when Ag is administered via intravenous 
(i.v.) or subcutaneous (s.c.) injection.   
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1.1.3.1 Possible role of peripheral tissue DCs in generating Th1/Tc1 responses  
Peripheral tissue DCs are found in areas of pathogen exposure, such as skin, gut and lungs.  The 
skin is one of the well-studied peripheral organs and harbors two main DC populations: 
Langerhans cells (LCs) in the epidermis and dermal DCs (dDCs) in the dermis.  While LCs are 
generally identified by expression of CD11c, Langerin (CD207), EpCAMHi (CD326), CD1a and 
birbeck granules; dDCs are characterized by expression of CD11c and other C-type lectins such 
as mannose receptor (CD206), and several subtypes are capable of expressing low levels of 
CD1a and Langerin.78-81  Despite differences in phenotype, both LCs and dDCs are fully capable 
of capturing Ag in the skin, migrating to DLNs and generating T cell immunity.82-85  Indeed, 
blockade of epidermal and dermal DC migration after subcutaneous delivery of Ag in the skin 
prevents efficient activation of CD4+ T cell immunity.86  Further studies illustrate important roles 
for both LCs and dDCs to transfer Ag to lymphoid-resident DCs, and alternatively, directly 
stimulate CD4+ T cells in DLNs.86-89  In contrast, migratory DCs from the skin have thought to 
serve strictly as sources of Ag for CD8+ T cell immunity, enabling lymphoid-resident DCs to 
capture Ag and directly prime CD8+ T cells87.  Recent reports challenge this view, demonstrating 
that novel populations of migratory DCs (CD103+ and Langerin+CD8α+ subtypes) are capable of 
migrating to DLNs and directly cross-presenting Ag for the induction of CD8+ T cell 
immunity.45,90 
 In other peripheral tissues, migratory DCs have also been demonstrated to be crucial in 
regulating T cell tolerance and immunity.91  Although their potential to serve as sources of Ag to 
lymphoid-resident DCs or directly prime CD4+ and CD8+ T cell responses warrants further 
investigation. 
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1.1.3.2 Possible role of lymphoid-resident DCs in generating Th1/Tc1 responses 
In contrast to migratory DCs from peripheral tissues, lymphoid-resident DCs in secondary 
lymphoid organs are believed to be the main inducers of CD8+ T cell immune responses.  
Lymphoid-resident DCs are identified in mice by differential expression of CD8α and/or CD4 
molecules.  The spleen possesses 3 major DC populations of CD8α+CD4-CD11b-, CD8α-
CD4+CD11b+ and CD8α-CD4-CD11b+ phenotypes; while skin-DLNs contain an additional DC 
population identified by CD8αloCD4-CD11b+ expression, which is thought to represent 
migratory DC populations from the skin.92  It should be noted that human DCs found in 
lymphoid tissues lack CD8α, but do display differential regulation of CD4 and CD11b. 
CD8α+ DCs in secondary lymphoid organs have been implicated in the induction of type-
1 T cell responses.  Initial studies demonstrated that CD8α+ DCs are capable of internalizing 
dying cells in vitro and in vivo, leading to Ag processing and presentation into MHC class I and 
II molecules.93  Indeed, CD8α+ DCs lie in T cell-rich areas of lymphoid tissues and serve as 
potent producers of IL-12p70,94,95 ultimately leading to the generation of robust Th1/CTL 
responses.96   Carbone and colleagues proposed that lymphoid-resident CD8α+ DCs internalize 
Ag from migrating DC populations, and subsequently, prime naïve CD8+ T cells.97  CD8α+ DCs 
were also shown to be equally important in directly priming CD4+ T cells.98  The role of 
lymphoid-resident CD8α- DCs, excluding DCs derived from peripheral tissues, is less 
understood but these DCs are believed to participate in eliciting CD4+ Th2 responses.96,99 
Studies dissecting the immune-stimulatory role of DCs derived from peripheral and 
lymphoid tissues based on CD8α expression are complicated by the recent observation that 
different DC populations can up-regulate the CD8α molecule after homing into DLNs.100  
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Indeed, it has recently been demonstrated that migrating Langerin+ DCs enhance CD8α 
expression and are vital to cross-present Ag and produce IL-12p70 in secondary lymphoid 
tissues,45  suggesting the  possibility that CD8α+ DCs used in  the experiments mentioned  above  
may represent such migratory DC populations.  Furthermore, Morelli et al. have demonstrated 
that CD8α- DCs in the spleen are capable of up-regulating the CD8α molecule then migrating 
into the follicular T cell-rich area.101 
Adoptively transferred DCs are exposed to pro-apoptotic signaling in peripheral injection 
sites, and subsequently, the remaining viable DCs (<1%) then migrate to DLNs where they are 
found to accumulate near lymphoid-tissue DCs.  Thus, it is likely that short-lived adoptive 
transferred DCs interact with endogenous DC populations from peripheral and lymphoid tissues 
to mediate their Th1/Tc1 responses.74  Studies described above, utilizing regional or systemic 
delivery of Ag, demonstrate that subtypes of peripheral and lymphoid tissue DCs serve as a 
collaborative network to elicit CD4+ and CD8+ T cell immunity.  Whereas, the survival and 
immune-stimulatory function of adoptively transferred DCs are appreciated, it will be interesting 
to determine the role of endogenous DC populations in mediating the effects of adoptively 
transferred DCs. 
1.2 MAMMALIAN TACHYKININS AND IMMUNITY 
Mammalian tachykinins comprise of a group of bioactive neuropeptides that are secreted in 
peripheral and lymphoid tissues, regulating a wide variety of biological functions, ranging from 
smooth muscle contraction, pain transmission, hematopoiesis, vasodilation, neurogenic 
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inflammation and immunity.102  Whereas most neuropeptides, including somatostatin and 
products of proopiomelanocortin (POMC) cleavage, inhibit developing immune responses;103-105 
tachykinins that bind the neurokinin 1 receptor (NK1R), such as substance P (SP) and 
hemokinin-1 (HK-1), represent some of the few neuropeptides that are immune-stimulatory.106-
109  Despite these observations, it is still unknown whether immune-stimulatory tachykinins 
modulate the ability of DCs to promote cellular immunity. 
1.2.1 Mammalian tachykinins  
Mammalian tachykinins are short hydrophobic peptides defined by expression of the C-terminal 
motif: Phe-X-Gly-Leu-Met-NH2 [X represents an aromatic (Phe or Tyr) or hydrophobic (Val or 
Ile) residue] (Table 1).  The C-terminal sequence of tachykinins is highly conserved and essential 
in mediating their biological functions.110  Historically, the tachykinin family has included SP, 
neurokinin A (NKA), neurokinin B and two elongated forms of NKA; neuropeptide K (NPK) 
and neuropeptide-γ (NP-γ).  The recent identification of a novel gene precursor, and its splice 
variants, has led to the discovery of new tachykinins, including HK-1 and elongated forms of 
HK-1 termed endokinins (EKs).  Tachykinins are derived from 3 genes named preprotacykinins 
(referred to as TAC1, TAC3 and TAC4; HUGO Gene Nomenclature Committee).  TAC1 
encodes SP, and through alternative splicing, gives rise to transcripts also encoding NKA, NPK 
and NP-γ.  TAC3 generates NKB transcripts, while the newly identified TAC4 encodes HK-1, 
and in humans, undergoes alternative splicing to give rise to transcripts encoding tachykinins 
EKA and EKB and tachykinin-like peptides EKC and EKD.111 
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Table 1:  The Mammalian Tachykinins. 
Tachykinin Amino Acid Sequence Ref. 
Substance P R  P  K  P  Q  Q  F  F  G  L  M  -NH2 112 
Neurokinin A H  K  T  D  S  F  V  G  L  M  -NH2 113,114 
Neurokinin B D  M  H  D  F  F  V  G  L  M  -NH2 115 
Neurokinin-γ* H  K  T  D  S  F  V  G  L  M  -NH2 116 
Neuropeptide K* H  K  T  D  S  F  V  G  L  M  -NH2 117 
Hemokinin-1 R  S  R  T  R  Q  F  Y  G  L  M  -NH2 118-120 
Hemokinin-1 (h) T  G  K  A  S  Q  F  F  G  L  M  -NH2 119 
Endokinin A* (h) G  K  A  S  Q  F  F  G  L  M  -NH2 118 
Endokinin B* (h) G  K  A  S  Q  F  F  G  L  M  -NH2 118 
* Abbreviated sequence of the last 10 amino acids. Sequences of human tachykinins are distinguished 
from mice by indication of (h). 
 
1.2.1.1 Distribution of tachykinins in tissues 
Historically, tachykinins were thought to be strictly of neuronal origin.  Initial studies detected 
tachykinins in neurons within the central nervous system (CNS) and primary afferent neurons 
innervating peripheral and lymphoid tissues.108,121-125  The dogma that tachykinins are restricted 
to nerve-fiber terminals has been challenged repeatedly in the past 20 years, and it is now well-
understood that tachykinins are expressed throughout the mammalian body in both neuronal and 
non-neuronal sources.  Indeed, immunoassays utilizing antibodies specific to the C-terminal 
motif of tachykinins have implicated peptide expression in tissues devoid of innervation, 
including the placenta.118,126  Granulomas are also absent of innervation and express tachykinins.  
For example, SP mRNA and protein have been found in eosinophils and neutrophils from 
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granulomas in murine schistosomiasis mansoni127 and periadicular granulomas after LPS 
treatment,128 respectively.  Mononuclear immune cells, including macrophages, DCs and T cells 
produce SP and express transcripts also encoding NKA, NPK and NP-γ.129-133  TAC4-derived 
HK-1134-137 and human EKs118,138 are also expressed in a variety of immune cells present in 
peripheral and lymphoid tissues.  In contrast, TAC3-derived NKB is widely expressed in the 
CNS,139 although recent reports have detected expression in several immune cells.135   
1.2.1.2 Metabolism of tachykinins 
The biological functions of tachykinins are tightly regulated by the activity of a variety of tissue-
specific membrane-bound and soluble peptidases.  Inhibition of such peptidases prevents proper 
control of tachykinin function, leading to exacerbation of various inflammatory diseases (e.g., 
psoriasis,140 IBD,141 asthma142 and rhinosinusitis143).  Whereas the metabolism of most 
tachykinins is not entirely known, degradation of SP and NKA by neutral endopeptidase (NEP) 
and angiotensin converting enzyme (ACE) are well-studied.  Both kinase type-II enzymes target 
and cleave the C-terminal region of SP, yielding the generation of small peptide fragments that 
are biologically inactive in peripheral tissues.144  Dipeptidyl aminopeptidase IV (DAP IV) is a 
homodimeric type 11 transmembranic glycoprotein that also targets SP, leading to truncations in 
the N-terminal region.145  Since the C-terminal region is still intact, these peptide fragments are 
still biologically active but are highly susceptible to further degradation by aminopeptidase M 
(AmM).146  In contrast, NKA has been demonstrated to be generally resistant to AEC and DAP 
IV cleavage, but still susceptible to NEP degradation.146  The unique ability of NKA to be 
resistant  to most SP-degrading  enzymes  might  allow NKA signaling to predominate,  while SP 
  
19
would be cleared faster to avoid excessive stimulation.  Thus, understanding the expression and 
regulation of tachykinins and their degrading enzymes during the course of infection and 
inflammation might be relevant in the control of immunity. 
1.2.2 Neurokinin receptors 
Tachykinins mediate their function through three mammalian tachykinin receptors (known as 
neurokinin receptors), belonging to the family of rhodopsin-like G protein-coupled receptors 
(GPCRs).  Currently, three distinct neurokinin receptors (NK1R, NK2R and NK3R) have been 
cloned and are expressed in tissues of different species including human, mouse and rat.  
Although all tachykinins act as full agonists through each neurokinin receptor, deviations in the 
N-terminus allow tachykinins to preferentially bind certain neurokinin receptors with greater 
affinity than others.  For example, NK1R exhibits high affinity for SP, while NK2R preferably 
binds NKA, NPK and NP, and NK3R favorably ligates NKB.147  Recent studies demonstrate the 
capability of HK-1 and human EKs to behave as SP-like peptides and exhibit high selectively 
towards NK1R in comparison to NK2R and NK3R.111  However, it has been observed that HK-1 
stimulates the proliferation of IL-7-expanded B cell precursors and promotes the survival of 
early B cells, whereas SP has minimal effect.134  Future studies are needed to determine whether 
there exist novel HK-1- and EK-specific neurokinin receptors, or whether these SP-like 
tachykinins differentially bind the NK1R.    
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Neurokinin receptors are usually co-expressed with their ligands.  Likewise, NK1R and 
NK2R are widely expressed throughout the nervous system and periphery (peripheral and 
lymphoid tissues), whereas NK3R is largely confined to the CNS, with exceptions including the 
placenta and uterus.147    
1.2.2.1 Signal transduction and cellular responses following agonistic binding of NK 
receptors 
Agonistic signaling via neurokinin receptors, as with all GPCRs, leads to the recruitment and 
activation of G proteins that potentiate cellular responses (Figure 3).  Depending on the type of 
agonist and conformation state of the receptor, all tachykinin receptors have been described to 
temporally activate Gαq/11 and Gαs proteins to some extent.148  NK2R and NK3R typically 
couple to Gαs proteins that activate adenylyl cyclase (AC) to elicit cyclic adenosine 
monophosphate (cAMP) production.  In contrast, NK1R signaling predominately couples to 
Gαq/11 proteins that stimulate phospholipase C-γ (PLC-γ) activity, leading to the generation of 
second messengers inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG).149,150  IP3 
releases calcium (Ca2+) from intracellular stores via binding specific receptors on the 
endoplasmic-reticulum (ER).  DAG activates conventional protein kinase C (PKC) isoforms to 
potentiate Ca2+ release from intracellular stores and induce a variety of signaling networks, 
including MAPK/Erk stimulation.  Likewise, induction of PKC-Ca2+-MAPK/Erk pathways has 
been demonstrated to prevent cell death in neurons when signaled with NK1R agonists.151  
Recent reports have indicated that agonistic signaling via the NK1R participates in 
additional intracellular signaling pathways.  Studies utilizing human colonocytes demonstrate 
that NK1R signaling activates PI3K and Akt to promote cell longevity.152  It is currently 
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unknown whether NK1R stimulation utilizes PI3K-Akt activation downstream or independently 
of G protein signaling.  In addition to intracellular signaling via PI3K/Akt, Bhatia and colleagues 
have described that NK1R signaling induces the activation of PKC (atypical and novel isoforms) 
and MAPK (Erk and p38) pathways, which converge to elicit NF-κB activity for enhanced 
chemokine production in mouse macrophages.153  Furthermore, β-arrestins have been 
documented to interact with agonistic-bound NK1R to serve as scaffolds for MAPK/Erk 
activation, ultimately leading to cell survival.154  Thus, it is likely that agonistic signaling via the 
NK1R utilizes multiple pathways that cross-talk to modulate cellular responses.  
Importantly, it should be noted that a sub-population of NK1R has been described to exist 
in peripheral tissues with a truncation in the C-terminal region, preventing sufficient coupling to 
G proteins.  Indeed, truncated-NK1R does not activate conventional G protein-dependent 
signaling pathways, nor stably interacts with β-arrestins, to promote cellular responses. 155,156  
However, Douglas and colleagues have proposed that the truncated-NK1R exhibits functionality, 
as observed by enhancement of monocyte chemotaxis after SP treatment.157  Further information 
is required to elucidate the disparity between NK1R variants in modulating cellular responses 
mediated by NK1R agonists.  
 
 Figure 3:  Classical and novel signaling pathways via the neurokinin 1 receptor. 
Agonistic signaling via the NK1R leads to the activation of a variety of intracellular signaling 
pathways. Classically, agonistic signaling via the NK1R enables receptor coupling to Gαq/11 and 
Gαs proteins, leading to elicitation of PLC-γ and AC activity, respectively.  Activation of PLC 
results in a transient increase in intracellular IP3, DAG, Ca2+ and PKC, whereas AC induces 
cAMP production.  Alternatively, agonistic signaling via the NK1R has been shown to activate 
PI3K/Akt and β-arrestin pathways, resulting in NF-κB and MAPK (Erk and p38) activation, 
respectively. 
 
1.2.3 NK1R signaling and immune regulation 
Tachykinins are becoming recognized as crucial regulators of immune responses.  Lymphoid 
organs and peripheral tissues are highly innervated with tachykinin-expressing nerve-fiber 
endings that lie in close proximity to various immune cell populations expressing neurokinin 
receptors.123,158  In contrast to other neurokinin receptors, there is increasing evidence that 
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signaling via the NK1R plays essential roles in promoting development and survival of immune 
cells, inflammatory responses and cellular immunity.159-162  Thus, the rest of this chapter will be 
focused specifically on the role of agonistic signaling via the NK1R in modulating immunity. 
1.2.3.1 Role of NK1R in hematopoiesis and cell survival 
Within the past two decades, endogenous (SP and HK-1) and synthetic agonists for the NK1R 
have been demonstrated to participate in an integrated network of factors that promote the 
hematopoiesis and survival of lymphoid and myeloid cells.  Preliminary reports have described 
that mice treated with capsaicin, a neurotoxin that depletes SP-containing sensory neurons in 
peripheral tissues, or synthetic NK1R antagonists, exhibit defects in thymic weight and 
elimination of CD4+CD8+ double positive (DP) cells in the thymus, suggesting impairment of T 
cell development.163,164  Further reports have demonstrated that application of exogenous HK-1 
to fetal thymic organ cultures increases the number of CD4+CD8+ DP cells during T cell 
development, which was prevented when cultures were supplemented with NK1R 
antagonists.137,165  Similar to T cell development, administration of NK1R antagonists in vivo 
results in a reduction of early B cell populations in mice, suggesting NK1R relevance in the 
hematopoiesis of B cells.134  Consistent with these results, addition of HK-1 to a pre-B cell line 
(70Z/3) or primary bone marrow B lineage cells enhances survival and proliferation in the 
absence of IL-7, which is a crucial growth factor for B cell development.  As expected, NK1R 
antagonists further enhances apoptosis induced by IL-7 withdrawal.134,165  Collectively, these 
results demonstrate the involvement of NK1R agonistic signaling in promoting the development 
and survival of developing lymphocytes.   
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Additional investigations have suggested a role of NK1R agonistic signaling in the 
development and survival of myeloid cells.  Likewise, physiological concentrations of SP (10-8 
to 10-11M) have been reported to replace or act in concert with suboptimal concentrations of 
various hematopoietic growth factors (e.g., GM-CSF) in stimulating the colony formation of 
myeloid lineages from bone marrow cultures.159,166  Detailed experiments have elucidated the 
ability of SP to ligate the NK1R on stromal cells to induce secretion of a variety of 
hematopoietic growth factors (IL-3, IL-6, GM-CSF and M-CSF)167 and directly signal 
hematopoietic stems in the absence of stromal cells to generate myeloid lineages.168  In addition 
to differentiation of myeloid cells, agonistic signaling via the NK1R has been demonstrated to 
promote the survival of neutrophils169 and macrophages.170,171  The significance of NK1R-
mediated survival of granulocytes for the outcome of immunity is currently being investigated, 
but most likely contributes to sustaining inflammatory responses. 
1.2.3.2 Role of NK1R in inflammation 
It is established that agonistic signaling via the NK1R promotes neurogenic inflammation in the 
skin, gut and lungs.106,108,110  During inflammatory responses, chemotaxis is a crucial process to 
ensure that phagocytes respond quickly to internalize foreign Ag and relay antigenic information 
for the generation of T cell immunity in DLNs.  Likewise, SP has been shown to participate in 
the chemotaxis of granulocytes162,172 and mononuclear cells.161  In vivo administration of SP 
leads to the adherence of granulocytes to vascular endothelial and bronchial epithelial cells, 
allowing for extravasation into peripheral sites of inflammation.162,173  Extravasation of 
granulocytes involves the up-regulation of selectin molecules (membrane glycoproteins) on the 
endothelium and integrins (carbohydrates) on migrating granulocytes, ultimately leading to cell 
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adhesion and migration.  SP enhances the expression of β2-integrin ligands ICAM-1 and 
VCAM-1 on vascular endothelial cells.174  There is evidence that SP may increase the expression 
of integrins on migrating granulocytes.175  In addition to up-regulating adhesion molecules, SP 
may also enhance the expression of chemokine receptors and promote the induction of 
chemotactic cytokines, including IL-8 and MIP-2, which lead to the accumulation of neutrophils 
in inflamed tissues.176  As granulocytes migrate into inflamed tissues, SP is well known to induce 
degranulation of mast cells177 and respiratory bursts in neutrophils,178 ultimately perpetuating 
inflammatory responses. 
The chemotaxtic effect of SP is also observed for mononuclear cells, including DCs 
(Section 1.2.4), macrophages and T cells.  Indeed, several studies describe that splenic T cell 
populations migrate towards SP release via LFA-1 and ICAM-1 interactions.179  In addition, 
monocyte and macrophage stimulation with SP enhances the induction of chemokines (MIP-2 
and MCP-1)180 and pro-inflammatory cytokines (IL-12p70, IL-1, IL-6 and TNF-α),181 while 
diminishing production of the anti-inflammatory cytokine TGF-β1.182  It is likely that SP release, 
via nerve-fiber terminals or immune cells, favors chemotaxis of granulocytes, APCs and effector 
T cells to sites of inflammation.   
1.2.3.3 Role of NK1R in the generation of type-1 T cell responses 
Due to the observation that SP secretion and NK1R expression are enhanced in inflammatory 
and autoimmune disorders characterized by a type-1 T cell bias,183-186 there has been a recent 
focus on the ability of NK1R signaling to promote the development of CD4+ Th1 and CD8+ 
CTL/Tc1 T cell responses.  As observed in vitro and in vivo, SP stimulation of murine and 
human CD4+ T cells leads to the polarization of Th1 cells secreting IFN-γ.187   Interestingly, SP 
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stimulation has been reported to drive established Th2 clones to a Th1 profile,188 and suggested 
to switch Th2-driven atopic dermatitis to a chronic Th1-mediated disease.189  The capability of 
NK1R signaling to promote type-1 T cell immunity has been suggested to occur for CD8+ T cell 
responses.  A recent study demonstrates that administration of SP in vivo enhances CD8+ CTL 
secretion of IFN-γ.190  Furthermore, mice that are defective in NK1R signaling mount weak CTL 
responses and are highly susceptible to intracellular pathogens, including gamma herpes virus 
68191 and Salmonella.192  We have reported that application of the selective NK1R agonist 
[Sar9Met(O2)11]-SP (SarSP, 10-9 M) in vivo leads to the development of enhanced Th1 and Tc1 
responses.84  Cytokines that are associated with Th1/Tc1 immunity, including IL-12p70, IL-18 
and IFN-γ, have been demonstrated to enhance SP and NK1R expression in T cells and 
macrophages.130,193  In contrast, the anti-inflammatory cytokines IL-10 and TGF-β1 diminish SP 
and NK1R expression in T cells and macrophages.185  Collectively, these results demonstrate an 
association of NK1R agonistic signaling and the induction of type-1 T cell responses.  However, 
it is not completely understood if NK1R signaling promotes type-1 T cell responses via 
stimulation of DCs. 
1.2.4  NK1R signaling and DC function 
Increasing evidence suggests that SP may directly regulate the immune-stimulatory function of 
DCs.  Previous studies have determined that DCs lie in close proximity to SP-expressing nerve-
fiber  terminals  innervating  lymphoid194  and  peripheral  tissues,122,195  and  express  full-length  
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NK1R.196  Additionally, it has been reported that DCs express TAC1 mRNA and SP protein,197 
although secretion of SP has yet to be published.  Therefore, DCs might serve dual roles in 
inducing and reinforcing NK1R-mediated immunity. 
  Not surprisingly, initial studies investigating the role of NK1R signaling in modulating 
DC function have implicated NK1R agonists as chemoattractants for DCs migrating into 
inflamed sites in peripheral tissues.  Kraid et al. have demonstrated that physiological 
concentrations of SP (10-10 M) enhance the migration of rat pulmonary DCs to sites of 
inflammation during responses to inhaled Ag.198  Likewise, Kanieder et al. have reported that 
murine DCs signaled via the NK1R augment prion-protein (PrP)-induced chemotaxis of DCs.199  
In contrast, one study describes that only high concentrations of SP (10-4 M) induce modest 
chemotaxis of DCs in vitro, which may indicate a non-physiological finding or an emergency 
case scenario where SP is secreted from nerve-fibers following pro-inflammatory stimuli.200   
During infection, DCs in peripheral tissues take up Ag, mature and migrate to DLNs as 
they process and present Ag in the context of MHC class molecules for the presentation to naïve 
T cells.  Our laboratory has observed that administration of SarSP (10-9 M) in vivo enhances the 
ability of LCs loaded with Ag to migrate from the periphery into skin-DLNs.84  Furthermore, we 
report that SarSP induces the generation of lymphatic vessels expressing the DC chemoattractant 
CCL21 in skin-DLNs, which correlated with a quicker disappearance of DCs in the epidermis 
and their redistribution in skin-DLNs.  It can be speculated that SP signaling via the NK1R 
attracts and arrests immature DCs to inflamed sites as they recognize danger signals and undergo 
maturation.  Acquiring the capacity to migrate to DLNs, SP-mediated chemotaxis might serve to 
guide DCs into DLNs, allowing them to relay antigenic information to T cells for the elicitation 
of adaptive immunity.  
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Due to the association of NK1R signaling and their ability to generate Th1/Tc1 
responses, our lab has postulated that NK1R agonists signal DCs to elicit type-1 T cell responses.  
As discussed above, application of SarSP (10-9 M) in vivo promotes LC activation in the 
epidermis and their subsequent migration to the DLNs, where they polarize robust Ag-specific 
Th1 and Tc1 immune responses.  Further studies are needed to determine whether SP directly 
activates LCs, or if neighboring cells, such as keratinocytes, bind SP and secrete IL-6 and IL-
12p70 to induce the ability of LCs to promote Ag-specific type-1 T cell responses. 
There are relatively few studies investigating the direct effects of signaling DCs with 
NK1R agonists in modulating T cell stimulatory function (Figure 4).  Pharmacological studies 
conducted by Marriott and colleagues have demonstrated that treatment of DCs with SP 
promotes Ca2+ influx and NF-κB nuclear translocation.201  NF-κB is a transcription factor that is 
responsible for up-regulating MHC class II molecules, co-stimulatory molecules and the Th1-
biasing cytokine IL-12p70.  Interestingly, it has yet to be reported whether NK1R agonists can 
induce DC maturation and IL-12p70 secretion.  Lambrecht et al. have demonstrated that addition 
of a selective NK1R antagonist (SR140333), but not NK2R and NK3R antagonists, abrogates T 
cell proliferation in allogeneic and Ag-specific DC-CD4+ T cell co-cultures, confirming the 
importance of endogenous NK1R signaling in promoting T cell responses.197  However, it is still 
unclear whether NK1R agonists signal DCs to elicit type-1 cell responses, or if they signal T 
cells directly to enhance IFN-γ secretion.187 
 
 Figure 4:  Current model representing NK1R signaling of DCs and CD4+ T cells. 
NK1R agonists elicit DCs to increase cytosolic Ca2+ concentration and nuclear translocation of 
NF-κB.  In addition, CD4+ T cells are capable of responding to SP, leading to greater T cell 
proliferation, and in some context, elevated secretion of IFN-γ.  It is unknown whether SP 
signals DCs to induce NK1R-mediated induction of type-1 biased T cell responses.      
1.3 CELLULAR IMMUNITY 
Immune responses generated from immunization and infections have historically been divided 
into two arms of defenses, including humoral-mediated or cell-mediated immunity.  While, 
humoral immunity provides protection found in the serum via secretion of antibodies that target 
extracellular pathogens; cellular immunity relies on the activation of cells to provide protection 
against intracellular infection and cancer.  Successful cellular immunity is mediated by the 
induction of Ag-specific type-1 CD8+ CTL/Tc1 and CD4+ Th1 cell responses, along with 
phagocytosis  and  secretion  of  pro-inflammatory cytokines from macrophages and NK cells. In  
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most models, CD8+ CTLs play crucial roles in eradicating tumor and intracellular 
infections.202,203  Further studies have elucidated the importance of CD4+ Th1 cells in providing 
aid to CTL responses, in addition to their unique roles in immunity.204  
1.3.1  CD8+ Tc1 responses 
CD8+ CTLs recognize infected or abnormal cells via Ag-specific interactions communicated 
through TCR and MHC class I/peptide complex signaling.  As infected and tumor cells are 
poorly immune-stimulatory, mature Ag-loaded DCs migrating to DLNs serve as the main cell 
type to stimulate naive CD8+ T cells.  Activated CTLs then migrate to inflamed peripheral 
tissues where they eliminate intracellular bacteria, viruses and tumors by efficiently recognizing 
foreign Ag-encoded peptides presented in the context of MHC class I molecules on the cell 
surface of infected cells, leading to apoptosis via two possible distinct mechanisms.  The first 
scenario includes the secretion of perforin and cytotoxic granules.  The cytotoxic granule 
granzyme B (GrB) has been demonstrated to mediate CTL killing, and abrogation of either 
GrB205 or perforin206 leads to impaired CTL responses in several models of infections.  Both GrB 
and perforin are secreted simultaneously in the area of the target cell and coordinate together to 
elicit apoptosis.  GrB binds to the mannose-6-phosphate receptor and enters the target cell via the 
endocytic pathway.  Perforin then disrupts the plasma membrane of the endosomes, allowing 
GrB to escape and initiate apoptosis by cleaving several substrates, including caspases.  
Alternatively, CTLs can also induce apoptosis via cross-linking death receptors on the surface of  
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target cells.  Most notably from the TNF family, Fas-FasL signaling has been described to recruit 
pro-apoptotic adaptor proteins and activate caspase cascades to elicit apoptosis.207  It is likely 
these pathways act together to elicit CTL function to clear pathogens and tumors.208 
As described in section 1.1.1.2, type-1 polarized CD8+ CTL/Tc1s preferentially secrete 
IFN-γ, TNF-α and IL-2 with little production of type-2 (IL-4, IL-5 and IL-13) and type-17 (IL-
17 and IL-22) cytokines.  Some studies report that CD8+ Tc1 cells are superior in killing their 
targets, due to enhanced cytotoxicity coupled with prolonged survival and IFN-γ secretion.209  
Data from HIV models of infection suggest that CD8+ T cells become less efficient in killing 
targets by developing into Tc2 cells, due to a deficiency in IL-12p70 signaling or conditions that 
favor excess IL-4 production.210  In addition, Tc17 cells do not express GrB and other CTL 
effector molecules, and are subsequently less efficient at mediating cell lysis of targets in vitro.  
However, recent reports demonstrate that adoptive transfer of Tc17 cells can protect against 
influenza lethal challenge by accumulating more neutrophils and converting to a Tc1-like subset 
that secretes high levels of IFN-γ.211  
In addition to short-lived effector populations, Tc1 central memory cells are able to 
persist in DLNs for long periods of time and become quickly re-activated to suppress re-
challenge of tumor and infectious Ag.  Memory Tc1 cells also promote cellular immunity by 
enhancing DC function.  For example, memory Tc1 cells secrete IFN-γ to elevate the production 
of IL-12p70 in DCs25,212,213 and TNF-α to protect DCs from CTL killing by enhancing 
expression of GrB inhibitor 9.214  Thus, the ability of memory Tc1 cells to prevent DCs from 
CTL killing could allow for better generation of Ag-specific CD8+ CTL/Tc1 responses. 
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1.3.2 CD4+ Th1 responses 
Similar to Tc1 cells, CD4+ Th1 cells secrete significant levels of IFN-γ, TNF-α and IL-2, and 
additionally, play significant roles in aiding primary, secondary and memory CTL responses 
(Figure 5).204  Upon Ag recognition and co-stimulation provided by mature DCs in DLNs, CD4+ 
Th1 cells up-regulate cell-surface expression of CD40L and produce high amounts of IFN-γ and 
IL-2.  CD40 ligation during the DC-CD4+ T cell synapse fully activates DCs, enabling them to 
effectively provide the ‘license to kill’ to stimulate CD8+ T cells specific for the presenting 
Ag.215  CD40 signaling has been observed to enhance IL-12p70 and IL-15 secretion and co-
stimulatory molecule (B7, CD70 and 4-1BBL) expression in DCs.216,217  IL-2 and IL-15 have 
been demonstrated to provide maintenance for Ag-specific CD8+ CTL effector and memory 
responses, respectively.218,219   
Matzinger and colleagues have demonstrated that CD4+ Th1 cells are more effective than 
CD8+ T cells in eradicating tumors without the aid of exogenous cytokines or treatment.220  In 
addition to helping CD8+ CTL responses, it has been reported that CD4+ Th1 cells promote anti-
tumor responses via cytokine signaling.  For example, adoptive transfer of CD4+ Th1 cells can 
mediate transplanted, endogenous or β-cell tumor rejection by inhibiting tumor angiogenesis and 
proliferation while promoting apoptosis via secretion of IFN-γ and TNF-α.221  Indeed, Th1 cells 
only induce tumor regression in these studies when IFN-γ and TNF-α signaling are intact, while 
impairment of these cytokines resulted in tumor growth.  Other studies suggest that Th1 cells 
directly induce apoptosis of tumors cells via ligation of FasL and TRAIL or secretion of perforin 
and GrB.222  In contrast, CD4+ Th2 cells do not elicit tumor rejection due to their poor secretion 
of IFN-γ.  Similar to their roles in favoring anti-tumor responses, Th1 cells are highly efficient in 
eradicating intracellular infections.  Mechanistic analysis demonstrates that IFN-γ secretion from 
Th1 cells, along with Tc1 cells, enhances the immune-stimulatory activity of phagocytes 
harboring intracellular pathogens by promoting phagosomal fusion, nitric oxide production and 
expression of molecules involved in the MHC class I and II Ag processing and presentation 
pathways.223,224 
 
 
Figure 5:  Role of CD4+ Th1 cells in promoting cellular immunity. 
Activated CD4+ Th1 cells eradicate tumors and infected cells by (A) licensing DCs via CD40 
ligation to favor CD8+ CTL effector and memory responses, (B) secreting IL-2 to directly 
maintain developing CD8+ T cell responses and (C) inducing apoptosis of target cells via 
secretion of IFN-γ, TNF-α and granzymes or ligation of FasL/TRAIL molecules. 
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1.4 SPECIFIC AIMS 
The activation and survival of DCs are critical for generating robust cellular immunity, and for 
that purpose, these features are currently being exploited in DC-based immunotherapy protocols 
designed to elicit successful cellular-based vaccinations.  It is becoming increasingly evident that 
the nervous system, via secretion of pro-inflammatory tachykinins that bind with high affinity to 
the NK1R, promotes immune cell survival and type-1 T cell responses.  However, the ability of 
NK1R agonists to modulate the immune-stimulatory function of DCs remains unknown.  In these 
studies, we formulate and investigate two specific aims addressing the immunological role of 
stimulating murine BMDCs via the NK1R to enhance DC longevity (Aim 1) and induce potent 
type-1 T cell responses (Aim 2) in vivo.  
1.4.1 Specific Aim 1 (Chapter 2):  To analyze the capacity of agonistic signaling via the 
NK1R to modulate the viability of DCs 
Given the importance of DC longevity in mediating enhanced Th1 and Tc1 responses, we 
investigated the role NK1R agonists serve in modulating the viability of DCs when exposed to 
apoptotic signaling in vitro and in vivo.  In this chapter, we describe that BMDCs express the 
full-length functional NK1R, and agonistic signaling via the NK1R activates a pro-survival 
PI3K-Akt intracellular pathway to rescue DCs from apoptosis induced by GM-CSF and IL-4 
withdrawal.  After adoptive transfer, we discovered that NK1R-signaled BMDCs loaded with or 
without Ag persist longer in DLNs, which was mediated by a combination of NK1R signaling in 
vitro and CD40 signaling in vivo, and promote robust cellular immunity as assessed in DTH 
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assays.  These findings demonstrate for the first time that neuropeptides binding the NK1R are 
capable of modulating DC function, including their survival and ability to elicit cellular 
immunity.   
1.4.2 Specific Aim 2 (Chapter 3):  To assess the ability of NK1R-signaled DCs to promote 
Ag-specific CD4+ Th1 and CD8+ CTL/Tc1 responses 
NK1R signaling favors the generation of Th1 and Tc1 responses.187  Thus, we addressed the 
ability of NK1R agonists to modulate the immune-stimulatory function of DCs, and 
subsequently, their ability to tailor Ag-specific Th1/Tc1 responses.  Initial results demonstrate 
that signaling DCs with NK1R agonists in vitro enhances their maturation, while significantly 
diminishing the production of anti-inflammatory cytokines IL-10 and TGF-β1.  Furthermore, 
adoptive transfer of NK1R-signaled DCs promotes robust OVA-specific Th1/Tc1 responses in 
vitro and in vivo.   
 Mechanistic analysis demonstrates the necessity of endogenous IL-12p70 secretion and 
survival of endogenous DCs to amplify robust Ag-specific Th1/Tc1 responses in vivo mediated 
by adoptive transfer of DCs.  These results suggest that endogenous DC populations play crucial 
roles in interacting with adoptively transferred DCs to generate Th1/Tc1 responses.  As we 
illustrate and discuss, the unique ability of NK1R-signaled DCs to down-regulate the secretion of 
IL-10 allows for greater induction of Th1/Tc1 responses, which may be contributed to 
interactions   with   endogenous   DC   populations   in   peripheral   or   lymphoid    tissues,   and  
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alternatively, greater direct priming of CD4+ and CD8+ T cells.  Collectively, these novel 
findings demonstrate the unique ability of tachykinins, acting via the NK1R, to promote 
immune-stimulatory DCs that initiate robust Th1/Tc1 responses in vivo. 
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2.0  CHAPTER TWO:  PRO-INFLAMMATORY TACHYKININS THAT SIGNAL 
DENDRITIC CELLS VIA THE NEUROKININ 1 RECEPTOR PROMOTE CELL 
SURVIVAL AND INDUCTION OF CELLULAR IMMUNITY 
Brian M. Janelsins, Alicia R. Mathers, Olga A. Tkacheva, Geza Erdos, William J. Shufesky, Adrian 
E. Morelli, and Adriana T. Larregina. 
Blood. 2009;113:3017-3026. 
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2.1 ABSTRACT 
DCs are the preferred targets for immune-therapy protocols focused on stimulation of cellular 
immune responses.  However, despite initial promising results, ex vivo-generated DCs do not 
always promote immune-stimulatory responses.  The outcome of DC-dependent immunity is 
regulated by pro-inflammatory cytokines and neuropeptides.  Pro-inflammatory neuropeptides of 
the tachykinin family, including SP and HK-1, bind the NK1R and promote stimulatory immune 
responses.  Nevertheless, the ability of pro-inflammatory tachykinins to affect the immune 
functions of DCs remains elusive.  In the present work, we demonstrate that murine BMDCs 
generated in the presence of GM-CSF and IL-4 express functional NK1R.  Signaling via NK1R 
with SP, HK-1, or the synthetic agonist SarSP rescues DCs from apoptosis induced by 
deprivation of GM-CSF and IL-4.  Mechanistic analysis demonstrates that NK1R agonistic 
binding promotes DC survival via PI3K-Akt signaling cascade.  In adoptive transfer 
experiments, NK1R-signaled BMDCs loaded with Ag exhibit increased longevity in draining 
lymph nodes, resulting in enhanced and prolonged effector cellular immunity.  Our results 
contribute to the understanding of the interactions between the immune and nervous systems that 
control DC function, and present a novel approach for ex vivo-generation of potent immune-
stimulatory DCs.  
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2.2 INTRODUCTION 
Due to their crucial role in initiation and control of innate and adaptive immunity, myeloid DCs 
are the preferred target Ag-presenting cells for positive cellular vaccination protocols.225  During 
the past decade, ex vivo-generated DCs have been used in immunization approaches for 
prevention and treatment of cancer and infectious diseases.226  Current DC-based vaccines focus 
on the adjuvant effect of pro-inflammatory mediators conferring DCs the capability to initiate 
and bias T cell immune responses.27,43,227  However, in spite of initial promising results, DC-
based vaccines do not always elicit potent T cell immunity.73   
Generation of efficient T cell immunity using ex vivo-generated DCs requires a critical 
number of adoptively transferred DCs capable of surviving apoptosis.54  Indeed, DCs used as 
cellular vaccines are exposed to pro-apoptotic stimuli at the injection sites and in DLNs.54,228  
Accordingly, exposure of DCs to pro-apoptotic stimuli triggered by lytic infections, UVB-
irradiation, tumor mediators, and cytotoxic cells results in immune-suppression.53  Additionally, 
interaction of DCs with cells in early apoptosis down-regulates the T cell-stimulatory ability of 
DCs and induces immunological tolerance.101,229-231 Conversely, pro-inflammatory mediators and 
growth factors promoting DC survival, including GM-CSF,57 PG-E2,56 LPS,63 and CCR767 and 
CD40232 ligands, correlate with enhanced T cell immunity.  
 The intracellular signaling involved in DC survival is currently being elucidated.  
Activation through CD40 promotes DC survival by favoring a positive balance of NF-κB vs. 
Jnk-AP-1 pathway,70 whereas GM-CSF, LPS, and PG-E2 prevent DC apoptosis by signaling via 
PI3K and Akt.56,57,64  In contrast, the immune-suppressive drug Rapamycin induces DC death by 
antagonizing GM-CSF signaling via inhibition of the PI3K-Akt signaling cascade.57,233  
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Recently, it has become evident that the outcome of the immune response is highly 
regulated by neuropeptides.  The balance between anti-inflammatory and pro-inflammatory 
neuropeptides is crucial to maintain the immune privilege of the CNS and the steady-state 
condition in peripheral tissues, and altering this delicate balance plays a role in the pathogenesis 
of chronic inflammatory and autoimmune diseases.106,107,234-236  Pro-inflammatory neuropeptides 
like SP favor CD4+ Th1 bias and cellular immunity, while vasoactive intestinal peptide (VIP) 
promotes CD4+ Th2 bias.84,110,160,187,237-240  Conversely, calcitonin gene-related peptide (CGRP) 
and the anti-inflammatory products of POMC cleavage, α-melanocyte stimulating hormone (α-
MSH) and adrenocorticotropic hormone (ACTH), are potent suppressors of cellular immunity.235  
The pro-inflammatory tachykinins SP and HK-1 exert their immune-stimulatory 
functions by binding with high affinity to the NK1R, a seven transmembrane domain GPCR.241  
SP and HK-1 induce IFN-γ secretion and proliferation of T cells.106,107,134,137,197  Our laboratory 
has recently reported that skin DCs express functional NK1R and elicit in vivo CD4+ Th1 and 
CD8+ CTL immunity in response to NK1R agonists.84  Nevertheless, because the NK1R is 
expressed by several types of skin cells, the potential of NK1R agonists to modulate directly the 
immune-stimulatory function of DCs remains unknown.   
In the present study, we examined the expression of functional NK1R by BMDCs and the 
ability of NK1R agonists SP, HK-1, and SarSP to rescue BMDCs from apoptosis induced by 
deprivation of GM-CSF and IL-4.  We also investigated in vivo the immunological relevance of 
signaling BMDCs with these pro-inflammatory neuropeptides. 
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2.3 MATERIALS AND METHODS 
2.3.1 Mice 
Eight- to twelve-week old wild-type C57BL/6 mice (B6) (The Jackson Laboratory, Bar Harbor, 
ME) and B6 NK1R-/-KO mice (kindly provided by Dr. Christopher Paige, University of Toronto, 
Canada) were housed in the pathogen-free animal facility of the University of Pittsburgh and 
used according to institutional guidelines with approval of the University of Pittsburgh 
IACUC.    
2.3.2 Generation of BMDCs 
BMDCs were generated by culturing mouse BM-precursors for 6d in RPMI-1640 medium 
supplemented with 10% fetal bovine serum (Gemini, West Sacramento, CA) (complete medium) 
and GM-CSF and IL-4 cytokines (both at 1,000 U/ml) (R&D, Minneapolis, MN), as previously 
described.242,243  Total CD11c+ BMDCs were purified by histodenz gradient (16% wt/vol, purity  
of CD11c+ cells ≥85% as determined by FACS-analysis).  The DC morphology was confirmed 
in cytospins of purified CD11c+ cells obtained, as previously described,244 and stained with 
Hema-3 (Fisher, Pittsburgh, PA). 
2.3.3 Quantitative RT-PCR 
The expression of NK1R mRNA was detected by SYBR green-based quantitative RT-PCR 
(qRT-PCR) using reverse transcribed cDNA isolated from CD11c+ BMDCs cultured for 24h in 
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complete medium with or without LPS (500 ng/ml, Sigma).  Total RNA was isolated using the 
RNeasy isolation kit (Qiagen, Valencia, CA) and was reverse transcribed using the QuantiTect 
Reverse Transcription Kit (Invitrogen, Carlsbad, CA), according to manufactures’ instructions.  
cDNA template amplification was performed by using the Quantitect SYBR Green PCR kit with 
specifically designed NK1R and phosphoglycerate kinase 1 (PGK1) primers (Qiagen).  qRT-
PCR was conducted using the ABI Prism 7900HT system (Genomics and Proteomics Core 
Laboratories, Univ. of Pittsburgh, Pittsburgh, PA) with cycling conditions consisting of 15 min 
Taq activation at 95oC followed by denature, anneal, and extension phases for 15 sec at 94oC, 30 
sec at 54oC,  and 30 sec at 72oC, respectively, for 40 cycles.  Analysis was performed using 
Sequence Detection System software 2.2.2 (Applied Biosystems, Foster City, CA), and the 
quantification of PGK1-normalized NK1R was expressed as mRNA fold increase.    
2.3.4 Immunofluorescence microscopy and FACS-analysis 
The expression of NK1R protein on the surface of BMDCs was analyzed in cytospins.  BMDC 
suspensions were FcR-blocked with anti-CD16/32 mAb, fixed in 2% paraformaldehyde (PFA), 
and stained with a purified goat anti-mouse IgG specific for the N-terminus domain of the NK1R 
(Santa Cruz Biotechnology, Santa Cruz, CA), followed by donkey anti-goat FITC-IgG F(ab’)2 
(Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).  After labeling, BMDCs were 
cytospun as described242 and analyzed using an AxioStar Plus microscope equipped with epi-
fluorescence, an AxioCamera, and the image analyzing software AxioVision (Carl Zeiss Vision 
Imaging Systems, Thornwood, NY).  
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Quantification of NK1R in BMDCs was performed by FACS-analysis (FACSCaliburTM, 
Becton Dickinson, Palo Alto, CA).  BMDCs were: i) stained with anti-mouse APC-CD11c and 
PE-CD86 or PE-CD83 mAbs (BD-PharMingen, San Diego, CA); ii) fixed in 2% PFA; iii) 
permeabilized in 0.1% saponin (Sigma); and iv) incubated with goat anti-NK1R IgG 
(recognizing the N-terminus domain) or rabbit anti-NK1R IgG (specific for the C-terminus 
domain) (Advanced Targeting Systems, San Diego, CA), followed by anti-goat or anti-rabbit 
FITC-IgG F(ab’)2 (Jackson).  Negative controls included species-matched isotype IgG and 
secondary Abs.   
Quantification of anti- and pro-apoptotic proteins in BMDCs was assessed by 
intracellular staining and FACS-analysis.  BMDCs were cultured in complete medium or 
supplemented with SarSP (10-9 M) or GM-CSF and IL-4 (both at 1,000 U/ml).  After 24h, cells 
were: i) labeled with FITC-CD11c mAb (BD-PharMingen); ii) fixed and permeabilized as 
described above; and iii) incubated with one of the following anti-mouse mAbs, Alexa Fluor 
488-pAktSer473 (Abcam, Cambridge, MA), PE-active caspase 3 (BD-PharMingen) or PE-Bcl-2 
(BD-PharMingen).  For detection of pBad, BMDCs were incubated with goat anti-mouse 
pBadSer136 mAb (Santa Cruz Biotechnology) followed by anti-goat FITC-IgG F(ab’)2. 
2.3.5 Induction and quantification of apoptosis 
BMDCs were cultured for 24-72h in complete medium with or without the NK1R antagonist 
WIN-51708 (10-8 M) (Sigma) and/or one of the following NK1R agonists: i) SarSP (Sigma); ii) 
SP (Bachem, King of Prussia, PA); or iii) HK-1 (Bachem) (all at 10-9 or 10-5 M).  Positive 
controls included BMDC cultures supplemented with GM-CSF and IL-4 or agonistic CD40 mAb 
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(10 µg/ml, BD-PharMingen).244  At the indicated time points, BMDCs were harvested and cell 
viability was assessed by trypan blue exclusion.  The morphology of BMDCs undergoing 
apoptosis was examined in cytospins stained with HEMA-3 (Fisher) or DAPI (Invitrogen).  DNA 
fragmentation was further assessed by FACS-analysis in BMDCs immunostained using a 
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) kit (Roche, 
Indianapolis, IN), according to manufactures’ protocol.  For quantification of apoptosis, FACS-
analysis was performed on BMDCs that were immunostained with APC-CD11c, FITC-Annexin 
V (BD-PharMingen), and propidium iodide (PI, Sigma).  Percentage of apoptotic cell rescue was 
calculated by the formula: [1-(% of apoptotic NK1R-signaled BMDCs) / (% of apoptotic non-
treated BMDCs)] x 100.   
Experiments addressing specificity of signaling via NK1R utilized BMDCs generated 
from B6 NK1R-/-KO and B6 NK1R+/+ mice, the later treated for 30 min with WIN-51708 (10-8 M 
or 10-5M) prior to stimulation with SarSP (10-9 M).   
2.3.6 Blockade of intracellular signaling 
BMDCs were cultured in complete medium with one of the following cell-permeable inhibitors: 
i) LY294002 (PI3K inhibitor, 5 μM, Biomol, Plymouth Meeting, PA); ii) Akt inhibitor X (5 μM, 
Calbiochem, San Diego, CA); iii) PD98059 (ERK inhibitor, 20 μM, Biomol); iv) SN-50 (NFκB 
inhibitor, 18 μM, Calbiochem); or v) Jnk inhibitor II (10 μM, Calbiochem).  Following 30 min 
blockade, BMDCs cultures were treated or not with SarSP (10-9 M) for 24h.  Quantification of 
apoptotic BMDCs was analyzed by FACS as described above.   
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2.3.7 Adoptive transfer of BMDCs 
BMDCs were cultured in complete medium with or without SarSP (10-9 M).  After 24h, BMDCs 
were left untreated (DCs, control) or haptenized with trinitrobenzene sulfonic acid (TNBS, 1 
mM, 25 min at 37°C) (Sigma) (TN-DCs).  DCs and TN-DCs were then labeled with 
carboxyfluorescein succinimidyl ester (CFSE, 1 µM, 15 min at 37°C) (Invitrogen).  After 
thorough rinsing, CFSE-labeled DCs and TN-DCs were adoptively transferred (2x106 cells / 
50μl PBS, footpad, s.c.) into B6 mice (n=3 animals per group).   
For in vivo studies analyzing the survival of DCs in the presence or absence of CD40 
ligation, mice were treated (or not) with two doses of anti-CD154 blocking MR1 mAb (Bio 
Express, West Lebanon, NH) injected simultaneously and 2d after BMDC transfer (250 μg per 
dose, flank, i.p.).  At indicated time points, mice were euthanized and local (popliteal) and 
distant (cervical and axillary) DLNs were dissected.  The number of viable CFSE-labeled 
CD11c+ BMDCs in DLNs was analyzed by FACS, as previously described.84  An equal number 
of CD11c+ DCs (106) per experimental situation was acquired by FACS and the percentage of 
CFSE-labeled CD11c+ BMDCs was calculated with the following formula: [(number of 
CFSE+CD11c+ BMDCs) / (total number of CD11c+ DCs) x100]. 
2.3.8 Delayed-type hypersensitivity (DTH) assays 
B6 mice (n=6 animals per group) were sensitized with one dose of BMDCs (2x106 cells / 50μl 
PBS, footpad, s.c.) pre-treated as follows: i) TNBS haptenized (TN-DCs); ii) TN-DCs cultured 
with SarSP (10-9 M) (SarSP-TN-DCs); iii) TN-DCs cultured with CD40 mAb (CD40-TN-DCs); 
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iv) non-haptenized DCs (DCs); or v) non-haptenized DCs cultured with SarSP (SarSP-DCs).  
Elicitation of DTH was performed 6d after sensitization by applying trinitrochlorobenzene 
(TNCB, 1% in acetone:olive oil, 4:1) (Sigma) on the dorsal surface of the ears.  The severity of 
the DTH responses was assessed by comparing the thickness of ears measured prior and after 
elicitation for up to 6d, using an electronic caliper (Mitutoyo, Aurora, IL).  The DTH responses 
were expressed as the percent in ear thickness increase using the formula: [(thickness of 
challenged ear – thickness of control ear) / (thickness of control ear) x 100].  For histological 
analysis, mice were euthanized 6d after elicitation and samples from ear skin were fixed in 4% 
formaldehyde, embedded in paraffin, stained with H&E, and analyzed by microscopy or 
embedded in Tissue-Tek OCT (Miles Laboratories, Elkhart, IN) and snap-frozen in methyl-
butane (Sigma).  The composition of the cellular infiltrate 6d after elicitation was assessed by 
immunofluorescence microscopy of cryostat sections of the ears, as previously described.84  
Cryostat   sections   (8 μm)   were   mounted   on  slides   pre-treated   with   Vectabond   (Vector 
Laboratories, Burlingame, CA), fixed in cold 96% ethanol, and incubated with Alexa Fluor 488-
CD4 mAb (Invitrogen) and biotin-CD8 (eBioscience, San Diego, CA) or biotin-F4/80 mAbs 
(Invitrogen), followed by Cy3-streptavidin (Jackson).  Cell nuclei were stained with DAPI. 
 
 
  
47
2.3.9 Statistical analysis 
Statistical analysis was performed using the GraphPad Prism® 4 software (GraphPad software, 
San Diego, CA).  Differences between more than two means ± 1SD were analyzed by a one-way 
ANOVA analysis followed by a Student Newman Keuls test.  Comparisons between two 
different means ± 1SD were performed by a Student’s “t” test. A “p” value <0.05 was considered 
significant. 
2.4 RESULTS 
2.4.1 Expression of NK1R in BMDCs 
The population of d6 BMDCs was composed of immature and mature CD11c+ DCs.  Similar 
percentages of CD11c+ DCs exhibited short dendrites and a round nucleus, features of immature 
DCs, or well-developed dendrites and a bean-shaped nucleus, indicative of mature DCs (Figure 
6A).  Likewise, FACS-analysis demonstrated that BMDC cultures contained CD11c+CD86-
/lowCD83- immature DCs and CD11c+CD86highCD83+ mature DCs (Figure 6A).  
To determine whether BMDCs might be targets of pro-inflammatory neuropeptides that 
signal via NK1R, we investigated NK1R protein and mRNA transcript expression in BMDCs.  
Presence of NK1R was analyzed by fluorescence microscopy (Figure 6B) and FACS (Figure 6C) 
using an Ab recognizing the N-terminus extracellular domain of the receptor.  Both immature 
and mature BMDCs expressed surface NK1R (Figure 6B and C, upper panels).  
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Since NK1R exists as a full-length (functional) or a C-terminus truncated variant 
(deficient in signaling),245 we investigated whether BMDCs express functional NK1R, utilizing 
an Ab recognizing the C-terminus motif of the receptor.  As determined by FACS-analysis, 
immature and mature BMDCs expressed the functional variant of NK1R (Figure 6C, lower 
panels).   
Next, we analyzed whether BMDCs up-regulate NK1R mRNA following exposure to the 
pro-inflammatory stimulus LPS by quantifying NK1R transcripts via qRT-PCR.  The levels of 
NK1R mRNA increased 3-fold in BMDCs cultured with LPS (p<0.05) (Figure 6D).  These 
results demonstrate that mature and immature BMDCs express surface functional NK1R, and 
transcription of NK1R mRNA was up-regulated by the DC-activating mediator LPS. 
 
 
 
 
 Figure 6: Mature and immature BMDCs express the full-length NK1R.   
(A)  Microscopic and phenotypic characteristics of d6 BMDCs.  Cytospin showing immature 
DCs (arrows) identified by round nuclei and short membrane prolongations and mature DCs 
(asterisks) with long membrane processes and bean-shaped nuclei. Hema-3 stain, 500x; scale bar 
= 5μm. Dot plots of BMDCs illustrating the percentages (numbers in dot plots) of mature 
(CD11c+CD86high or CD11c+CD83+) and immature (CD11c+CD86-/low or CD11c+CD83-) DCs. 
(B and C) Expression of NK1R by BMDCs. (B) Cytospin of purified BMDCs showing the 
expression of NK1R on their cell surface. Fluorescence microscopy, 500x; scale bar = 5 μm. (C) 
NK1R expression by CD11c+CD86highCD83+ mature and CD11c+CD86-/lowCD83- immature DCs 
analyzed by FACS. Mature and immature BMDCs express the N-terminal (upper panels) and the 
C-terminal (lower panels) motifs of the NK1R, indicating expression of the full-length functional 
NK1R. (A-C) Data are representative of 5 independent experiments. (D) qRT-PCR analysis of 
NK1R mRNA transcripts in BMDCs cultured with or without LPS. *P < 0.05. Means (+ SD) of 
3 independent experiments are shown. 
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2.4.2 Agonistic signaling via the NK1R rescues BMDCs from apoptosis 
Withdrawal of GM-CSF and IL-4 from BMDC cultures triggers DC death.57,246,247  Therefore, 
we investigated the effects of signaling through NK1R on the viability of BMDCs following 
cytokine withdrawal.  BMDCs were cultured for 24h in complete medium with or without GM-
CSF and IL-4, the synthetic NK1R agonist SarSP (10-9 M),248 or agonistic CD40 mAb (DC 
survival signal, positive control).  Withdrawal of GM-CSF and IL-4 significantly decreased the 
number of viable BMDCs (p<0.001), whereas addition of SarSP, CD40 mAb, or GM-CSF and 
IL-4 yielded similar high numbers of viable BMDCs (Figure 7A).  GM-CSF and IL-4 
withdrawal induced apoptosis of BMDCs characterized by plasma membrane blebs, nuclear 
condensation, and DNA fragmentation (Figure 7B and C).  Conversely, DCs cultured in medium 
with SarSP or agonistic CD40 mAb exhibited the morphology of viable cells (Figure 7B).  
Accordingly, SarSP reduced DNA fragmentation in BMDC cultures deprived of GM-CSF and 
IL-4, as determined by fluorescent microscopy and FACS-analysis of nuclear staining with 
DAPI and TUNEL, respectively (Figure 7C).   
The ability of SarSP to rescue BMDCs from apoptosis was quantified by FACS in 
BMDCs stained with Annexin V and PI.  Withdrawal of GM-CSF and IL-4 increased 
significantly the percentage of apoptotic BMDCs, whereas addition of SarSP, at physiological 
concentration, reduced the level of apoptosis by 47% (p<0.001) (Figure 7D).  The anti-apoptotic 
effect of SarSP was sustained up to 72h, and addition of higher concentrations of SarSP (from 
10-7 to 10-5M) did not result in further apoptotic cell rescue (not shown).  Cultures of BMDCs 
supplemented   with   agonistic  CD40  mAb  showed  a  slightly  less  anti-apoptotic  effect  than  
  
51
BMDCs treated with SarSP or GM-CSF and IL-4, a result that could be explained by the low 
percentage of immature BMDCs that do not express CD40.242  These results indicate that NK1R 
agonistic signaling rescues BMDCs from apoptosis induced by GM-CSF and IL-4 withdrawal. 
 
 
 
 
 
 
 Figure 7:  Agonistic signaling through the NK1R in BMDCs prevents apoptosis.  
(A) Number of viable CD11c+ BMDCs recovered 24 hours after culture in different conditions. 
***P less than .001. Means (+ SD) of 6 independent experiments are shown. (B and C) 
Morphological and nuclear characteristics of apoptosis by BMDCs harvested 24 hours after 
culture in different conditions. (B) Morphological analysis of apoptosis as evaluated by cytospins 
of CD11c+ BMDCs stained with Hema-3. (C) Nuclear analysis of apoptosis as determined by 
cytospins of CD11c+ BMDCs stained with the nuclear dye DAPI (left panels) or suspensions of 
CD11c+ BMDCs stained with TUNEL (right panels). Withdrawal of GM-CSF (GM) and IL-4 
(Medium) induces apoptosis of BMDCs characterized by surface membrane blebs (B, upper 
right panel, asterisk), nuclear breakage (B upper panel, arrows), chromatin condensation, and 
DNA fragmentation (C, upper panels, arrows), 500x ; scale bar = 20 μm. (D) Quantification of 
apoptosis in CD11c+ BMDCs by FACS analysis of Annexin V and PI labeling. Numbers in dot-
plots represent percentage of cells. Signaling via NK1R with SarSP (10-9 M) prevents apoptosis 
of BMDCs to a similar extent as signaling via CD40 or addition of GM and IL-4 (positive 
controls). Data are representative of 10 independent experiments. 
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2.4.3 Pro-inflammatory tachykinins prevent apoptosis of BMDCs via signaling of the 
NK1R 
The naturally-occurring NK1R agonists SP and HK-1 also ligate NK2R and NK3R,249 which 
decreases their pro-inflammatory function.  In addition, at very high concentrations, SP and HK-
1 bind other neuropeptide receptors250 or exert effects independently from receptor ligation251.  
Therefore, we investigated if similar to SarSP, SP and HK-1 induce anti-apoptotic effects on 
BMDCs and whether the apoptotic cell rescue induced by SarSP is mediated through NK1R 
signaling. 
SP, HK-1, and SarSP exerted similar anti-apoptotic effects on BMDCs at their 
physiological concentration (10-9 M) (p<0.001), and a higher concentration (10-5 M) did not 
enhance this effect (p>0.05) (Figure 8A).  The anti-apoptotic effect of SarSP was mediated by 
NK1R binding, as demonstrated by the lack of apoptotic rescue by SarSP, in NK1R blockade 
assays of BMDCs pre-treated with the selective NK1R antagonist WIN-51708 (p<0.001) or in 
BMDCs generated from B6 NK1R-/-KO mice (p<0.001) (Figure 8B and C, respectively).  
Blockade of NK1R in BMDC cultures, with WIN-51708 by itself, did not significantly increase 
the level of apoptosis induced by GM-CSF and IL-4 withdrawal (Figure 8D).  Together, these 
results demonstrate that the synthetic NK1R agonist SarSP, SP, and HK-1 exert similar anti-
apoptotic effects on BMDCs, which requires signaling via NK1R. 
           
Figure 8: Pro-inflammatory tachykinins specifically prevent apoptosis of BMDCs by NK1R 
signaling. 
Pro-inflammatory tachykinins prevent apoptosis of BMDCs by NK1R signaling. (A) 
Comparison of the anti-apoptotic effects of SarSP, SP, and HK-1 at physiological (10-9 M) and 
nonphysiological (10-5 M) concentrations on CD11c+ BMDCs as determined by FACS analysis 
of Annexin V and PI labeling. (B and C) Bar-diagrams representing the anti-apoptotic effect of 
SarSP on CD11c+ BMDCs is abrogated by (B) preincubation with the highly selective NK1R 
antagonist WIN-51708 or (C) in NK1R-/-KO BMDCs. ***P less than .001. (A-C) Means (1 + SD) 
of 3 independent experiments are illustrated. (D) Dot-plots illustrating the percentage of 
apoptosis (numbers in dot-plots) of CD11c+ BMDCs signaled with NK1R antagonist WIN-
51708 alone. Data are representative of 4 independent experiments. 
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2.4.4 Agonistic binding of the NK1R activates the intracellular PI3K-Akt pathway to 
prevent apoptosis of BMDCs 
The mechanisms by which NK1R agonists exert their anti-apoptotic effect on BMDCs were 
analyzed by investigating the role of intracellular pathways involved in DC survival in blockade 
assays using cell-permeable inhibitors specific for PI3K (LY294002),54,64,252 NF-κB (SN-50),65 
Erk (PD98059),63 and Jnk-AP-1 (JNK inhibitor II).70  Blockade of PI3K decreased significantly 
the ability of SarSP to rescue BMDCs from apoptosis (p<0.001), whereas inhibition of Erk or 
NF-κB exerted lower but still significant decreases of BMDC apoptosis (Figure 9A).  
Conversely, inhibition of Jnk-AP-1 did not interfere with the anti-apoptotic effect of SarSP 
(p>0.05) (Figure 9A). 
Since the previous experiment demonstrated that DC survival promoted by the NK1R 
agonist was abrogated by PI3K blockade, we further investigated the role of effector molecules 
downstream PI3K that could be involved in the anti-apoptotic effect of SarSP on BMDCs.253  We 
analyzed whether signaling via NK1R in BMDCs activates Akt by intracellular labeling with an 
Ab recognizing phosphorylated-Akt at the Ser473 residue (pAKTSer473), an event that occurs 
downstream of PI3K and is necessary for full-activation of Akt.  Signaling BMDCs with SarSP 
increased the percentage of BMDCs expressing pAktSer473 from 31% to 72%, as determined by 
FACS-analysis (Figure 9B).  Moreover, blockade of pAktSer473 with the Akt Inhibitor X 
decreased the anti-apoptotic effect of SarSP (p<0.001) to a similar extent as observed with PI3K 
blockade (Figure 9C).  
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Next, we compared the abilities of SarSP and GM-CSF and IL-4 to: i) induce 
phosphorylation of Bad, reducing its pro-apoptotic activity; ii) increase anti-apoptotic Bcl-2 
expression; and iii) decrease pro-apoptotic caspase 3 activity, which are the final effectors of the 
PI3K-Akt cascade.254,255  Signaling BMDCs with SarSP or GM-CSF and IL-4 induced similar 
significant increases of intracellular levels of the Akt-dependent phosphorylated-Bad at the 
Ser136 residue (pBadSer136) and Bcl-2 (Figure 9D).  Importantly, we observed a significant 
decrease of active caspase 3 levels, a protease that executes apoptosis by activation of nuclear-
DNAses.256,257  Collectively, these results demonstrate that SarSP promotes survival of BMDCs 
through activation of the PI3K-Akt pathway. 
 Figure 9:  Signaling BMDCs via the NK1R prevents apoptosis through activation of the 
PI3K-Akt cascade.   
(A) Histogram representing the effect of intracellular pathway blockade on the anti-apoptotic 
effect exerted by SarSP on CD11c+ BMDCs. Before culture with or without SarSP, BMDCs 
were left untreated (control) or incubated with the cell-permeable inhibitors LY294002 (PI3K), 
PD98059 (Erk), SN-50 (NF-κB), or Jnk II (Jnk-AP1). ***P less than .001. (B) FACS analysis 
showing the level of pAktSer473 expression by CD11c+ BMDCs cultured in the presence of 
SarSP (gray empty histogram) or medium alone (gray filled histogram). (C) Comparative 
analysis of the effects of LY294002 and Akt inhibitor X (pAktSer473 inhibitor) on the anti-
apoptotic effect of SarSP on BMDCs. ***P less than .001. (D) FACS analysis illustrating the 
level of pBadSer136, Bcl-2, and active caspase 3 expression by CD11c+ BMDCs cultured in the 
presence of SarSP (black empty histogram), GM, and IL-4 (gray empty histogram), or medium 
alone (gray filled histogram). (A and C) Means (+ SD) of four independent experiments are 
shown. (B and D) Data are representative of 4 independent experiments. Numbers in histograms 
indicate percentage of CD11c+ BMDCs. 
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2.4.5 NK1R-signaled BMDCs show enhanced survival in vivo 
The relevance of our previous results was analyzed in vivo by studying the effect of signaling via 
NK1R on the survival of adoptively transferred BMDCs.  CFSE-labeled BMDCs, pre-incubated 
or not with SarSP (SarSP-DCs and DCs, respectively), were injected (footpad, s.c.) into B6 mice, 
and the number of viable CFSE-labeled CD11c+ BMDCs was quantified in local DLNs for a 
period of 7d by FACS.  Two days after adoptive transfer, similar numbers of SarSP-DCs and 
control DCs were detected in DLNs, indicating that both DC subsets displayed equivalent DLN-
homing capacities (Figure 10A).  Five days after injection, 95% of SarSP-DCs remained in 
DLNs compared to 63% of control DCs and by d7 42% of SarSP-DCs were present vs. 24% of 
control DCs (Figure 10A). No CFSE dilution was detected in CD11c+ BMDCs homed to local 
DLNs, indicating that the higher percentage of SarSP-DCs observed in the LNs was due to 
prolonged DC survival and not DC proliferation (Figure 10A).258  Conversely, CFSE+ cells were 
not detected in non-draining homolateral or collateral LNs (not shown).   
These findings confirm that signaling via NK1R enhances survival of BMDCs in vivo.  
Next, we addressed whether SarSP prolongs survival of Ag-loaded BMDCs in DLNs.  CFSE-
labeled SarSP-DCs or control DCs were left untreated or haptenized with TNBS (SarSP-TN-DCs 
and TN-DCs, respectively), injected (footpad, s.c.) into B6 mice, and quantified by FACS-
analysis of DLNs at d2, 5 and 7 following transfer.  Regardless of the treatment, BMDCs showed 
similar DLN-homing capacities (not shown).  However, the percentage of TN-DCs detected in 
DLNs  5  and  7d  after  DC  administration  was  significantly  lower  than  the  number  of  non- 
haptenized DCs (p<0.001) (Figure 10B).  Importantly, the percentage of SarSP-TN-DCs homed 
in DLNs was significantly higher than that of TN-DCs, indicating that signaling via NK1R 
prolongs the survival of Ag-loaded BMDCs in DLNs. 
 
Figure 10:  Agonistic signaling via the NK1R prolongs BMDC survival in vivo. 
(A) Contour-plots illustrating the percentage of SarSP-DCs or control DCs (CD11c+CFSE+) in 
DLNs after their adoptive transference into B6 mice and quantification by FACS analysis at 
different time points. Data are representative of 3 independent experiments. (B) Comparative 
analysis of the percentages of CD11c+CFSE+ BMDCs in DLNs after adoptive transference of 
TN-DCs, SarSP-TN-DCs, SarSP-DCs, or untreated DCs as quantified by FACS analysis at 
different time points. ***P < 0.001. Means (+ SD) of three independent experiments are 
displayed. 
 
2.4.6 NK1R and CD40 signaling act synergistically to prolong BMDC survival after 
adoptive transfer 
The finding that SarSP-TN-DCs exhibit prolonged survival once they home in DLNs could be 
ascribed to sustained expression of anti-apoptotic molecules induced by SarSP or a combined 
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effect of NK1R and CD40 signaling, the later provided by DC-activated CD4+ T cells in 
DLNs.215,228,259-262  Thus, we analyzed the individual and combined contribution of NK1R and 
CD40 signaling in the expression of Bcl-2 and on the viability of BMDCs in vitro and in vivo, 
respectively.  
For in vitro experiments, BMDCs were pre-treated (or not) with SarSP during the first 
24h of culture, and signaled with agonistic CD40 mAb added at 24h of culture.  Expression of 
Bcl-2 by CD11c+ BMDCs was quantified up to 96h by FACS.  As expected, NK1R signaling 
significantly increased the percentage of BMDCs expressing Bcl-2 after 24h of culture 
(p<0.001), and signaling via CD40 further enhanced Bcl-2 expression in both SarSP-DCs and 
control DCs 48h after culture (p<0.001) (Figure 11A).  By 96h, the percentage of BMDCs 
expressing Bcl-2 diminished, regardless of the treatment employed; however, CD40 ligation of 
SarSP-DCs significantly enhanced the number of cells expressing Bcl-2 vs. DCs (p<0.001), 
SarSP-DCs (p<0.01) or DCs signaled only via CD40 (p<0.05) (Figure 11A).  
Next, we compared in vivo the survival of adoptively transferred BMDCs homed in 
DLNs in the presence or absence of CD40-CD40L (CD154) interaction blockade.  CFSE-labeled 
TN-DCs or SarSP-TN-DCs were injected (footpad, s.c.) into B6 mice treated or not with CD154 
(CD40L) blocking MR1 mAb (250 μg, i.p.) simultaneously and 2d after DC administration.  In 
vivo blockade of the CD40-CD154 interaction decreased the percentage of transferred TN-DCs 
and SarSP-TN-DCs in DLNs 5d after injection.  Nevertheless, mice that were non-treated with 
CD154 blocking mAb had a significantly higher number of SarSP-TN-DCs remaining in DLNs 
compared to TN-DCs (Figure 11B).  Together, these results suggest that the prolonged viability 
of BMDCs homed in DLNs was caused by a synergistic effect of NK1R and CD40 signaling.  
 
 Figure 11:  NK1R and CD40 signaling act synergistically to promote BMDC survival. 
(A) Bar-diagram representing the percentage of CD11c+ BMDCs expressing Bcl-2 after 
culture in medium alone or with SarSP for different time points. Agonistic CD40 mAb was 
added at 24 hours to cultures, and the percentage of CD11c+ BMDCs expressing Bcl-2 was 
analyzed at each time point. *P < 0.05, **P < 0.01, and ***P <0.001. Means (+ SD) of 3 
independent experiments are shown. (B) Contour-plots illustrating the presence of SarSP-TN-
DCs or TN-DCs (CD11c+CFSE+) in DLNs 5d after adoptive transference of DCs in B6 mice 
treated with or without the CD154 (CD40L) neutralizing mAb.  Data are representative of 3 
independent experiments. 
 
2.4.7 BMDCs signaled via the NK1R promote enhanced cellular immunity 
The previous results indicate that combination of NK1R and CD40 signaling enhances the 
interaction of BMDCs with T cells in DLNs, which might result in robust immune responses.  To 
evaluate the immunological relevance of our findings, we compared the capability of TN-DCs 
and SarSP-TN-DCs to induce DTH responses.  B6 mice were sensitized by administration of 
TN-DCs or SarSP-TN-DCs (footpad, s.c.) and DTH was elicited 5d after by topical TNCB 
application to the dorsal skin of the ears.  Mice were injected with haptenized CD40-TN-DCs or 
non-haptenized (untreated or SarSP-signaled) DCs to be included as positive and negative 
controls, respectively.  The effector cellular immune response was analyzed by measuring the 
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increase of ear thickness up to 6d post-elicitation.  As expected, mice sensitized with TN-DCs, 
SarSP-TN-DCs, and CD40-TN-DCs exhibited a significant ear thickness increase vs. control 
mice 1d post-elicitation (p<0.001) (Figure 12A).  In mice sensitized with TN-DCs, the ear 
thickness diminished significantly 2d after elicitation, and showed minimal differences vs. 
control mice 3d post-elicitation (Figure 12A).  Conversely, mice sensitized with SarSP-TN-DCs 
and CD40-TN-DCs exhibited a further increase 2d after elicitation, and showed a significant 
prolonged increase in ear thickness in comparison to TN-DCs and control mice for up to 6d.  We 
also characterized the cellular infiltrate in the ears of mice obtained 6d after elicitation by 
microscopic analysis.  Mice sensitized with TN-DCs presented scarce cellular infiltrate, whereas 
mice sensitized with SarSP-TN-DCs exhibited severe inflammatory infiltrate composed of 
mononuclear cells  (Figure 12B and C).   Immunofluorescence-microscopy analysis revealed that 
the enhanced cellular inflammatory infiltrate consisted of epidermal CD8+ T cells and dermal 
CD4+ T cells and F4/80+ macrophages (Figure 12C), demonstrating that the immune response 
generated was a type-1 DTH response. 
 
 Figure 12:  Signaling BMDCs via the NK1R prolongs effector cellular immune responses. 
(A) Ear thickness increase of mice sensitized with adoptively transferred TN-DCs, SarSP-
TNDCs, CD40-TN-DCs, or control (nonhaptenized) SarSP-DCs or untreated DCs, as analyzed at 
different time points after DTH elicitation. Means (+ SD) of 6 mice per experimental group are 
illustrated. ***P < 0.001. (B) Histological analysis of ear skin sections dissected 6 days after 
DTH elicitation shows severe mononuclear cell infiltrate in samples obtained from mice 
sensitized with SarSP-TN-DCs compared with mice sensitized with TN-DCs or control SarSP-
DCs or untreated DCs. The mononuclear cell infiltrate is shown at higher magnification in the 
insets. Arrows indicate the thickness of the skin (excluding the hypodermis). H&E, 200x (insets, 
1000x); scale bar = 20 μm. (C) Characterization of the cellular infiltrate in ear skin of mice 
sensitized with TN-DCs or SarSP-TN-DCs. Doted-lines indicate the epidermal-dermal junction. 
Immunofluorescence, 500x; scale bar = 20 μm. (B and C) One representative skin section of 5 
analyzed per experimental group is shown. 
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2.5 DISCUSSION  
The survival of DCs transporting Ag from peripheral tissues to DLNs is crucial for initiation of 
cellular immunity, and administration of DCs unable to survive in the periphery or DLNs 
represents a major drawback for current DC-based immune-stimulatory therapies. Despite the 
relevance of DC survival for the purpose of positive vaccination, the mechanisms that control 
viability of adoptively transferred DCs have not been fully elucidated.  
Recently, it has been demonstrated that the nervous and immune systems interact to 
modulate the immune response via secretion of neuropeptides.  The balance of pro-inflammatory 
and anti-inflammatory neuropeptides in the CNS and peripheral tissues is crucial in maintaining 
self-tolerance under the steady-state.  Indeed, a predominant secretion of the pro-inflammatory 
SP vs. anti-inflammatory neuropeptides favors chronic inflammatory and autoimmune disorders 
in the CNS and peripheral tissues.  
We hypothesized that agonistic binding of NK1R promotes DC viability during their 
migration from peripheral tissues and in DLNs, which will result in a more efficient DC-T cell 
interaction.  Likewise, it has been demonstrated that pro-inflammatory tachykinins that signal via 
NK1R promote survival of neutrophils, macrophages, and B and T cell precursors.  Recent 
publications have demonstrated that SP recruits immature DCs to inflammation sites, and that 
signaling skin DCs via NK1R participates in Th1 polarization and induction of CTL/Tc1 bias.   
However, the mechanisms involved in the relevant DC-stimulatory activities of pro-
inflammatory tachykinins remain largely unknown.  Moreover, the ability of pro-inflammatory 
tachykinins to promote the survival of ex vivo-generated DCs relevant for DC-based immune-
therapies has not been investigated. 
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In the present work, using a model of ex vivo-generated BMDCs, we demonstrated that 
regardless of their maturation stage, BMDCs expressed constitutively the functional variant of 
NK1R.  Importantly, BMDCs increased the levels of NK1R mRNA following LPS stimulation, 
indicating that DCs are capable of up-regulating NK1R and serving as direct targets of the 
increased levels of pro-inflammatory neuropeptides that are secreted during inflammation.  
 Current approaches for adoptive transference of mouse or human DCs utilize BM 
precursor- or monocyte-derived DCs generated ex vivo in the presence of GM-CSF and IL-4, 
and deprivation of these cytokines results in DC apoptosis. Here, we confirmed that deprivation 
of GM-CSF and IL-4 results in significant apoptosis of BMDCs, and this effect is prevented by 
signaling BMDCs via NK1R with the natural agonists SP or HK-1 or the synthetic NK1R ligand 
SarSP.   
At high concentrations, SP and SP analogs bind other neuropeptide receptors, including 
bombesin and serpin-enzyme complex receptors, or alternatively, exert their functions 
independently from receptor-ligation as described for mast cells. Under our conditions, the pro-
inflammatory tachykinins induced their anti-apoptotic effects on BMDCs at physiological 
concentrations and this function was abrogated completely by the presence of NK1R antagonists 
or in BMDCs generated from NK1R-/-KO mice, demonstrating that the effect of the tachykinins 
on DC survival was mediated by NK1R binding.  Moreover, our data suggest that antagonistic 
blockade of the NK1R does not exert apoptosis per se, but prevents NK1R agonistic apoptotic 
rescue by competing for NK1R binding.  Additionally, BMDCs might not secrete significant 
levels of endogenous NK1R agonists to account for apoptotic rescue via an autocrine feedback 
loop. 
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Our results showed that signaling BMDCs through NK1R with pro-inflammatory 
neuropeptides activates the PI3K-Akt cascade to prolong DC survival.  In addition, we observed 
that NF-κB or Erk signaling was less significant in the anti-apoptotic effect mediated by NK1R 
agonists.  These findings agree with recent studies, which emphasized the relevance of the PI3K-
Akt cascade in promoting DC survival, with less prominent roles of MAPK and NF-κB 
pathways. Under our conditions the relative lower contribution of Erk and NF-κB activation 
could be attributed to their interaction with the PI3K-Akt cascade since cross-activation of these 
pathways has been described.  
Downstream effectors of the PI3K-Akt cascade include the anti-apoptotic proteins from 
the Bcl-2 family. The Bcl-2 family includes anti- and pro-apoptotic proteins with characteristic 
homology sequences (BH domains) that are crucial for regulating mitochondrial outer membrane 
permeability, leading to inhibition or activation, respectively, of terminal effector caspases. 
Accordingly, Bad, a pro-apoptotic Bcl-2 family protein, exerts its effects by sequestering the 
anti-apoptotic Bcl-2 through dimerization.  Phosphorylation of Bad at the Ser136 residue by Akt 
disrupts its affinity for Bcl-2, allowing the free Bcl-2 to block the release of cytochrome C from 
the mitochondria and prevent the activation of caspases.  Our results demonstrate that NK1R 
signaling of BMDCs promotes Akt-dependent pBadSer136 and enhances Bcl-2 expression, with 
a consequent decrease of caspase 3 activity.   
DCs homing in secondary lymphoid organs become targets of CD8+ CTLs and NK cells 
that eliminate DCs in Ag-dependent or -independent fashions, respectively.  Conversely, cognate 
activation via CD40 provided by CD4+ Th cells presents DCs with anti-apoptotic signals 
necessary to survive CTL killing. Our data demonstrate that signaling via NK1R prolongs 
survival of BMDCs adoptively transferred into mice and their subsequent homing into DLNs, in 
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both Ag-independent and Ag-dependent manners.  Mechanistic analysis of the latter 
phenomenon revealed that signaling BMDCs via NK1R followed by CD40 stimulation exerted a 
synergistic effect to sustain in vitro Bcl-2 expression and prevent in vivo, the clearance of 
BMDCs homed in DLNs.  The synergistic effect of signaling BMDCs via NK1R and CD40 was 
further confirmed in vivo by those results showing a significant increase of viable SarSP-TN 
DCs in the absence of the CD40L inhibition, compared to the number of TN-DCs that received 
CD40 signaling in the absence of exogenous NK1R agonist.  The fact that inhibition of CD40-
CD40L interaction diminished greatly the anti-apoptotic effects exerted by both DC survival 
signals demonstrates the relevance of DC-CD4+ Th cell interaction in DLNs for prolonging 
survival of NK1R-signaled BMDCs. 
Importantly, enhanced longevity of Ag-loaded BMDCs signaled via NK1R and CD40 
resulted in elicitation of a potent and sustained cellular immunity mediated mainly by CD8+ T 
cells and macrophages.  Moreover, the observation that elicitation of DTH responses promoted 
by BMDCs signaled via NK1R persisted up to one week implies that the effector cells overcame 
the mechanisms of resolution of inflammation and remained active for the period that the Ag was 
present in the skin. 
In conclusion, we have demonstrated that signaling BMDCs via NK1R with pro-
inflammatory tachykinins enhances DC survival in vitro and in vivo, resulting in induction of 
potent immune-stimulatory DCs that promote robust cellular immunity.  Our data provide insight 
into the mechanisms by which the nervous system regulates the function of DCs and the 
subsequent cellular immune responses, and helps to understand the requirements for the 
development of more effective immune-stimulatory DCs for cell-based vaccination. 
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3.0  CHAPTER THREE:  PRO-INFLAMMATORY TACHYKININS SIGNAL 
DENDRITIC CELLS VIA THE NEUROKININ 1 RECEPTOR TO ELICIT ROBUST 
TYPE-1 CD4+ AND CD8+ T CELL RESPONSES  
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3.1 ABSTRACT 
DCs generated ex vivo constitute as a desired target for cellular-based vaccine protocols due to 
their efficient ability to bias robust Ag-specific Th1 and Tc1 responses against cancer and 
intracellular pathogens.  However, DC-based vaccines do not always promote immune-
stimulatory responses, and thus, further understanding of the immune mechanisms that govern 
the ability of DCs to elicit Th1/Tc1 immunity is required.  Previously, we demonstrated that 
signaling murine BMDCs with pro-inflammatory neuropeptides from the tachykinin family, 
including SP, HK-1 and SarSP, bind the NK1R to enhance DC longevity and their ability to 
induce cellular immunity.  In the present work, we extend our findings to demonstrate that 
signaling BMDCs with NK1R agonists promotes DC maturation and low production of IL-
12p70, while inhibiting the secretion of anti-inflammatory cytokines IL-10 and TGF-β1.  
Subsequently, adoptive transfer of NK1R-signaled BMDCs enhanced Ag-specific Th1/Tc1 
responses in vivo by down-regulating the secretion of IL-10.  The ability of NK1R-signaled 
BMDCs to generate robust Ag-specific Th1/Tc1 responses in vivo was dependent on the survival 
of endogenous DCs and the production of endogenous IL-12p70, suggesting the possible 
activation and transfer of Ag to endogenous DC populations.  Collectively, our data demonstrate 
that pro-inflammatory tachykinins, signaling via the NK1R, enhance the immune-stimulatory 
function of BMDCs that allows for induction of potent type-1 T cell immunity in vivo, which 
include immune-stimulatory contributions from both exogenous and endogenous DC 
populations. 
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3.2 INTRODUCTION 
Due to their crucial role in biasing robust Th1/Tc1 immunity, DCs are the preferred target APCs 
for positive cellular vaccination protocols for the prevention and therapy of cancer and infectious 
diseases.76,225,226  However, in spite of initial promising results, current DC-based vaccines do not 
always elicit potent Th1/Tc1 immunity,73 and further understanding of immune mechanisms is 
warranted to determine ideal adjuvants for DCs.   
 Generation of potent Th1/Tc1 responses in vivo requires signaling DCs with pro-
inflammatory mediators that (i) favor cell longevity after adoptive transfer54,71,72,228 and (ii) 
induce immune-stimulatory DCs,263 including their ability to enhance the Th1-driving cytokine 
IL-12p70, while inhibiting anti-inflammatory cytokines IL-10 and TGF-β1.  Adoptive transfer of 
DCs expressing Ag are short-lived and exposed to pro-apoptotic stimuli at the injection site and 
in DLNs,53,54 allowing DCs to serve as sources of Ag to endogenous DC populations in 
peripheral and lymphoid tissues, respectively.  Indeed, DCs are capable of transferring Ag to 
other DC populations in vivo.264-266  Thus, it is becoming evident that endogenous DCs may play 
important roles in mediating the effects of DC-based vaccines; however, the means involved 
remain unclear. 
Along with well-known pro-inflammatory mediators, various neuropeptides have 
recently been implicated in modulating T cell immunity.15,108,239,267  Most neuropeptides released 
in peripheral and lymphoid tissues are immune-inhibitory; however, mammalian tachykinins SP 
and HK-1 promote robust immune-stimulatory Th1/Tc1 responses by binding the 
NK1R.84,106,191,241   
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Our laboratory has demonstrated that administration of a highly selective NK1R agonist 
(SarSP) in vivo leads to DC activation and migration into DLNs where they generate robust Ag-
specific Th1/Tc1 responses.84  However, it is unknown whether NK1R agonists directly 
stimulate DCs to induce Ag-specific Th1/Tc1 responses, or modify the DC microenvironment to 
promote DC activation and their ability to polarize Th1/Tc1 responses.  Recently, we have 
published (Chapter 2) that BMDCs express functional (full-length) NK1R, and agonistic 
signaling enhances DC longevity and their ability to promote cellular immunity.268  However, the 
capability of signaling DCs with NK1R agonists to preferentially elicit Ag-specific Th1/Tc1 
immune responses remains unclear. 
             In this study presented herein, we investigated the ability and mechanisms employed by 
signaling BMDCs with endogenous (SP and HK-1) and synthetic (SarSP) agonists for the NK1R 
to promote Th1/Tc1 responses against the model Ag ovalbumin (OVA).  Through the utilization 
of various expression systems [adenoviral transduction of BMDCs and mice transgenic for 
diphtheria toxin receptor (DTR) under the CD11c promoter and knockout for IL-12p35], we 
assessed the role of cytokines IL-12p70 and IL-10, along with the contribution of endogenous 
DC populations, in modulating Ag-specific Th1/Tc1 responses induced by the adoptive transfer 
of NK1R-signaled BMDCs. 
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3.3 MATERIALS AND METHODS 
3.3.1 Mice 
Eight- to twelve-week old wild-type C57BL/6 (B6), B6.129S1-Il12atm1Jm/J (B6.IL-12p35-/-KO), 
B6.FVB-Tg(Itgax-DTR/EGFP)57Lan/J (B6.CD11c-DTR), C57BL/6-Tg(TcraTcrb)1100Mjb/J 
(B6.OT-I) and B6.Tg(TcraTcrb)425Cbn/J (B6.OT-II) mice were purchased through The Jackson 
Laboratory.  Mice were housed in the pathogen-free animal facility of the University of 
Pittsburgh and used according to institutional guidelines.    
3.3.2 Generation of BMDCs 
BMDCs were generated by culturing mouse BM-precursors isolated from the tibiae and femurs 
of B6, B6.IL-12p35-/-KO or B6.CD11c.DTR mice for 6d in complete medium supplemented with 
GM-CSF and IL-4 cytokines (both at 1,000 U/ml) (R&D systems), as previously described.242,243  
Total CD11c+ BMDCs were purified by histodenz gradient (16% wt/vol, purity of CD11c+ cells 
≥85% as determined by FACS-analysis).  The DC morphology was confirmed in cytospins of 
purified CD11c+ cells obtained, as previously described,244 and stained with Hema-3 (Fisher). 
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3.3.3 Analysis of BMDC gene expression 
The gene expression pattern of control BMDC groups was analyzed by probing isolated total 
RNA using the Affymetrix’s Mouse Genome 430A v.2.0 arrays.  Briefly, BMDCs (3x106) were 
cultured in complete media supplemented with or without SarSP (10-9 M, 18 h).  After harvest, 
BMDCs were homogenized and isolated for RNA (Qiagen).  Total RNA sample integrity and 
quality were tested using agarose gel electrophoresis and PCR using an S15 primer set (S15-F: 
TTCCGCAAGTTCACCTACC and S15-R: CGGGCCGGCCATGCTTTACG) to detect 
potential DNA contamination.  Samples with positive PCR signal were re-digested to remove 
contaminating genomic DNA using DNase I enzyme.  Only DNA contamination-free samples 
were used for the array-experiment.  Fifteen mg of total RNA was used for each sample in one-
cycle target labeling reaction according to the recommendations of Affymetrix.  The 
hybridization (GeneChip Array Station) and scanning/data collection (GeneChip Scanner 3000) 
were done at the facilities of Genomics and Proteomics Core Laboratories of the University of 
Pittsburgh. 
Raw data collected by Affymetrix GeneChip Command Console Software (AGCC) was 
imported to Affymetrix Expression Console software and processed.  Data were sorted and better 
then p<0.05 data points were transferred into flat files.  These data-files were processed by 
Microsoft Excel to build Microsoft Access databases for analysis. 
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3.3.4 Analysis of BMDC phenotype and cytokine production 
For experiments analyzing cell-surface expression of DC maturation molecules, BMDCs were 
cultured in complete medium supplemented or not with SarSP (10-9 M, 18 h).  DCs were 
collected and FcR-blocked with anti-CD16/32 mAb (BD-PharMingen) in 10% goat serum 
(Sigma) then stained with anti-mouse Alexa Flour 488-CD11c mAb in combination with PE-
CD86, PE-I-Ab (MHC class II) or PE-CD40 mAbs (BD-PharMingen).  Negative controls 
included cells stained with species-matched isotype IgG and non-stained cells.  The cell-surface 
expression of CD11c, CD86, I-Ab and CD40 was quantified by FACS-analysis (FACSCaliburTm, 
Becton Dickinson).   
To address BMDC cytokine production, BMDCs were cultured in the presence or 
absence of SarSP (10-9 M), LPS (500 ng/ml; Sigma) or αDC1 signaling-cocktail (IFN-γ, 20 
µg/ml; polyI:C, 20 µg/ml; TNF-α 20 µg/ml and IL-1β, 20 µg/ml) (Sigma) for 18 h.  We analyzed 
the secretion of IL-12p70 (ebioscience), IL-10 (BD-PharMingen) and TGF-β1 (BD-PharMingen) 
by ELISA, according to manufacturers’ protocols, and quantified using an Emax microplate 
reader (Molecular Devices, Sunnyvale, CA). 
3.3.5 OT-II CD4+ T cell assays 
Naive CD4+ T cells were obtained from RBC-lysed spleens of transgenic OT-II mice, and 
purified by negative selection columns (R&D systems).  BMDCs were pre-treated or not with 
SarSP, SP or HK-1 (10-9 M, 18 h) then selected groups were further cultured with OVA (1 
mg/ml, 3 h).  Afterwards, OVA-loaded BMDC groups were co-cultured with CD4+ T cells at a 
ratio of 1:20 (DCs-CD4+ T cells) in 96-well round bottom plates for a period of 3 days.  Control 
groups included BMDCs co-cultured with CD4+ T cells without OVA exposure or CD4+ T cells 
pulsed with OVA.  Select DC-CD4+ T cell co-cultures were supplemented with neutralizing 
antibodies targeting IL-12p40 (C17.8, 20 μg/ml; ebioscience), IL-12p35 (C18.2, 20 μg/ml; 
ebioscience), IL-23p19 (G23.8, 20 μg/ml; ebioscience), CD40L (MR-1, 10 μg/ml; ISC 
BioExpress) and/or IFNγ (20 μg/ml; BD-PharMingen). 
For experiments analyzing CD4+ T cell proliferation, BMDC groups were -irradiated 
(2000 Gy) prior to co-culture with isolated CD4+ T cells.  For the final 18 h, wells were pulsed 
with 1 µCi (0.037 MBq) [3H] thymidine.  The amount of radioisotope incorporated was 
determined using a scintillation counter. Assays were performed in triplicate, and results are 
expressed as mean counts per minute ± 1 SD.  
To assess cell cytokine production, supernatants were collected from non-irradiated co-
cultures on day 3, and the secretion of IFN-γ (BD-PharMingen), IL-5 (ebioscience), IL-13 
(ebioscience) and IL-12p70 (ebioscience) was analyzed by ELISA using an Emax microplate 
reader. 
3.3.6 Induction of OVA-specific CD4+ T cells in vivo 
BMDCs were generated from B6 mice and were cultured with or without SarSP (10-9 M) for 18 
h, and selected groups were further incubated with OVA (1 mg/ml, 2 h).  BMDC groups were 
then extensively rinsed and adoptively transferred (footpad, s.c.; 1x106 DCs in 50 µl per footpad) 
into B6 mice (n=3 animals per group) on day 0, and in some experiments, mice received an 
additional boost on day 7 (Figure 14C and 15C).  Immunized mice receiving BMDCs without 
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OVA treatment and non-immunized mice (naïve) served as control groups.  Mice were sacrificed 
5 days after last immunization, and spleens were harvested and RBC-lysed to yield single-cell 
suspensions.  CD4+ T cells were purified by negative selection columns (R&D systems) and re-
stimulated with naïve BMDCs pulsed with or without OVA (1 mg/ml, 2 h) at a 1:20 ratio (DCs-
CD4+ T cells) in 96-well round bottom plates.  Supernatants were collected 3 days later, and the 
secretion of IFN-γ (BD-PharMingen), IL-5 (ebioscience) and IL-13 (ebioscience) was quantified 
by ELISA using an Emax microplate reader.   
To quantify the frequency of cytokine-secreting T cells, CD4+ T cells were co-cultured 
with naïve B6 BMDCs loaded with or without OVA, as described above, in 96-well ELISpot 
plates pre-coated with mAbs specific for IFN-γ (BD-PharMingen), IL-5 (ebiosciences) or IL-13 
(ebiosciences) for 18 h.  After culture, supernatants were discarded and plates were repeatedly 
washed and further incubated with biotin anti-IFNγ, IL-5 or IL-13 mAbs, followed by 
streptavidin-peroxidase inclusion, according to manufacturers’ protocols.  Plates were developed 
by adding the substrate 3-amino-9-ethylcarbazole (AEC) and spots were quantified with an 
ImmunoSpot automated counter (Cellular Technology). 
For investigations addressing the role of IL-12p70 in promoting CD4+ T cell responses in 
vivo, ELISA-based experiments were supplemented with additional groups utilizing BMDCs 
derived from B6.IL-12p35-/-KO mice and transferred into B6 and B6.IL-12p35-/-KO mice (n = 4 
mice per group). 
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3.3.7 Induction of OVA-specific CD8+ CTLs in vivo 
CD8+ CTL function induced by adoptive transfer of BMDCs was evaluated by performing an 
Ag-specific in vivo killing assay.  BMDCs generated from B6 mice were pre-treated or not with 
SarSP (10-9 M), and select groups were further cultured with OVA (1 mg/ml, 2 h) and OVA257-264 
(SIINFEKL, Sigma) (100 ng/ml, 45 min).  BMDC groups were extensively rinsed and adoptively 
transferred (footpad, s.c.; 1x106 DCs in 50 µl per footpad) into B6 mice (n=4 animals per group).  
Immunized mice without OVA and SIINFEKL exposure and non-immunized mice served as 
control groups.  Five days following immunization, the in vivo killing efficiency was assessed by 
using SIINFEKL-pulsed targets.  Briefly, naïve B6 splenocytes pulsed with SIINFEKL (250 
ng/ml, 45 min) and labeled with 5 µM CFSE (CFSEHigh) were used as target cells, while non-
pulsed B6 splenocytes labeled with 0.5 µM CFSE (CFSELow) were included as control cells.  
Target and control cells were mixed in a 1:1 ratio and transferred (tail vein, i.v.; 2x107 cells in 
200µl PBS/mouse) into immunized and non-immunized mice.  Four hours later, splenocytes 
were collected from harvested and RBC-lysed spleens.  The percentage of specific cell lysis 
(%SCL) was then calculated by using the formula:   %SCL = 100 x [(1 – (CFSElow:CFSEhigh of 
splenocytes from untreated mice)/(CFSElow:CFSEhigh of splenocytes from immunized mice))]. 
 To quantify the abundance of cytokine secretion from CD8+ T cells, the immunization 
scheme outlined above was followed with an additional boost 7 days after primary transfer.  Five 
days after last immunization, splenic CD8+ T cells were isolated from naïve and immunized 
mice.  Briefly, CD8+ T cells were purified by negative selection columns (R&D systems) and re-
stimulated  with  naïve B6  BMDCs  pulsed  with  or  without OVA (1 mg/ml, 2 h) at a 1:20 ratio  
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(DCs-CD8+ T cells) in 96-well round bottom plates for 3 days.  After culture, supernatants were 
collected, and the secretion of IFN-γ (BD-PharMingen), IL-5 (ebioscience) and IL-13 
(ebioscience) was quantified by ELISA using an Emax microplate reader. 
For investigations addressing the role of IL-12p70 in promoting in vivo CTL responses, 
in vivo killing assays were supplemented with additional groups utilizing BMDCs derived from 
B6.IL-12p35-/-KO mice and transferred into B6 and B6.IL-12p35-/-KO mice (n = 4 mice per group). 
3.3.8 Depletion of DC populations in vivo 
To deplete DCs in vivo, B6 mice transgenic for DTR expression under the CD11c promoter 
(B6.CD11c-DTR) was utilized.  BMDCs were generated from B6 or B6.CD11c-DTR mice and 
cultured with or without SarSP (10-9 M) for 18 h, followed by Ag loading with SIINFEKL (100 
ng/ml, 45 min) and/or OVA (1 mg/ml, 2 h).  To verify expression and functionality of the DTR, 
select B6.CD11c-DTR BMDC groups were cultured with diphtheria toxin (DT, Sigma) (10-7 M, 
18 h) and apoptosis was quantified by FACS-analysis of PI inclusion.  After extensive rinsing, 
B6 groups were adoptively transferred into B6.CD11c-DTR mice (n = 6 mice per group).  Select 
groups of immunized B6.CD11c-DTR mice received i.p. injection of DT (4 ng/lb of body mass; 
flank) (sigma) or PBS (control) immediately prior to adoptive transfer of B6 BMDC groups.  
ELISpot and cytotoxicity assays were performed to assess the impact of abolishing endogenous 
DC populations in mediating acquired Th1 and Tc1 responses, respectively.   
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3.3.9 Adenoviral transduction of BMDCs 
E1- E3- deleted rAds included (i) rAd-neo, lacking transgene or promoter (negative control) and 
(ii) rAd-mIL-10, encoding murine IL-10 cDNA under the control of the hCMV-MIE promoter 
[kindly provided by Paul Robbins (University of Pittsburgh) and expanded in our laboratory].  
rAd preparation was performed as previously described,243 and transduction was conducted at an 
MOI of 500 in serum-free RPMI media for 45 min.  After infection, BMDCs were cultured in 
complete media with or without SarSP (10-9 M) for 18 h or longer.    Efficiency of transduction 
was assessed by quantifying the secretion of IL-10 by ELISA (BD-PharMingen) using an Emax 
microplate reader (data not shown).  For adoptive transfer into B6 mice (n = 4 mice per group), 
transduced BMDCs were treated with 16% histodenz density centrifugation to remove any dead 
cells.  ELISpot and cytotoxicity assays were performed to assess the impact of over-expressing 
IL-10 in BMDC groups to mediate Th1 and Tc1 responses in vivo, respectively. 
3.3.10 Statistical analysis 
Statistical analysis was performed using the GraphPad Prism® 4 software (GraphPad software, 
San Diego, CA).  Differences between more than two means ± 1SD were analyzed by a one-way 
ANOVA analysis followed by a Student Newman Keuls test.  Comparisons between two 
different means ± 1SD were performed by a Student’s “t” test. A “p” value <0.05 was considered 
significant. 
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3.4 RESULTS 
3.4.1 Agonistic signaling via the NK1R enhances the immune-stimulatory function of 
BMDCs 
We have previously reported that BMDCs express the conventional full-length NK1R, and 
agonistic signaling via the receptor enhances DC longevity and their ability to elicit cellular 
immune  responses.268   To  analyze  whether  agonistic  signaling  via  the  NK1R  enhances  the  
immune-stimulatory profile of DCs, we initially investigated the ability of SarSP, a highly 
selective NK1R agonist, to promote DC maturation and modulate cytokines that favor (IL-
12p70) and inhibit (IL-10 and TGF-β1) the induction of cellular immunity. 
BMDCs cultured for 18 h in complete media were composed of mature and immature 
CD11c+ DCs, as denoted by heterogeneous cell-surface expression (percent positive, left panels 
and mean fluorescent intensity, right panels) of CD86 with moderate and low detection of MHC 
class II (I-Ab) and CD40 molecules, respectively (Figure 13A).  The expression of maturation 
molecules CD86, I-Ab and CD40 was elevated on BMDCs when cultures were supplemented 
with SarSP (10-9 M), demonstrating enhancement of DC maturation (Figure 13A). 
Supernatants from BMDC cultures were collected to determine the ability of SarSP to 
modulate secretion of the Th1/Tc1-biasing cytokine IL-12p70 and anti-inflammatory cytokines 
IL-10 and TGF-β1.  After 18 h of culture, BMDCs secreted negligible amounts of IL-12p70 in 
comparison to high levels of IL-10 and TGF-β1 production (Figure 13C and D, respectively).  In 
correlation with cDNA levels in BMDCs (Figure 13B), SarSP had no effect on IL-12p70 
modulation, while IL-10 and TGF-β1 secretion was significant inhibited in BMDC cultures 
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(Figure 13C and D, respectively).  BMDCs were capable of producing significant amounts of IL-
12p70, as detected when cultures were supplemented with LPS and a DC1 signaling-cocktail.  
LPS and DC1 cocktail stimulation inhibited production of TGF-β1, but greatly up-regulated IL-
10 production.  Addition of SarSP to these BMDC cultures slightly elevated IL-12p70 
production, while significantly reducing IL-10 and TGF-β1 secretion (Figure 13C and D, 
respectively).  
Collectively, these results demonstrate that agonistic signaling of BMDCs via the NK1R 
favors the profile of immune-stimulatory DCs: elevated levels of co-stimulatory and MHC class 
II molecules and reduced secretion of anti-inflammatory cytokines. 
 
 Figure 13:  Agonistic signaling via the NK1R enhances BMDC expression of co-stimulatory 
molecules and reduces the secretion of anti-inflammatory cytokines.   
Phenotype and cytokine analysis of BMDCs.  (A)  FACS-analysis illustrating the percent of cells 
(left panel) and mean fluorescent intensity (right panels) of CD11c+ BMDCs cultured in the 
presence (SarSP-DCs) or absence (DCs, control) of SarSP (10-9 M) expressing co-stimulatory 
molecules CD86, I-Ab and CD40.  Data is representative of 4 independent experiments.  (B)  
Modulation of genes encoding IL-12p35, IL-12p40 and IL-10 cDNA from SarSP-DCs in 
comparison to DCs (non-signaled, control). p<0.05.  (C and D) ELISA-analysis of CD11c+ 
BMDCs cultured with or without SarSP (10-9 M), LPS (600 ng/ml) and/or DC1 signaling-
cocktail (IFN-γ, 20 µg/ml; polyI:C, 20 µg/ml; TNF-α 20 µg/ml and IL-1β, 20 µg/ml) secreting 
(C) IL-12p70, (D) IL-10 (dark bars) or TGF-β1 (light bars).  (C-D) Means + 1 SD of 3 
independent experiments are displayed.  ***p<0.001.   
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3.4.2 Natural and synthetic NK1R agonists activate BMDCs with CD4+ Th1 stimulatory 
and biasing abilities in vitro and in vivo 
Induction of cellular immunity requires the ability of immune-stimulatory DCs to generate Ag-
specific type-1 T cell responses, particularly CD4+ Th1 responses.204  Due to observations 
demonstrating that SarSP enhances the immune-stimulatory features of BMDCs, we investigated 
the ability of signaling BMDCs via the NK1R to promote Ag-specific CD4+ Th1 responses using 
the model Ag OVA (1 mg/ml).  Initially, we assessed the ability of NK1R endogenous (SP and 
HK-1) and synthetic (SarSP) agonists (all at 10-9 M) to promote OVA-specific Th1 responses in 
vitro.  OVA-loaded BMDCs were used as stimulators of naive CD4+-purified OT-II T cells, 
which recognize the OVA323-339 peptide when presented in the context of I-Ab MHC class II 
molecules on the DC cell-surface.  As shown in Figure 14A and B, respectively, BMDCs loaded 
with OVA and signaled with SP, HK-1 or SarSP significantly enhanced the proliferation and 
IFN-γ secretion of CD4+ T cells in comparison to those stimulated with OVA-loaded BMDCs 
that were not stimulated with exogenous NK1R agonists (control).  The enhancement was Ag-
specific, as unloaded BMDCs were incapable of significantly inducing either CD4+ T cell 
proliferation or IFN-γ secretion.  In contrast to elevated secretion of the Th1 cytokine IFN-γ, 
NK1R agonists did not significantly modulate Th2 cytokines IL-5 and IL-13, demonstrating a 
preferential enhancement of the Th1 response (Figure 14B).   Interestingly, SarSP signaling of 
OVA-loaded BMDCs elicited the highest proliferation and IFN-γ secretion of CD4+ T cells in 
comparison to DC stimulation with NK1R physiological agonists, which could be attributed to 
greater stability of the synthetic agonist in culture or selective binding of the NK1R.   
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The relevance of our findings was further tested in vivo by adoptive transfer of BMDCs 
(DCs) vs. SarSP-signaled BMDCs (SarSP-DCs) loaded with or without OVA into B6 mice.  
Mice immunized with SarSP-DCs loaded with OVA enhanced the secretion of IFN-γ from re-
stimulated OVA-specific CD4+ T cells in comparison to those stimulated with control Ag-loaded 
DCs, while not inducing significant modulation in the production of Th2 cytokines IL-5 and IL-
13 (Figure 14C).  Together, these data demonstrate that BMDCs signaled with NK1R agonists 
promote robust Th1 responses in vitro and in vivo. 
 
 
 
 Figure 14:  Agonistic signaling via the NK1R promotes BMDCs to enhance Th1 responses 
in vivo.   
Immune-stimulatory function of BMDCs.  (A and B)  Bar-diagrams representing the (A) 
proliferation and (B) cytokine secretion [IFN-γ (black), IL-5 (white) and IL-13 (gray)] of CD4+ T 
cells (OT-II, splenic) stimulated with CD11c+ BMDCs loaded with or without OVA (1 mg/ml) 
and supplemented or not with SarSP, HK-1 or SP (all at 10-9 M).  (C)  Comparative analysis of  
splenic CD4+ T cells secreting cytokines IFN-γ (black), IL-5 (white) and IL-13 (gray) after 
adoptive transfer of OVA-loaded (or not, control) CD11c+ BMDCs signaled in the presence 
(SarSP-DCs) or absence (DCs) of SarSP.  Control groups also include splenic CD4+ T cells 
isolated from non-immunized (naïve) mice.  Isolated CD4+ T cells were re-stimulated by co-
culture with CD11c+ BMDCs loaded with OVA.  (A-C) Means + 1 SD of 4 independent 
experiments are displayed.  ***p<0.001. 
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3.4.3 NK1R-signaled BMDCs enhance Th1 responses in vivo which are dependent on 
endogenous production of IL-12 
Secretion of IL-12p70 is one of the main mechanisms known to promote Th1 responses in vitro 
and in vivo.45  Thus, we investigated the role IL-12p70 secretion serves to induce Th1 responses 
mediated by signaling BMDCs via the NK1R.  Given the importance of the DC-CD4+ T cell 
synapse to potentiate and optimize IL-12p70 production,216 we initially assessed the ability of 
BMDCs signaled with SarSP (10-9 M; SarSP-DCs) to promote IL-12p70 secretion in the context 
of OVA and in co-cultures with OT-II CD4+ T cells.  After OVA stimulation, SarSP-DCs did not 
produce significant amounts of IL-12p70 (Figure 15A).  However, SarSP-DCs loaded with OVA 
were able to up-regulate IL-12p70 secretion in co-culture with CD4+ T cells in comparison to co-
culture with control OVA-loaded DCs.  The enhanced IL-12p70 secretion in co-cultures of 
SarSP-DCs and CD4+ T cells was abrogated due to neutralization of CD40 ligation (MR-1 mAb, 
20 μg/ml), while inhibition of IFN-γ signaling (anti-IFN-γ, 20 µg/ml) did not significantly reduce 
IL-12p70 secretion (Figure 15A).  Although the levels of IL-12p70 are low in OVA-specific DC-
CD4+ T cell co-cultures, we observe that neutralizing antibodies specifically targeting the p35 
(anti-IL-12p35) and p40 (anti-IL-12p40) subunits of bioactive IL-12p70, but not the p19 subunit 
of IL-23 (anti-IL-23p19), impaired the enhanced Th1 response mediated by OVA-loaded SarSP-
DCs (Figure 15B).  These results suggest that SarSP-DCs promote Ag-specific Th1 responses in 
vitro by up-regulating IL-12p70 to a small extent during the DC-CD4+ T cell synapse. 
Due to the observations that (i) SarSP-DCs produce low levels of IL-12p70 and (ii) 
adoptively transferred DCs interact with local APC populations in vivo,74 we investigated 
whether IL-12p70 secretion in vivo is necessary to mediate the ability of adoptively transferred 
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SarSP-DCs to enhance the Th1 response, and if so, determine whether IL-12p70 is contributed 
by transferred DCs or endogenous APCs.  To address these questions, we performed a series of 
experiments utilizing CD11c+ BMDCs derived from B6 (wild-type, WT) and B6.IL-12p35-/- 
(p35-/-) mice, which were cultured in the absence (DCs) or presence (SarSP-DCs) of SarSP (10-9 
M) and loaded with OVA (1 mg/ml) prior to adoptive transfer into B6 and B6.IL-12p35-/- mice.  
As we observed before, transfer of WT-SarSP-DCs enhanced the OVA-specific Th1 response in 
comparison to transferred WT-DCs into B6 mice (Figure 15C).  The ability of SarSP-DCs to 
mount enhanced OVA-specific Th1 responses in vivo was almost completely abrogated if 
endogenous APCs could not produce bioactive IL-12p70, as indicated by a significant reduction 
in the amount of IFN-γ secreted from re-stimulated OVA-specific CD4+ T cells (Figure 15C).  In 
contrast, OVA-specific Th1 responses were only slightly diminished when p35-/--DCs were 
transferred into B6 mice, and p35-/--SarSP-DCs were still able to efficiently enhance the Th1 
response (Figure 15C).  These results demonstrate the importance of endogenous IL-12 in the 
Th1-biased observed under our experimental conditions. 
 
 Figure 15:  SarSP-DCs enhance Ag-specific Th1 responses in vivo which are dependent on 
endogenous production of IL-12.   
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(A) Bar-diagrams representing secretion of IL-12p70 in co-cultures of CD11c+ BMDCs 
loaded with OVA (1 mg/ml) in the presence or absence of SarSP (10-9 M) and CD4+ T cells (OT-
II, splenic).  Select co-cultures were supplemented or not with neutralizing antibodies targeting 
CD40 ligation (MR-1, 20 µg/ml) and/or IFN-γ (anti-IFN-γ, 20 µg/ml).  (B)  Comparative 
analysis of IFN-γ production in co-cultures of CD4+ T cells (OT-II mice, splenic) and OVA-
loaded CD11c+ BMDCs signaled in the absence (DCs, light bars) or presence (SarSP-DCs, dark 
bars) of SarSP.  Select co-cultures were supplemented with or without neutralizing antibodies 
specific to IL-12p35 (C18.2 20 µg/ml), IL-12p40 (C17.8, 20 µg/ml) and IL-23p19 (G23.8, 20 
µg/ml).  (C)  Bar-diagrams illustrating IFN-γ secretion form OVA-specific CD4+ T cells isolated 
from spleens of wild-type (B6, dark bars) or IL-12 deficient (B6.IL-12p35-/-, light bars) mice that 
were non-immunized (naïve, control) or immunized with B6 (WT) or B6.IL-12p35-/- (p35-/-) 
CD11c+ BMDCs signaled in the absence (DCs) or presence (SarSP-DCs) of SarSP.  Isolated 
CD4+ T cells were re-stimulated by co-culture with B6 CD11c+ BMDCs loaded with OVA.  (A-
C) Means + 1 SD of 3 independent experiments are displayed.  ***p<0.001. 
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3.4.4 NK1R-signaled BMDCs potentiate CD8+ CTL/Tc1 responses in vivo which are 
mainly dependent on the production of IL-12 
In addition to Ag-specific CD4+ Th1 immune responses, cellular immune responses are 
characterized by induction of functional CD8+ CTL responses that are biased to the Tc1 
phenotype.204,209  Initially, we investigated whether BMDCs signaled via the NK1R elicit OVA-
specific cytotoxic responses in vivo.  BMDCs were cultured in the absence (DCs) or presence 
(SarSP-DCs) of SarSP (10-9 M) then loaded with or without OVA (1 mg/ml) and SIINFEKL 
(SIINFEKL, 100 ng/ml) prior to adoptive transfer into B6 mice.  In comparison to adoptively 
transferred control DCs, SarSP-DCs elicited higher Ag-specific cell killing of targets (Figure 
16A).  Non-immunized mice (naïve) and mice immunized with non-loaded DCs did not elicit 
OVA-specific cell killing, suggesting the involvement of Ag-specific effector CTLs.  Effector 
CD8+ T cells mediated by adoptive transfer of Ag-loaded SarSP-DCs induced higher secretion of 
IFN-γ with little modulation of Tc2 cytokines IL-5 and IL-13, suggesting the enhancement of a 
biased Tc1 response (Figure 16B). 
 Since adoptive transfer of SarSP-DCs favors a Tc1 response, we addressed the role of IL-
12p70 contribution by transferred DCs and endogenous APCs.  IL-12p70 production provided by 
both endogenous APCs and transferred DCs was required to elicit optimal Ag-specific CTL 
responses mediated by SarSP-DCs, as depicted by reduced cytotoxicity of targets in vivo upon 
adoptive transfer of p35-/--SarSP-DCs into B6 and B6.IL-12p35-/- mice (Figure 16C). 
 Figure 16:  SarSP-DCs enhance Ag-specific CD8+ CTL/Tc1 responses in vivo which are 
mainly dependent on the production of IL-12.   
(A)  Comparative analysis of in vivo cytotoxicity assays induced by adoptive transfer of CD11c+ 
BMDCs cultured without (DCs) or with (SarSP-DCs) SarSP (10-9 M) then  loaded with or 
without OVA (1 mg/ml) and SIINFEKL (250 µg/ml).  (B)  Bar-diagrams representing cytokine 
secretion [IFN-γ (black), IL-5 (white) and IL-13 (gray)] of CD8+ T cells isolated from spleens of 
non-immunized mice (naïve) and immunized mice adoptively transferred with OVA/SIINFEKL-
loaded CD11c+ BMDCs cultured without (DCs) or with (SarSP-DCs) SarSP.  Isolated CD8+ T 
cells were re-stimulated by co-culture with CD11c+ BMDCs loaded with OVA and SIINFEKL. 
(C)  Comparative analysis of in vivo cytotoxicity assays induced by adoptive transfer of B6 
(WT) or B6.IL-12p35-/- (p35-/-) CD11c+ BMDCs cultured in the absence (DCs) or presence 
(SarSP-DCs) of SarSP and loaded with OVA and SIINFEKL into B6 (dark bars) or B6.IL-
12p35-/- (light bars) mice.    (A-C)  Means + 1 SD of 3 independent experiments are displayed.  
***p<0.001. 
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3.4.5 Endogenous DC populations are required to amplify Th1 and CTL responses 
mediated by adoptive transfer of NK1R-signaled BMDCs  
Local DC populations likely contribute the requirement of endogenous IL-12p70, as specific 
endogenous DC populations are highly efficient in capturing Ag and producing IL-12p70.45,95,96  
Therefore, we investigated the role endogenous DCs play by abrogating their presence in vivo 
during adoptive transfer of BMDCs signaled without (DCs) or with (SarSP-DCs) SarSP to 
determine their impact on acquired OVA-specific Th1 and CTL responses.  Utilizing mice 
transgenic for the DTR under the CD11c promoter, we are able to selectively deplete 
endogenous DC populations expressing DTR when DT is administered via i.p. injection.   
BMDCs derived from DTR mice (DTR+DCs) express similar levels of CD11c and 
maturation molecules CD86 and MHC class II molecules on their cell surface as wild-type 
BMDCs (data not shown), suggesting that the incorporation of DTR does not alter the generation 
or the immune-stimulatory phenotype of BMDCs.  DTR+DCs generated from DTR mice 
undergo significant apoptosis when DT (10-7 M) is supplemented to BMDC cultures for 18 h, 
and furthermore, we observe that addition of pro-survival SarSP was incapable of preventing 
cell-death induced by DT (Supplementary Figure 1; Appendix A).   
When endogenous DC populations from recipient DTR mice were depleted during 
adoptive transfer of OVA-loaded DCs and SarSP-DCs, adoptively transferred BMDC groups 
were not able to induce robust Th1 and CTL responses in vivo (Figure 17A and B, respectively).  
Interestingly, killing endogenous DC populations had a greater impact on Th1/CTL responses 
mediated by OVA-loaded DCs, while OVA-loaded SarSP-DCs still were capable of mounting 
significantly higher Th1 and CTL responses.  These results demonstrate that endogenous DC 
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populations play a crucial role in amplifying Th1/Tc1 responses induced by SarSP-DCs, and 
other mechanisms may be at hand to account for the ability for SarSP-DCs to stimulate enhanced 
Th1 and CTL/Tc1 immunity in vivo.  
 
 
 
 Figure 17:  Survival of endogenous DC populations is crucial to mediate robust Ag-specific 
Th1 and CTL responses induced by adoptively transferred SarSP-DCs. 
(A and B) Comparative analysis of (A) frequency of re-stimulated splenic CD4+ T cells secreting 
IFN-γ and (B) in vivo cytotoxicity assays induced by adoptive transfer of DCs or SarSP-DCs 
loaded with (A) OVA or (B) OVA and SIINFEKL into B6 mice pre-treated (i.p.) with PBS 
(control, 0 h; dark bars) or DT (10-7 M, 0 h; light bars).  (A-B) Means + 1 SD of 3 independent 
experiments are displayed.  ***p<0.001, **p<0.005. 
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3.4.6 NK1R signaling favors enhanced Th1 and Tc1 responses by inhibiting the secretion 
of IL-10 from adoptively transferred BMDCs 
Due to the observations that SarSP significantly inhibits the secretion of IL-10 from BMDCs in 
vitro, and adoptive transfer of genetically-modified BMDCs expressing IL-10 promotes 
tolerance;269,270 we investigated the impact of over-expressing IL-10 to abrogate the ability of 
SarSP-DCs to mount enhanced Th1 and CTL responses in vivo.  BMDCs transduced with 
adenoviral vector encoding mIL-10 cDNA (500 MOI) secrete high levels of IL-10 (rAd_IL-10) 
and reduce expression of CD86 and MHC class II molecules in comparison to DCs transduced 
with an empty vector (rAd_neo, control), demonstrating functionality of rAd_IL-10.271  
Furthermore, we observe that SarSP-DCs transduced with rAd_IL-10 were no longer able to 
abrogate IL-10 secretion (data not shown). 
Adoptive transfer of OVA- or OVA/SIINFEKL-loaded BMDCs transduced with rAd_IL-
10 significantly reduced OVA-specific Th1 (Figure 18A) and CTL (Figure 18B) responses in 
vivo, respectively, in comparison to BMDCs transduced with rAd_neo.  Furthermore, SarSP-
DCs over-expressing IL-10 were no longer able to exhibit significant increases (p>0.05) in Th1 
and CTL responses when compared to control Ag-loaded DCs (rAd_IL-10) (Figure 18A and B, 
respectively). Collectively, these results suggest that SarSP-DCs, when no longer capable of 
inhibiting IL-10, do not promote robust and enhanced Ag-specific Th1 and CTL/Tc1 immunity 
in vivo. 
 Figure 18:  Over-expression of IL-10 inhibits the ability of SarSP-DCs to promote 
enhanced Ag-specific Th1 and CTL responses in vivo. 
(A and B)  Bar-diagrams illustrating the (A) frequency of re-stimulated splenic CD4+ T cells 
secreting IFN-γ and (B) in vivo cytotoxicity assays induced by adoptive transfer of Ag-loaded 
[(A) OVA, (B) OVA and SIINFEKL] and transduced (rAd_neo, dark bars; rAd_IL-10, light 
bars) DCs or SarSP-DCs into B6 mice.  (A-B) Means + 1 SD of 3 independent experiments are 
displayed.  ***p<0.001. 
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3.5 DISCUSSION 
DCs are often used in immune-stimulatory therapies due to their ability to generate potent T cell 
immunity.76  However, the mechanisms by which adoptively transferred DCs promote Th1/Tc1 
responses in vivo have not been fully explored.  Recent studies suggest that in addition to the 
survival and immune-stimulatory profile of adoptively transferred DCs, their ability to activate 
and cross-prime endogenous DCs is vital for optimal induction of Th1/Tc1 responses in vivo.74 
Recently, it has been demonstrated that pro-inflammatory neuropeptides from the 
tachykinin family, including SP and HK-1, play crucial roles in favoring the induction and 
amplification of Th1 and Tc1 cells.84,187,188  Due to the observations that DCs are potent inducers 
of naïve T cells and lie in close proximity to sources of tachykinins (i.e., nerve-fiber terminals 
and immune cells),122,194,195 we hypothesized that agonistic binding of the NK1R favors immune-
stimulatory function of DCs, which will result in efficient generation of Ag-specific Th1/Tc1 
responses.  Indeed, it has been reported that NK1R ligands induce nuclear translocation of the 
pro-inflammatory NF-κB transcription factor,201 which is involved in the up-regulation of co-
stimulatory and MHC class molecules and the Th1/Tc1-biasing IL-12p70 cytokine.  However, 
the ability of NK1R ligands to promote immune-stimulatory features of DCs that are ideal for 
DC-based immune-therapies has not been investigated. 
In the present work, using a model of ex vivo-generated BMDCs, we demonstrate that 
agonistic signaling via the NK1R enhances the maturation of BMDCs and inhibits the secretion 
of anti-inflammatory cytokines IL-10 and TGF-β1, without modulating IL-12p70 production 
significantly.  Interestingly, NK1R agonists were able to slightly enhance IL-12p70 secretion 
mediated by pro-inflammatory mediators derived from peripheral and lymphoid tissues.  Our 
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results illustrate that while typical Th1/Tc1-inducing factors, including TLR agonists and DC1 
signaling-cocktail, produce paramount levels of IL-12p70; these stimulated BMDCs significantly 
enhance the secretion of IL-10 but not TGF-β1.  It is well appreciated that high levels of IL-10 
circumvent the induction of potent Th1/Tc1 cells, and DCs producing robust IL-10 may 
represent a major drawback in DC-based immune-stimulatory therapies.272   
Due to the unique ability of NK1R ligands to down-regulate IL-10 and up-regulate IL-
12p70 under certain pro-inflammatory conditions, we hypothesized that NK1R-signaled BMDCs 
may serve as beneficial adjuvants in biasing Th1/Tc1 responses in vivo.  Adoptive transfer of 
NK1R-signaled BMDCs elicits enhanced Th1/Tc1 responses.  Although exogenous IL-12p70 
produced by our conditioned-DCs is negligible, endogenous IL-12p70 is required for the ability 
of NK1R-signaled BMDCs to elevate Th1/Tc1 responses in vivo, suggesting the activation and 
passage of Ag to endogenous APCs.  In our experiments, endogenous IL-12p70 could be 
provided by DCs during T cell priming or during maintenance of the Th1 response by IFN-γ-
activated macrophages in peripheral tissues.  It is likely that IL-12p70 secretion is mainly 
attributed to DCs, as DC populations present in lymphoid tissues have been described to be 
potent contributors of IL-12p70 secretion and cross-priming.4,45  Likewise, we observe that if 
endogenous DC populations were abrogated in our hosts, and consequently are incapable of 
cross-presenting Ag and producing IL-12p70, adoptively transferred NK1R-signaled BMDCs 
induce severely impaired Ag-specific Th1/Tc1 responses in vivo.  Due to the observations that 
both DCs derived from migratory and lymphoid tissues capture and transfer Ag and are capable 
of directly priming and sustaining CD4+ and CD8+ T cell responses;89,98 future studies are 
required to determine which endogenous DC populations are responsible for Th1/Tc1 responses 
mediated by adoptive transfer of NK1R-signaled BMDCs and their ability to produce IL-12p70. 
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While the ability and necessity of NK1R agonists to signal adoptively transferred 
BMDCs to secrete IL-12p70 in vivo is less clear, their ability to down-regulate IL-10 production, 
and subsequently, favor potent Ag-specific Th1/Tc1 responses is evident.  We found that over-
expressing IL-10 in BMDCs significantly reduces acquired Ag-specific Th1/Tc1 responses, and 
importantly, transfer of NK1R-signaled BMDCs is no longer able to engender increases in 
comparison to non-signaled BMDCs.  It will be interesting to determine whether reduced IL-10 
secretion allows for greater activation and presentation of Ag to endogenous DC populations, 
and additively, enhances IL-12p70-responsiveness in developing Th1 and Tc1 cells.  
In conclusion, we provide evidence that signaling BMDCs via the NK1R with pro-
inflammatory tachykinins enhances the immune-stimulatory function of DCs to promote Ag-
specific Th1/Tc1 responses in vivo, which are dependent on their ability to inhibit IL-10 
secretion and promote immune-stimulatory interactions with endogenous DC populations.  Our 
data provide insight into the mechanisms by which adoptively transferred DCs promote Th1/Tc1 
responses in vivo, and help to elucidate ideal parameters when designing adjuvants for DC-based 
immune-stimulatory therapies.  
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4.0  CHAPTER FOUR:  SUMMARY 
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4.1 SIGNALING DENDRITIC CELLS VIA THE NK1R 
Tachykinins are now appreciated to be secreted from both neuronal and non-neuronal sources in 
peripheral and lymphoid immune-competent organs.123,158  As most immune cells express the 
NK1R and secrete NK1R agonists, tachykinins have been implicated in the modulation of 
cellular immunity.159-162  DCs are essential for cellular immunity; however, the ability of 
tachykinins signaling via the NK1R to exert the immune-stimulatory function of DCs remains 
elusive.  Our studies have allowed us to develop a model describing the ability and means by 
which NK1R agonists promote the T cell-stimulatory function of DCs (Figure 19).   
DCs, comprised of both immature and mature cells, express the functional full-length 
NK1R variant on their cell-surface.  DCs up-regulate the NK1R during inflammatory events, 
which often coincides with elevated secretion of SP, enabling DCs to be susceptible to further 
NK1R signaling.  As endogenous (SP and HK-1) and synthetic (SarSP) agonists ligate the full-
length NK1R, G proteins are able to interact with the C-terminus tail and intracellular loops of 
the receptor to mediate relevant immune function in DCs.  For example, signaling DCs via the 
NK1R activates the PI3K-Akt intracellular pathway, leading to increased cell longevity.  
Additionally, NK1R signaling enhances the maturation and pro-inflammatory capacities of DCs, 
as determined by elevated expression of cell-surface molecules CD86, CD40 and I-Ab and 
diminished secretion of anti-inflammatory cytokines IL-10 and TGF-β1.  NK1R-signaled DCs 
are capable of producing the Th1-biasing cytokine IL-12p70 during the DC-CD4+ T cell synapse, 
although at low levels.  In concert with enhanced cell survival and immune-stimulation mediated 
by NK1R signaling of DCs, these NK1R-signaled DCs are able to prime and generate enhanced 
Ag-specific CD4+ Th1 and CD8+ CTL/Tc1 responses.  
 Figure 19:  Proposed model for the role NK1R agonists mediate in modulating DC 
immune-stimulatory function. 
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4.2 INTERPLAY OF EXOGENOUS AND ENDOGENOUS DENDRITIC CELLS AND 
TYPE-1 T CELL IMMUNITY 
Adoptive transfer experiments utilizing NK1R-signaled DCs illustrate the immune-relevance of 
our previous findings.  NK1R-signaled DCs exhibit enhanced longevity and promote robust Ag-
specific type-1 DTH.  Mechanistic analysis demonstrates that endogenous DCs play essential 
roles in amplifying the ability of adoptively transferred NK1R-signaled DCs to induce robust 
Th1/Tc1 responses (Figure 20), which are crucial for the stimulation of effector cellular 
immunity.  
After adoptive transfer, NK1R-signaled DCs are able to home into DLNs where they 
survive longer because they are far less susceptible to Ag-dependent and -independent clearance 
from DLNs.  Our results show that the CD40 molecule, likely expressed by activated CD4+ T 
cells, synergizes with NK1R signaling to promote DC survival and prolong the longevity of 
NK1R-signaled DCs in DLNs.  The consequences of enhancing cell longevity of immune-
stimulatory DCs could be attributed to enhanced duration of direct Ag presentation to specific T 
cells and/or (ii) greater spreading of Ag and interaction with endogenous DC populations.  From 
our data, we conclude that the interaction between adoptively transferred DCs and endogenous 
DCs is crucial.  Whereas the presence of endogenous DCs is necessary to amplify Th1/Tc1 
responses, likely via IL-12p70 production; adoptively transferred DCs are still vital to control the 
microenvironment of the DC-T cell interaction as demonstrated by a crucial role of IL-10 
secretion in modulating the outcome of Th1 and Tc1 responses.  It could be postulated that 
adoptively transferred NK1R-signaled DCs migrate to DLNs and prime T cell responses, while 
spreading Ag to endogenous DC populations in lymphoid-tissues to further amplify the response.  
The ability of NK1R-signaled DCs to inhibit IL-10 secretion warrants further investigation to 
determine the outcome on the immune-stimulatory function of endogenous DC populations.  
Furthermore, since Ag-loaded NK1R-signaled DCs survive longer, it will be interested to 
elucidate whether their enhanced survival, coupled with reduced IL-10 secretion, leads to more 
efficient activation and transfer of Ag to endogenous DC populations or direct priming of T cells 
in DLNs.  Such experiments are currently being performed in our lab using the DTR model. 
  
 
 
Figure 20:  Possible mechanisms mediated by adoptive transfer of NK1R-signaled DCs to 
promote robust Th1/Tc1 responses in vivo. 
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4.3 CLINICAL IMPLICATIONS 
The novel findings presented herein bring in accountability of pro-inflammatory neuropeptides 
to orchestrate cellular immune responses, particularly by eliciting immune-stimulatory DCs to 
promote robust type-1 T cell responses.  Signaling DCs via the NK1R favors cell survival and 
potent Th1/Tc1 responses, demonstrating their potential application for immune-stimulatory 
therapies utilizing adoptive transfer of DCs or targeting DCs in vivo.  Therefore, the results 
obtained are highly relevant to the fields of vaccination and immune-therapies for tumor, 
infectious diseases and chronic inflammatory and autoimmune disorders.  
Likewise, we are currently investigating the ability of exogenous and endogenous NK1R 
agonists to signal DCs to promote anti-tumor immunity.  Manske and colleagues have provided 
initial studies demonstrating the ability of exogenous NK1R agonists to induce anti-tumor 
immunity and prevent tumor growth in a murine model of melanoma; an effect that was mainly 
mediated by T cells.273  In our unpublished findings, we observe that mice devoid of endogenous 
NK1R agonistic signaling (B6.NK1R-/-KO mice) are unable to elicit robust Th1 and CTL/Tc1 
responses against tumor-associated Ag and inhibit tumor growth in comparison to wild-type 
mice (manuscript submitted).  In this study, it is unknown whether endogenous NK1R agonists 
signal DCs to enhance Ag-specific type-1 T cell responses, or alternatively, directly ligate 
developing CD4+ and CD8+ T cells.  If the former occurs, it would be interesting to specifically 
target NK1R agonists to desired endogenous DC populations in vivo to elicit optimal anti-tumor 
immunity.  Since tumor cells express NK1R and agonistic signaling via the receptor induces 
tumor growth and survival,274,275 applying NK1R agonists systemically could inhibit the ability 
of the immune system to eradicate established tumors.  Thus, it may be important to administer 
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NK1R agonists away from the tumor micro-environment, while utilizing reagents to inhibit 
NK1R signaling directly on the tumor cells.  Indeed, previous studies support the concept of 
employing NK1R antagonists or over-expressing tachykinin-degrading enzymes (i.e., NEP) in 
the tumor-microenvironment.  NK1R antagonists have been shown to induce apoptosis of 
various tumor cell lines.276-278  In most forms of cancer, NEP expression is usually reduced,279 
and subsequently, studies show that increasing NEP activity on tumor cells leads to the 
prevention of survival and proliferative effects induced by NK1R agonists.280  In addition to 
application of NK1R agonists to DCs or NK1R inhibitory reagents in the tumor micro-
environment, it may be possible to increase endogenous levels of NK1R agonists by promoting 
the production of Th1-inducing (IL-12p70) and Th1 (IFN-γ and IL-2) cytokines, while inhibiting 
anti-inflammatory cytokines (IL-10 and TGF-β1) and neuropeptides (NPY, POMC derivatives, 
adrenomedullin, somatostatin, cortistatin and urocortin).130,234,281-283   
Alternatively, abrogation of NK1R signaling could be beneficial for immune-inhibitory 
therapies targeting chronic inflammatory and autoimmune disorders and T cell-mediated 
rejection in transplantation.  We have begun studies pioneering the ability of the NK1R 
antagonist (L-733,600) to block human and murine allogeneic CD4+ and CD8+ T cell responses 
mediated by DCs (manuscript in preparation).  It is important to note that the pathogenesis of 
various inflammatory and autoimmune disorders is associated with over-expression of NK1R 
and its agonists, leading to enhanced and sustained survival, chemotaxis and activation of 
immune cells.186,284,285   In a model of Th1-type colitis in IL-10-/- mice, NK1R agonists promote 
chronic inflammation, and the use of NK1R antagonists are able to reverse the ongoing 
inflammation.185  Moreover, evidence supports the notion that NK1R agonists contribute to 
inflammatory T cell responses in CNS autoimmunity, and abrogation of endogenous NK1R 
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signaling leads to impairment of disease serverity.234,286,287  Further investigation is warranted to 
determine the ability of NK1R antagonists and tachykinins binding anti-inflammatory NK2R and 
NK3R to signal DCs in vivo for the purpose of inducing tolerance towards self-Ag in 
autoimmune disorders and allograft acceptance in transplantation.   
4.4 FINAL STATEMENT 
The studies discussed in this dissertation have allowed us to conclude that pro-inflammatory 
tachykinins signaling DCs via the NK1R induce cell survival and immune-stimulatory function, 
ultimately leading to the generation of potent type-1 T cell immunity in vivo.  Due to the 
potential of DC-based vaccines for immune-therapies, further investigation is required to 
determine the efficacy of targeting exogenous and endogenous DCs via the NK1R to serve as 
adjuvants to promote immune-stimulation against tumors and intracellular infections.  
 
APPENDIX A  
 
Supplementary Figure 1:  NK1R signaling of BMDCs expressing DTR are not rescued 
from DT-induced apoptosis.  
Apoptosis of BMDCs generated from B6.CD11c.DTR mice as assessed by FACS-analysis of PI 
(50 µg/ml) inclusion.  CD11c+DTR+DCs were cultured with or without SarSP (10-9 M) and/or 
DT (10-7M) for 18 h.  Means (+ SD) of 3 independent experiments are shown.  ***p<0.05 
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APPENDIX B 
In Vivo Signaling through the Neurokinin 1 Receptor Favors Transgene Expression by 
Langerhans Cells and Promotes the Generation of Th1- and Tc1-Biased Immune 
Responses 
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Abstract 
The pro-inflammatory capacities of the skin and the presence of high numbers of resident 
dendritic cells (DCs) constitute an ideal microenvironment for successful immunizations.  
Regardless of the ability of DCs to respond to local inflammatory signals in an immune-
stimulatory fashion, the immune functions of skin resident DCs remain controversial, and 
epidermal Langerhans cells (LCs) have been referred to recently as anti-inflammatory / pro-
tolerogenic APCs. Substance P (SP) released by skin nerve fibers, is a potent pro-inflammatory 
neuropeptide that favors development of skin associated cellular immunity.  SP exerts its pro-
inflammatory functions by binding with high affinity to the neurokinin 1 receptor (NK1R).  Here 
we tested whether signaling skin cells via the NK1R promotes humoral and cellular immunity 
during skin genetic immunizations.  We utilized the gene gun to deliver transgenic (tg) Ag to the 
skin of C57BL/6 mice and the selective NK1R agonist [Sar9Met(O2)11]-SP as a potential pro-
inflammatory Th1-biasing adjuvant.  Our strategy expressed tg Ag exclusively in the epidermis 
and induced a preferential migration of activated LCs to skin draining lymph nodes (sDLNs). 
Local administration of the NK1R agonist during skin genetic immunizations increased 
significantly the expression of tg Ag by a mechanism involving the translocation of NF-κB into 
the nuclei of cutaneous DCs homing to sDLNs. Importantly, our immunization approach resulted 
in Th1 and Tc1 bias of effector T cells that supported cellular and Ab-mediated immune 
responses. We demonstrate that signaling skin cells via the NK1R provides the adjuvant effect 
which favors the immunostimulatory functions of LCs.  
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Introduction  
Efficient vaccine approaches for tumors and infectious diseases are designed to induce CD8+ T 
cytotoxic (CTL) -1 (Tc1) lymphocytes that are able to eliminate intracellular pathogens and 
neoplasic cells, and CD4+ T helper 1 (Th1) lymphocytes that support cellular immunity and CTL 
memory.288-293   
 The most efficient immunization methods to generate Th1 and Tc1 immunity rely on the 
direct administration of Ag to the skin, a highly immunogenic organ populated by dendritic cells 
(DCs), including epidermal Langerhans cells (LCs), dermal DCs (DDCs), and a pool of DC 
precursors.80,81,294  It is currently believed that, as professional APCs, skin-resident DCs are 
extremely efficient at (i) sensing the presence of pro-inflammatory mediators in their 
microenvironment; (ii) acquiring/processing extracellular Ag; (iii) transporting Ag from the skin 
to the skin draining lymph nodes (sDLNs); and iv) priming and biasing the differentiation of 
naïve CD4+ and CD8+ T cells into effector cells.1,80,295   
 In addition to their role during the initiation of acquired immunity, the skin cells and 
nerve endings release pro-inflammatory mediators including cytokines, hormones, and 
neuropeptides, which influence the immunostimulatory function of resident DCs.295,296  Pro-
inflammatory neuropeptides from the innate immune system are released immediately following 
skin injury.  Interestingly, epidermal LCs make physical contact with peripheral nerve δ fibers 
that secrete Substance P (SP) and Calcitonin Gene Related Peptide (CGRP).297,298  
 SP and the more recently described hemokinin-1 (HK-1) belong to the family of pro-
inflammatory neuropeptides known as tachykinins.  SP and HK-1 bind with high affinity the 
neurokinin 1 receptor (NK1R) and with low affinity the NK2R and NK3R.110,134,299,300  Binding 
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of the NK1R on naïve CD4+ T cells promotes proliferation, Th1 differentiation, and cellular 
immunity, whereas binding the NK2R inhibits the development of inflammatory 
responses.110,160,197,301,302  In the skin, signaling through the NK1R with SP or NK1R agonists 
prevents cutaneous tolerance induced by UV-B light and favors delayed type hypersensitivity 
(DTH) reactions through the release of IL-12p70, a potent Th1-biasing cytokine.160,237  Together, 
these observations highly suggest that signaling via the NK1R during the initiation of skin-
mediated immune responses will favor development of Th1 effector immunity.  
 Due to the accessibility of the skin immune system and the ease of targeting the 
epidermis, genetic immunizations by the gene gun (GG) have been used as an appropriate 
vaccination method to promote the generation of CTL immunity directed to transgenic (tg) 
Ag.303-306  However, there is increasing evidence that skin GG immunizations administered 
without Th1-biasing adjuvants generates Th2 effector cells, which are unable to sustain cellular 
immunity and CTL memory.293,307-310  The absence of Th1 responses following skin GG 
immunizations can be ascribed to either: i) lacking of a Th1-biasing adjuvant effect; or ii) 
delivery of tg Ag almost exclusively to epidermal LCs, which have been described recently as 
tolerogenic / anti-inflammatory skin DCs.311-314  Thus, for the purpose of skin genetic 
immunizations it would be relevant to determine whether: (i) administration of pro-inflammatory 
Th1-Tc1-biasing adjuvants provide LCs with the appropriate stimulus to favor effector cellular 
immunity during GG immunizations; or (ii) genetic immunizations should target exclusively 
DDCs, described as the most potent skin resident APCs.315-317  
 In the present work, we tested whether local administration of an NK1R agonist provides 
a Th1 adjuvant effect to favor the ability of skin DCs to induce Th1-Tc1 immunity during skin 
GG immunizations.  We used the synthetic NK1R agonist [Sar9Met(O2)11]-SP (NK1R agonist), a 
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highly stable SP derivative that binds exclusively to the NK1R but not to NK2R or NK3R.  We 
show that, after GG immunization, the expression of tg Ag was limited to the epidermis and 
sDLNs, and that the expression of tg protein was significantly increased by simultaneous 
administration of the NK1R agonist.  Mechanistic studies demonstrated that the NK1R agonist 
promoted acute inflammation in the skin, which correlated with rapid migration of epidermal 
LCs and their increased homing to sDLNs.  Molecular analysis revealed that the NK1R agonist 
favored the activation of skin LCs as determined by the high expression of cell-surface I-Ab 
molecules and the translocation of NF-κB into the nuclei of GG transfected LCs homed to 
sDLNs.  Importantly, our immunization approach stimulated efficient Ag specific humoral as 
well as Th1/Tc1-biased and CTL responses that supported effector cellular immunity as 
demonstrated in vivo by DTH assays.  
Material and Methods  
Mice 
Female C57BL/6 (B6) mice were purchased from The Jackson Laboratories (Bar Harbor, Maine) 
and used between the ages of 6 and 12 weeks.  Mice were housed under specific-pathogen-free 
conditions and treated according to the University of Pittsburgh’s institutional animal care 
guidelines. 
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Genetic immunization 
A He-powered (300 psi) GG was used to deliver naked plasmid DNA precipitated onto 1µm gold 
particles (Bio-Rad Laboratories, Hercules, CA) to the skin of B6 mice, as previously 
described.306  The following plasmids encoding reporter proteins or the model Ag chicken OVA 
under control of the human IE-CMV promoter used in this study have been previously 
described:244 i) pCMV-Luc encoding firefly luciferase (Luc); ii) pCMV-EGFP encoding the 
enhanced version of the green fluorescent protein (EGFP); and iii) pCMV-OVA-TR encoding 
the membrane-bound form of chicken OVA.  The plasmid pNFκB-Luc encoding Luc 
downstream of 4 tandem copies of the NF-κB consensus sequence fused to a TATA-like 
promoter region from the Herpes simplex virus thymidine kinase promoter was purchased from 
Clontech (Mountain View, CA).  Genetic immunizations with the GG were performed by 
delivery of 2 overlapping shots on the abdominal (shaved) skin.  Where indicated, mice were 
pre-treated with the synthetic NK1R agonist [Sar9Met(O2)11]-SP (BACHEM Bioscience Inc., 
King of Prussia, PA) or the non-peptide NK1R antagonist L733060 (Tocris Bioscience, 
Ellisville, MO) both at 10 nmol/100 μl PBS/per dose, administered i.d. locally immediately 
before immunization.  
Luciferase assays 
Detection of Luc was performed by luminescence in samples of skin of identical size, excised 
from the area transfected with the GG, and sDLNs.  Luc assays were performed using the Luc 
Assay System (Promega, Madison, WI), as previously described.244,303  The luminescence was 
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assessed in triplicates in 96-well plates using the Lmax luminometer (Molecular Devices, 
Sunnyvale, CA).  Results were expressed as Relative Luminic Units (RLU) per each sample 
analyzed.   
Histological analysis of skin and lymph nodes  
For histological analysis, skin samples and LNs were fixed in 4% formaldehyde/PBS solution.  
Twenty four h later tissues were processed and embedded for H&E staining.  Skin and LN 
sections were analyzed by light microscopy using an Axiovert microscope (Carl Zeiss 
MicroImaging, Inc., Thornwood, NY).  
Preparation of epidermal sheets and single cell suspensions from epidermis and lymph nodes  
Epidermal and dermal sheets were obtained by incubating the dorsal half of the ears (free of 
cartilage) in 0.02M EDTA/PBS pH 7.5, for 2 h at 37ºC.  After incubation, the epidermis was 
dissected from the dermis with fine forceps under a microscopic examination.  Unlike enzymatic 
digestions, EDTA treatment of the skin allows a clean separation of the epidermal/dermal 
junction and allows the purification of LCs without contamination with DDCs.  To obtain 
epidermal single-cell suspensions, the epidermis was dissected as described and incubated with 
0.25% trypsin / EDTA (Gibco, Grand Island, NY) for 15 min at 37ºC with continuous shaking.  
Trypsin activity was neutralized with FBS and single cell suspensions were obtained by vigorous 
pipetting (4°C) followed by filtration through a 70 µm cell-strainer (Falcon, Becton Dickinson 
Diagnostic Systems, Franklin Lakes, NJ).  Single cell suspensions from LNs were prepared by 
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teasing apart the tissue with 18-gauge needles followed by incubation in 1mg/ml collagenase 
(Sigma, St Louis, MO) and 0.02 mg/ml DNase I (Roche), 30 min at RT.  Further cellular LN 
dissociation was accomplished by adding 1M EDTA during the last 5 min of incubation followed 
by filtration through a 70 µm cell-strainer (Falcon, Becton Dickinson). 
Immunofluorescence staining of skin samples and lymph nodes 
For assessment of LCs in epidermis, epidermal sheets were fixed in cold acetone (15 min at -
20°C), washed in PBS, blocked with 10% normal goat serum in PBS, and incubated with biotin 
anti-DEC-205 mAb (clone NLDC-145, Cedarlane Laboratories Ltd. Hornby, Ontario, Canada) 
followed by Cy3-streptavidin (Jackson ImmunoResearch, West Grove, PA).  Epidermal sheets 
were mounted on slides with the dermal side up for microscopic evaluation. 
 For labeling of frozen tissues, samples of skin and LNs were embedded in Tissue-Tek 
OCT (Miles Laboratories, Elkhart, IN), snap frozen in pre-chilled methyl-butane (Sigma) and 
stored at -80°C until use.  Cryostat sections (8 μm) were mounted onto slides pre-treated with 
Vectabond (Vector Laboratories, Burlingame, CA), air-dried, and fixed in cold 96% ethanol (10 
min).  Tissue sections were blocked with 10% normal goat or donkey serum in PBS and the 
avidin/biotin blocking kit (Vector).  For co-detection of CD11c and NK1R in skin, cross-sections 
of mouse ear skin were incubated with biotin anti-CD11c mAb (BD Biosciences PharMingen, 
San Diego, CA) and rabbit anti-mouse NK1R polyclonal Ab (Advance Targeting Systems, San 
Diego, CA) followed by Cy2 anti-rabbit IgG and Cy3-streptavidin.  For co-detection of CD11c 
and langerin in LNs, sections were incubated with biotin anti-CD11c and alexa fluor 488 anti-
langerin mAb (BD-PharMingen) followed by Cy3-streptavidin.  For detection of T cells in the 
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skin, cross-sections were incubated with alexa fluor 488 anti-CD4 mAb (Caltag, Burlingame, 
CA) and biotin anti-CD8α mAb (eBioscience, San Diego, CA) followed by Cy3-streptavidin.  
For detection of macrophages in skin, sections were incubated with biotin anti-F4/80 mAb 
(Caltag) followed by Cy3-streptavidin.  Nuclei were stained with 4’6-diamidino-2-phenylindole 
2HCl (DAPI; Molecular Probes, Eugene, OR).  To identify lymphatic vessels expressing the 
chemokine CCL21/SLC in LNs, sections of sDLNs were incubated with the lymphatic vessel 
specific anti-LYVE-1 mAb and with biotin anti-CCL21/SLC (R&D Systems, Minneapolis, MN) 
followed by Cy3 anti-goat IgG and Cy2-streptavidin (Jackson ImmunoResearch). 
Flow cytometric analysis of single cell suspensions 
LC-enriched epidermal cell suspensions were blocked with 10% normal donkey serum and 
incubated (30 min, 4°C) with PE anti-CD11c mAb in combination with goat anti-mouse NK1R 
polyclonal Ab, recognizing the N-terminus epitope of the human and mouse NK1R (Santa Cruz 
Biotechnology, Inc. Santa Cruz, CA) followed by FITC conjugated donkey anti-goat IgG, 
F(ab’)2 fragment (Jackson ImmunoResearch).  Negative controls included cells incubated with 
goat serum followed by FITC anti-goat IgG F(ab’)2 fragment.  LN cells were labeled with 
combinations of allophycocyanin anti-CD11c, PE anti-IAb, FITC anti-CD11b mAbs, and alexa 
fluor 488 anti-langerin (CD207) polyclonal Ab.  All Abs were purchased from BD-Biosciences 
PharMingen with the exception of langerin (e-Bioscience).  Appropriate fluorochome-conjugated 
species and isotype-matched irrelevant mAbs were used as negative controls.  After staining, 
cells were fixed with 2% paraformaldehyde and analyzed with a FACSCalibur flow cytometer 
(BD Biosciences Immunocytometry Systems, San Jose, CA).  
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ELISA and ELISPOT assays  
Analysis of OVA specific total IgG was performed by ELISA and the Th1 and Tc1 bias of OVA-
specific CD4+ and CD8+ T cells were assessed by ELISPOT assays.  For these experiments mice 
were GG immunized on the abdominal skin with pCMV-OVA-TR (1 priming + 2 boosting 
doses, 7 d apart) in the presence (or not, control) of the NK1R agonist.   
 For ELISA, 96 well EIA/RIA flat bottom plates (Costar, Corning, NY) were coated with 
100 μg/ml OVA in a 0.05M carbonate-bicarbonate buffer (Sigma) (overnight at 4°C).  Then, 
plates were washed in PBS supplemented with 0.05% Tween-20 (Sigma), blocked with 3% BSA 
(wt/vol) (2 h at RT) and 100 μl of serially-diluted serum samples or reference serum (diluted in 
10% FBS) were added to the wells and incubated overnight at 4°C.  The plates were then rinsed 
and incubated (1 h at RT) with 0.04 μg/ml of biotin goat anti-mouse IgG (Caltag) in 10% 
FBS/PBS.  Plates were washed and 100 μl of an Avidin-HRP (BD-Pharingen) solution diluted in 
10% FBS/PBS was added to the wells (30 min at RT).  After rinsing, the plates were developed 
with the TMB system (Sigma).  The reaction was stopped  with 0.5M H2SO4 and read at 450 nm 
on the Emax microplate reader (Molecular Devices).   
 For ELISPOT assays, splenic CD4+ and CD8+ T cells (positively selected by magnetic 
sorting, Miltenyi Biotec, Auburn, CA) from B6 mice non-immunized (control) or GG-
immunized with pCMV-OVA-TR (in the presence or absence of NK1R agonist) were used as 
responder cells.  As stimulators, we used bone marrow (BM)-derived DCs generated in vitro as 
previously described.244  Day 6 BMDCs were pulsed (2 h, 37ºC) with either (i) 100 ng/ml of the 
H-2Kb-restricted OVA257-264 peptide (SIINFEKL); (ii) 10 µg/ml of the IAb-restricted OVA323-339 
peptide (ISQAVHAAHAEINEAGR); or left untreated (control).  BMDCs were then γ-irradiated 
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and co-cultured with 2 x 105 CD4+ or CD8+ responder T cells, respectively (1:5 stimulator : 
responder cell ratio) in 96-well ELISPOT plates pre-coated with anti-IFN-γ or anti-IL-5 mAb 
(BD Biosciences).  ELISPOT plates were cultured for 36 h at 37ºC followed by incubation with 
biotin anti-IFN-γ or biotin anti-IL-5 mAb, streptavidin-peroxidase and the substrate 3-amino-9-
ethylcarbazole.  Spots were quantified with an ImmunoSpot™ automated counter (Cellular 
Technology Ltd., Cleveland, OH).    
In vivo killing assay   
B6 mice were GG immunized (abdominal skin) with pCMV-OVA-TR (1 priming + 1 or 2 
boosting doses, 7 d apart) in the presence (or not, control) of the NK1R agonist.  Non-immunized 
mice were used as controls.  Target B6 splenocytes were pulsed with SIINFEKL (0.25 µg/ml, 45 
min, 37ºC) and labeled with 5 µM CFSE (CFSEhigh).  Control (non-pulsed) B6 splenocytes were 
labeled with 0.5 µM CFSE (CFSElow).  Five days following the last boosting dose, target cells 
(CFSEhigh SIINFEKL-pulsed B6 splenocytes) and control cells (CFSElow non-pulsed B6 
splenocytes) were injected i.v. (2 × 107 cells in 300 μl PBS per mouse, 1:1 target : control cell 
ratio) into pre-immunized and control (untreated) mice.  Four h later, the relative percentage of 
splenic CFSEhigh and CFSElow cells was assessed by flow cytometry.  The percentage of specific 
cell lysis (%SCL) was then calculated by using the formula: %SCL= 100 × [1-(CFSElow : 
CFSEhigh of splenocytes from untreated mice) / (CFSElow : CFSEhigh of splenocytes from 
immunized mice)].43 
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DTH assay 
B6 mice were sensitized with the pCMV-OVA-TR delivered with the GG to the abdominal skin 
(1 priming + 2 boosting doses, 7 d apart).  Sensitization was performed in the presence (or not, 
control) of the NK1R agonist or the non-peptide NK1R antagonist L733060 (Tocris Bioscience), 
both used at 10 nmol/100μl PBS/ per dose and administered i.d. locally immediately before 
immunization.  Three d following the last immunization, mice were challenged with the pCMV-
OVA-TR delivered with the GG to the dorsal surface of the right ear.  Controls included mice 
sensitized with pCMV-Luc (irrelevant gene) and non-sensitized mice but GG transfected in the 
ear with pCMV-OVA-TR 24h before ear measurement.  The thickness of the right (challenged) 
and left ear pinna (control) was measured with a digital caliper (Mitutoyo Corp, Aurora, IL) at 
different time points.  The severity of the DTH response was assessed by the swelling of the 
challenged ear (right) compared with the thickness of the control ear (left) in sensitized animals 
and was expressed as percentage increase in ear thickness based on the formula: [(thickness of 
challenged ear - thickness of control ear) / thickness of control ear x 100].  In some experiments, 
mice were injected with the anti-CD154 blocking mAb MR1 (a single 250μg dose, BIO Express, 
West Lebanon, NH) administered i.p. at the time of immunizations. 
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Statistical analysis 
Results from multiple different groups were compared using a one-way analysis of variance 
(ANOVA) followed by Tukey’s multiple comparison post-hoc test.  Comparison of 2 groups was 
performed by a 2-tailed Student’s T-test.  A p value of < 0.05 was considered statistically 
significant.   
Results 
Immunization using the GG restricts expression of tg Ag to epidermis and sDLNs 
The individual contributions of LCs and DDCs to the outcome of cutaneous immunity remain 
controversial.  Recent studies indicate that DDCs and lymph node-resident CD8αα+ DCs  are the 
main APCs that trigger T cell immunity following skin Ag insult, whereas epidermal LCs play 
tolerogenic / anti-inflammatory roles.88,312-315,189,318-320  Therefore, we analyzed whether tg Ags 
encoded by plasmid DNA (pDNA) and GG-delivered to the skin (ear) of mice were expressed in 
the epidermis and/or in the dermis wherein LCs and DDCs reside, respectively.  The anatomical 
localization of the 1μm gold particles in the skin was investigated immediately after treatment 
with the GG.  This strategy allowed us to analyze the original distribution of the particles in the 
skin before mobilization of epidermal LCs containing gold particles, through the dermal 
lymphatic vessels. Histological analysis of cross-sections of skin demonstrated the presence of 
gold particles mainly in the epidermis, with very few beads at the epidermal-dermal junction 
however, no particles were found in the dermis (Fig. 1A). 
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 Next, we assessed the expression of the reporter protein EGFP in epidermis and dermis 
following delivery of pCMV-EGFP by the GG.  Twenty four h after transfection, the expression 
of EGFP was detected exclusively in the epidermis (Figs. 1B-D).  This result was further 
confirmed by quantification of the reporter protein Luc in the whole skin, as well as in separated 
epidermal and dermal layers of mouse skin transfected by the GG with the pCMV-Luc or with a 
control plasmid encoding no transgene (pBackbone).  High levels of Luc were detected in the 
cell lysates prepared from whole skin (Fig. 1E) as well as in those obtained from epidermal 
sheets (Fig. 1F).  However, the levels of Luc in the dermis remained low and were similar to 
those detected in dermis from control mice transfected with pBackbone (Fig. 1F).  
 Our laboratory and others have shown that treatment of the skin with the GG results in a 
rapid migration of cutaneous DCs to the sDLNs.303,305,321  As a consequence, reporter proteins 
encoded by pDNA delivered by the GG were detected in the sDLNs as soon as 24 h after 
cutaneous immunization.305  However, it is unknown for how long these tg proteins are being 
expressed in the skin and sDLNs, a relevant aspect for the purpose of genetic immunization.  
Thus, we delivered pCMV-Luc to abdominal skin of mice and we analyzed the levels of 
expression of tg Luc in skin and inguinal (local) sDLN cells up to 7d following cutaneous 
immunization by the GG.  The levels and length of expression of Luc observed in the skin (Fig. 
1G) correlated with the levels and length of Luc expression in the sDLNs (Fig.1H).  The highest 
expression of Luc in the sDLNs was observed 24 h after immunization and decreased but was 
still detectable up to 4 d (Fig. 1H).  Luc expression in cervical sDLNs situated distant from the 
area  of  gene  delivery  remained  low and  was  similar to background levels observed in sDLNs  
  
122
after transfection of the skin with pBackbone (negative control).  Together these results 
demonstrate that tg Ags delivered to the skin by the GG are expressed up to 3-4 d by cells of the 
epidermis and by migratory cells that traffic from the epidermis to sDLNs.  
 
LCs and DDCs constitutively express NK1R  
Our goal was to test whether the NK1R agonist SarSP enhances the ability of skin DCs to 
promote the differentiation of Th1 and Tc1 cells following vaccination by the GG, therefore, we 
analyzed the expression of NK1R in skin cells from untreated mice.  By double-
immunofluorescence microscopy of cross-sections of skin and using CD11c as a murine DC 
specific marker, we demonstrated that the NK1R was constitutively expressed by CD11c 
positive epidermal LCs and DDCs, as well as by CD11c negative cells including keratinocytes, 
and some cells located in the dermis (likely, mast cells) (Fig. 2A-F).  Expression of NK1R on the 
surface of CD11c positive LCs was further confirmed by flow cytometric analysis of epidermal 
cell suspensions enriched in LCs (Fig. 2G).  
Signaling via NK1R triggers skin acute inflammation and enhances transgene expression 
It is our hypothesis that signaling via the NK1R at the time of GG immunization triggers acute 
inflammation in the skin and therefore provides the appropriate “danger signal” to promote the 
activation and migration of epidermal LCs transporting tg Ags to the sDLNs.  Therefore, we 
assessed the damage caused to the skin by the NK1R agonist or by the GG in combination (or 
not, control) with the NK1R agonist administered by local i.d. injection immediately before 
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immunization.  The NK1R agonist alone induced a moderate acute inflammatory infiltrate 
composed mainly of polymorphonuclear granulocytes (PMNs) in the dermis of treated mice (Fig 
3B).  Whereas, fewer PMNs were observed infiltrating the epidermis and in the papillary dermis 
of mice treated with GG alone compared to untreated skin (Fig 3A and 3C).  By contrast, 
immunization with the GG combined with the NK1R agonist triggered a severe and extensive 
PMN infiltrate in the epidermis and dermis of mouse skin (Fig. 3D).  
 Next, we tested whether administration of the NK1R agonist affects the level of 
expression of tg Ag in skin and sDLNs induced by the GG.  To address this question, mice were 
transfected with pCMV-Luc in the skin (abdomen) with the GG in the presence (or not, control) 
of the NK1R agonist.  Injection of the NK1R agonist in combination with the GG increased 
significantly the expression of Luc in the skin compared to the skin of mice treated with the GG 
alone (Fig. 3E), as determined by luminometry in cell lysates obtained from identical sized 
whole skin samples.  Importantly, treatment with the GG and the NK1R agonist resulted in a 6-
fold increase of Luc expression in the sDLNs compared to the expression observed in sDLNs 
obtained from mice treated with the GG alone (Fig. 3F).  Luc expression in the sDLNs induced 
by the GG alone diminished significantly after local administration (i.d.) of the NK1R antagonist 
L733060.  This latter result indicates that the GG exerts, to some extent, an intrinsic NK1R 
agonistic activity, likely through local release of endogenous SP in the skin. 
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Signaling via NK1R favors homing of activated LCs and expression of tg proteins in sDLNs  
GG-transfection of the skin triggers activation and migration of LCs to sDLNs.303,305,306  In 
response to DC-activation signals, LCs translocate NF-κB into the nuclei, a phenomenon that 
triggers LC maturation and enhances the expression of those transgenes controlled by hIE-CMV 
promoter.243,244,322  Therefore, the augmented expression of tg proteins in the sDLNs that follows 
skin GG-transfection with the NK1R agonist may be ascribed to a higher number of activated 
LCs expressing transgenes and mobilized to the sDLNs.  Thus, we analyzed i) the mobilization 
of epidermal LCs to sDLNs; and ii) the expression of tg Luc in sDLNs dependent on NF-κB 
translocation by migrating LCs that follows skin GG immunization in the presence of the NK1R 
agonist.    
 First, we assessed whether the NK1R agonist decreases the number of LCs resident in the 
epidermis 24 h after i.d. injection in the presence or absence of GG transfections of the skin 
(Fig.4A-E).  The NK1R agonist alone induced a significant decrease in the number of LCs in 
epidermal sheets compared to control skin samples (p<0.001) (Fig 4A and 4B).  GG transfections 
alone triggered a highly significant reduction of the density of LCs (> 90%, from 1,350±90 to 
110±30 and LCs /mm2 of skin, p<0.0001) (Fig. 4C).  As expected, this pronounced mobilization 
of epidermal LCs could not be further augmented by GG plus NK1R agonist treatments (Fig. 4C-
E). 
 Nevertheless, the fact that 90% of LCs diminished from the epidermis following GG 
treatments does not necessarily imply that all these cells will home efficiently to the sDLNs.  
Indeed, it has been shown that after GG or i.d. administration of DC-based vaccines only a small 
percentage of cutaneous DCs reach the local sDLNs.321,323  The NK1R agonist is a pro-
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inflammatory neuropeptide that even when administered locally (i.d.), might elicit functional 
changes in the skin and sDLNs, which may enhance the “danger-induced” chemotaxis of skin 
LCs, a phenomenon that is highly relevant for the outcome of skin genetic immunizations.  We 
hypothesized that the intense inflammation induced in the skin following GG immunizations in 
the presence of NK1R agonist might augment the number of lymphatic endothelial cells 
expressing the chemokines known to attract LCs to the sDLNs.  Therefore, we analyzed the 
presence of lymphatic vessels (identified by the specific lymphatic endothelial cell marker 
LYVE) expressing the DC chemoattractant CCL21/SLC under our experimental conditions.  
Twenty four h following GG immunizations, we observed an expansion of sub-capsular LYVE-
1+ lymphatic vessels co-expressing CCL21/SLC compared to sDLNs isolated from naïve mice 
(Fig. 4F).  Importantly, administration of NK1R agonist together with the GG resulted in a 
significantly increased expansion of lymphatic vessels expressing CCL21/SLC throughout the 
whole parenchyma of the sDLNs (Fig. 4F).  These results highly suggest that the combination of 
GG and the NK1R agonist promotes a more efficient homing of skin LCs to sDLNs by 
increasing the number of lymphatic endothelial cells expressing CCL21/SLC.  
 To test this hypothesis we further addressed the homing of LCs to sDLNs under our 
experimental conditions.  First, we analyzed the inflammatory changes induced by the GG and 
the NK1R agonist in sDLNs.  As shown in Figure 5; 24 h after skin treatment with the GG or the 
NK1R agonist we observed sinus hyperplasia limited to the subcapsular and paracortical areas of 
sDLNs (Fig. 5B and 5C).  Following the combination of the GG with the NK1R agonist the sinus 
hyperplasia replaced a high percentage of the normal histological architecture observed in 
sDLNs of untreated mice (Fig. 5A and 5D).  These changes were characterized by infiltration of 
the subcapsular and paracortical areas of the sDLNs with cells having abundant pale cytoplasm, 
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some of them with indented peripheral nuclei and dendritic membrane processes (Fig. 5B and 
5C).  Importantly, after GG treatment alone or in combination with NK1R agonist several cells 
with DC morphology contained 1μm gold beads, a further indication that these cells were 
mobilized from the skin (Fig 5C and 5D, insets).  
 A phenotypic analysis performed in sections of sDLNs, 24 and 48 h after treatments, 
demonstrated that the GG or the NK1R agonist by themselves increased significantly the 
population of DCs co-expressing CD11c (red) and langerin [CD207, (green)] situated in the 
subcapsular and in the paracortical areas of sDLNs compared to the population of CD11c and 
langerin double-positive cells present in the sDLNs of untreated animals (Fig. 5 E-H).  A 
combination of GG and NK1R agonist further increased the number of CD11c and langerin 
double-positive cells in sDLNs compared to NK1R agonist or GG treatments administered alone 
(Fig. 5H).  Few CD11c+ DCs expressing langerin were detected in control inguinal LNs of non-
immunized mice or in mesenteric LNs (non-sDLNs) of mice immunized in the abdomen with 
GG plus the NK1R agonist (data not shown).  
 To further determine whether treatment with the NK1R agonist facilitates the homing of 
LCs and/ or DDCs to sDLNs, we quantified by flow cytometry the percentage of both migratory 
skin DC subsets, LCs [CD11c+CD11b+ MHC-II (IAb)high, langerin+] and DDCs (CD11c+ CD11b+ 
MHC-IIhigh langerin-) present in the sDLNs 24, 48, and 96 h following skin treatments.  Based on 
previous publications the following markers were used to identify LCs from DDCs and other DC 
populations homing to sDLNs:315,311  i) surface CD11c (a pan DC marker in mice); ii) surface 
CD11b (expressed by myeloid DCs and not by CD8αα+ DCs); iii) surface MHC-IIhigh (DC 
activation marker highly expressed by skin derived DCs), and iv) intracellular langerin [CD207 
(expressed by LCs and not by DDCs)].  Skin migratory LCs, expressing CD11c, CD11b, MHC-
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IIhigh and langerin, were the main skin DC subset that increased in the sDLNs after GG 
immunization in the presence of the NK1R agonist (Fig.5I).  Langerin negative skin migratory 
DDCs expressing CD11c, CD11b, and MHC-II high were increased following GG treatments 
alone but reduced following GG plus NK1R agonist treatments.  The high increase of LCs 
homing to sDLNs was observed 24 h after skin treatment and decreased gradually thereafter (48 
and 96 h follow up, data not shown).  Additionally, a population of langerin+ CD11b- DCs were 
detected in the sDLNs (Fig. 5I), which was not affected by any treatment group.  These cells 
likely represent the population of CD8αα+langerin+ LN resident DCs previously described as 
blood-derived langerin+ DCs.315  Together these results indicate that the GG in combination with 
i.d. injections of the NK1R agonist preferentially favors the LN-homing of activated LCs, which 
are the only skin DC-subset expressing tg Ag under our experimental conditions. 
 To further confirm that the enhanced expression of transgenes observed was dependent 
on the activation state of LN-homing LCs, which have translocated NF-κB into their nuclei, we 
GG- transfected the skin (abdomen) of mice with the plasmid pNFκB-Luc encoding Luc under 
control of a promoter containing upstream 4 tandem copies of the NF-κB consensus sequence.  
Mice were sacrificed 24 h later and Luc assays were performed on sDLN cells.  GG transfections 
of mouse skin i.d. injected with the NK1R agonist resulted in a 9-fold increase in NF-κB 
promoter activity in sDLNs, compared to Luc expression in sDLNs of control mice transfected 
with GG alone (Fig. 5J).  This latter result further confirms that the addition of NK1R agonist to 
GG immunizations enhances transgene expression in sDLNs by favoring the arrival of LCs from 
skin transfected sites.  These LCs were highly activated and consequently have translocated 
efficiently NF-κB into their cell nuclei.  
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Signaling via NK1R enhances OVA-specific IgG production and secretion of IFN-γ by T cells 
stimulated by cutaneous GG immunizations  
Our results indicate that genetic immunizations of the skin with the GG in combination with the 
NK1R agonist (i) targets epidermal LCs; (ii) increases the homing of epidermal LCs to the 
sDLNs; and (iii) enhances the capability of migrating LCs to express tg proteins driven by 
promoters with NF-κB responsive elements (i.e. CMVp).  An important function of an adaptive 
immune response is the production of Ag-specific Igs particularly relevant for the purpose of 
anti-viral vaccines.  Thus, we analyzed whether the NK1R agonist favors high levels of Ag 
specific IgG.  For this purpose mice were immunized with the GG on the abdominal skin (1 
priming + 2 boosting doses, 7d apart) with pCMV-OVA-TR in the presence (or not, control) of 
the NK1R agonist.  The titer of OVA-specific IgG was assessed in mouse serum 5 d following 
the last immunization dose.  GG immunizations alone increased the production of OVA-specific 
IgG (detected at a dilution of 1:1,000) (Fig. 6A and 6B), whereas the administration of the NK1R 
agonist during GG immunizations significantly increased the production of OVA-specific IgG 
(detected at a dilution of 1:16,000) (Fig. 6A and 6B).    
 To further analyze the adjuvant effects of the NK1R agonist we investigated its ability to 
promote development of Th1- and Tc1-biased immunity following GG immunizations.  Five d 
after the second boost, the frequency of purified splenic CD4+ and CD8+ T cells secreting IFN-γ 
or IL-5 in response to re-stimulation with syngeneic bone-marrow DCs pulsed with either IAb-
OVA323-339 or H-2Kb-OVA257-254 restricted peptides, was measured by ELISPOT assays.  The 
NK1R agonist significantly increased the number of IFN-γ-secreting CD4+ and CD8+ T cells 
when compared to T cells from mice immunized with GG alone (Fig. 6C and 6D).  Secretion of 
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IL-5 remained at background levels in all groups (Fig. 6C and 6D).  As controls, splenic CD4+ 
and CD8+ T cells from untreated mice or mice immunized with the irrelevant pCMV-Luc did not 
secrete detectable levels of IFN-γ or IL-5 in response to re-stimulation (data not shown).  
Additionally, we tested whether the NK1R agonist augmented the capability of skin GG 
immunizations to promote the development of CD8+ effector T cells with cytotoxic function by 
in vivo killing assays.  B6 mice were GG-immunized on the abdominal skin with pCMV-OVA-
TR as aforementioned, in the presence (or not, control) of the NK1R agonist.  Five d following 
the last immunization, target cells (CFSEhigh SIINFEKL-pulsed B6 splenocytes) and control cells 
(CFSElow non-pulsed B6 splenocytes) were adoptively transferred (i.v.) into immunized mice.  
Four h later the relative percentage of splenic CFSEhigh and CFSElow cells was assessed by flow 
cytometry.  The percentage of specific cell lysis (%SCL) was then calculated by using the 
formula: %SCL= 100 × [1-(CFSElow : CFSEhigh of splenocytes from untreated mice) / (CFSElow : 
CFSEhigh of splenocytes from immunized mice)]. 
 Induction of robust CTL responses by genetic immunizations delivered with the GG 
require an aggressive immunization scheme consisting of one priming dose followed by two or 
more boosting doses.306  Using such an immunization protocol, under our experimental 
conditions, the GG induced a robust CTL function in vivo (as high as 79% of Ag-specific cell 
killing), which was augmented by combining GG with the NK1R agonist (as high as 92% of 
specific cell killing) (not shown).  To further determine whether the NK1R agonist adjuvant 
activity favors robust CTL responses during a suboptimal GG immunization protocol we 
analyzed the Ag-specific CTL function induced in B6 mice immunized by one priming and one 
boosting   dose  in   the   presence   or   absence  of  NK1R   agonist.    Under   these   suboptimal  
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immunization conditions the NK1R agonist induced a significantly higher CTL response 
compared to GG immunizations alone (Fig. 6E) demonstrating that the NK1R agonist promotes 
both Th1 and CTL-Tc1 immune responses.        
 
Signaling via NK1R favors skin effector cellular immune responses 
The potential of the NK1R agonist to promote differentiation of effector T cells under our 
experimental conditions was investigated by DTH assays.  Mice were immunized on the 
abdomen with pCMV-OVA-TR delivered by GG immunizations in the presence (or not, control) 
of the NK1R agonist.  Three d after the last immunization, DTH responses were elicited by GG 
delivery of pCMV-OVA-TR to the ear pinna.  The effector cellular immune response was 
assessed by measuring the increase of ear thickness 24, 48, and 72 h following elicitation.  
Negative controls included mice immunized with pCMV-Luc (irrelevant gene) and animals not 
sensitized but elicited with pCMV-OVA-TR 24 h before measuring of ear thickness.  
Immunization with the GG in the presence of the NK1R agonist increased significantly the 
intensity of the DTH reaction compared to GG immunizations alone (Fig. 7A).  Interestingly, the 
DTH response elicited by the GG was almost completely abrogated by the NK1R antagonist 
L733060 administered i.d., indicating that in the absence of exogenous [Sar9Met(O2)11]-SP, 
immunization of the skin with the GG stimulates the release of low levels of endogenous NK1R 
agonists (likely SP) (Fig. 7A).  Likewise, blockade of CD40-CD40L interaction by the 
neutralizing Ab CD154 (MR1), injected i.p. before immunizations, abrogated completely the 
induction of DTH responses (not shown).  This result indicates the relevance of CD4+Th cells for 
the effector cellular immunity induced by our immunization approach.  
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 The characterization and severity of the cellular immune infiltrate of DTH responses 
were assessed in ear skin sections obtained 72 h after elicitation.  Histological analysis 
demonstrated a dramatic increase in the thickness of the epidermis and dermis in those animals 
immunized with GG in the presence of NK1R agonist compared to GG alone or control groups 
(Figs. 7B-E).  Increase of skin thickness correlated with the presence of severe cellular infiltrates 
composed of mononuclear cells localized mainly in the epidermis where the tg Ag was expressed 
(Fig. 7E).  Compared to control mice, GG alone induced significant mononuclear inflammatory 
infiltrate, which localized mainly in the dermis (Fig. 7B-D).  Phenotypic analysis by 
immunofluorescent microscopy demonstrated that the inflammatory infiltrate observed with GG 
in the presence or absence of the NK1R agonist was a Th1 mediated DTH response, composed 
mainly of CD4+ and CD8+ T cells and macrophages (Fig. 7F-K).  Importantly, quantification of 
the inflammatory infiltrate demonstrated a significantly higher number of CD8+ T cells and 
macrophages in the skin of mice treated with GG and NK1R agonist compared to GG alone (Fig. 
7L). 
Discussion 
Rational vaccine designs must induce long-lasting Th1- and Tc1-biased immunity, both critical 
for eradication of intracellular pathogens and tumor cells.  Skin genetic immunizations have been 
proven to elicit potent T cell immune responses characterized by high levels of transgene 
expression combined with rapid activation and mobilization of cutaneous DCs.  For genetic 
immunizations in vivo, delivery of pDNA is preferred over recombinant vectors, which provide 
the immune system with additional immune-dominant epitopes.244,323-325  Using the GG as a 
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method to deliver pDNA to the skin results in high efficient transfection of epidermal 
cells.303,305,306,326  Importantly, our laboratory and others have demonstrated that cutaneous 
immunizations with the GG are followed by CTL responses that depend on the activation and 
migration of directly transfected DCs as well as of DCs that have acquired tg proteins from 
neighboring cells.  Nevertheless, regardless of the ability of the GG to promote CTL 
differentiation, the critical development of a Th1-biased immune response necessary to support 
cellular immunity and CTL memory after GG immunization is, to some extent, 
lacking.307,309,310,327   
 In the present work, we have investigated two of the main reasons by which cutaneous 
immunizations with the GG fail to induce efficient cellular immunity: i) the possibility that the 
GG transfects mostly epidermal LCs that, unlike the DDCs, have been recently described as 
APCs with regulatory function;88,315,317,323 and ii) the lack of or insufficient Th1-biasing adjuvant 
effect.   
 Currently, the individual contributions of epidermal LCs and DDCs to the outcome of 
skin related immune responses are controversial.  Although, several studies have described LCs 
as potent APCs,328-333 recent observations propose a rather tolerogenic role for LCs.  Utilizing 
pathogenic infections or LC-depleted tg mice recent studies implicate LCs as having an immune 
suppressive role and they point toward DDCs and CD8αα+ blood-derived DCs as the main 
inducers of efficient antiviral, allogeneic, and hypersensitivity immune responses.88,315,318-320,323   
 Different from these observations, our results demonstrate that GG-immunization 
delivers pDNA to the epidermis and support the idea that epidermal LCs, instead of DDCs, are 
the main skin DCs transfected by the GG.  Epidermal LCs loaded with tg Ag migrated rapidly to 
the sDLNs, as shown by the presence of DCs containing gold particles and by the expression of 
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the intact tg proteins in the inguinal LNs of mice GG-immunized on the abdomen 24 h earlier.  
The possibility that the tg protein expression observed in sDLNs may have been caused by free 
naked DNA or secreted tg protein mobilizing from the skin via lymph is very unlikely.  The GG 
delivers pDNA either into the cytoplasm/nucleus of cells or in the extracellular compartment.  
pDNA delivered to the extracellular compartment is highly unstable and becomes degraded by 
tissue DNAses soon after being released.334,335  Under our experimental conditions the possibility 
that tg protein secreted by transfected keratinocytes could have reached the sDLNs has been 
excluded since tg Luc remains intracellular and cervical sDLNs distant from the skin transfected 
area did not express tg proteins.  
 Our results demonstrated that, following a rather aggressive protocol of GG 
immunizations, targeting exclusively the epidermis induced a robust CTL response accompanied 
by a weak Th1 biasing of CD4+ T cells, an indication that under our experimental conditions LCs 
are immunostimulatory rather than tolerogenic APCs.  Thus, the second question addressed was 
whether a potent pro-inflammatory Th1-biasing mediator administered during GG 
immunizations enhances the ability of LCs to generate/amplify Ag-specific CD4+ Th1 responder 
cells and the CTL function of CD8+ Tc1 cells.  We chose the pro-inflammatory neuropeptide 
NK1R agonist SarSP as a Th1-Tc1 biasing adjuvant based on the fact that signaling T cells via 
the NK1R favors Th1-biased responses and local injection of NK1R agonist prevents the 
tolerogenic effects exerted by irradiation of the skin with UV-B light.237  In addition, the NK1R 
agonist mimics the endogenous secretion of SP during the initial stages of acute inflammation of 
the skin.106,336  Likewise, our results demonstrated that the NK1R agonist increased the ability of 
the GG to trigger acute inflammation of the skin at the site of immunization and favored a more 
effective homing of activated epidermal LCs to sDLNs.  
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 Although the pro-inflammatory effects that follow cutaneous administration of the NK1R 
agonist can be attributed to the secretion of mediators by mast cells and keratinocytes as 
previously described,337,338 other reports201 have shown that murine DCs in secondary lymphoid 
organs and commercially available human DCs express NK1R.  Importantly, our data 
demonstrate for the first time, constitutive expression of the NK1R by murine LCs indicating 
that signaling LCs directly via the NK1R may affect their APC function and ability to express 
transgenes.  Accordingly, neuropeptides such as SP and CGRP, secreted by cutaneous δ fibers, 
exert important immune-modulation of LCs296 and previous reports237,339 have shown that the 
NK1R agonist down-regulates the migratory function of LCs.  However, our results clearly 
indicate that the NK1R agonist triggers a massive and rapid LC mobilization out of the 
epidermis.  These discrepancies can be ascribed to the use of different experimental models and 
time points analyzed.  Nevertheless, in our studies we should not overlook that besides epidermal 
LCs, keratinocytes and skin-resident leukocytes (i.e. mast cells, DDCs) might also be direct 
targets of the NK1R agonist.  In this scenario, the beneficial effects of the NK1R agonist on GG 
immunizations might be the result of the release of inflammatory mediators by by-stander cells 
combined to the direct signaling of LCs during the initiation of the acute skin inflammatory 
response.  
 The observation that local administration of the NK1R antagonist L733060 decreased the 
ability of the GG immunization to induce the expression of transgenes in skin and sDLNs and to 
promote a potent DTH response against the tg Ags indicates that the GG treatment by itself 
releases endogenous NK1R agonists, likely SP.  However, the levels of endogenous NK1R 
agonist released by GG immunizations alone were not sufficient to trigger the inflammatory 
changes observed in the skin and sDLNs after administration of the NK1R agonist alone or in 
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combination with the GG.  Accordingly, administration of exogenous NK1R agonist induced the 
highest expression of transgenes driven by transpromoters containing NF-κB responsive 
elements (i.e. CMV promoter) by migrating LCs.244,322  This phenomenon was due to a 
combination of the following factors: (i) a high level of activation of LCs, which have 
translocated NF-κB into their nuclei and (ii) an efficient homing of LCs to sDLNs.  The rapid 
homing of LCs to the sDLNs observed here, is in contrast to previous reports, describing a slow 
migration of LCs even 96 h after treatment of the skin with an irritant and the sensitizer 
tetramethylrhodamine-5-(and 6)-isothiocyanate.315  In this regard, we have previously shown that 
the treatment of the skin with the GG induces a rapid and massive mobilization of human 
epidermal LCs that begins as soon as 3 h following GG treatment.303  Accordingly, Porgador et 
al.305 have demonstrated homing of directly transfected DCs expressing tg reporter proteins in 
sDLNs 24 h following GG immunization of mouse skin.  Moreover, the present work shows that 
the pro-inflammatory effects of the NK1R agonist combined with the GG induced 
immunologically relevant changes in sDLNs as demonstrated by significant expansion of 
lymphatic vessels expressing CCL21/SLC and by extensive sinus hyperplasia.  Thus, we can 
conclude that the rapid mobilization of LCs from the epidermis to sDLNs observed in our study 
was caused by a combination of factors including the damage triggered by the GG in the skin 
and the pro-inflammatory effects exerted by the NK1R agonist in the skin and sDLNs.  In 
agreement with our data, a recent report340 has demonstrated a higher DC mobilization from the 
periphery into the sDLNs following inflammatory expansion of lymphatic vessels after skin 
treatments with keyhole limpet haemocyanin in the presence of CFA.   
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 The NK1R agonist neuropeptide [Sar9Met(O2)11]-SP meets the requirements for a Th1- 
Tc1-biasing adjuvant while also favoring the elicitation of Ab responses.  Our data demonstrates 
that GG immunizations induced the secretion of Ag-specific IgG as well as cellular immunity 
mediated by CD8+ and CD4+ T cells.  Importantly, these immunological responses were greatly 
increased by the presence of NK1R agonist as demonstrated by the significantly higher number 
of IFN-γ secreting Ag-specific CD4+ Th1 and CD8+ Tc1 cells.  Moreover, the NK1R agonist was 
able to trigger strong CTL function of CD8+ T cells in vivo following a suboptimal GG 
immunization protocol.  Importantly, the adjuvant effect of the NK1R agonist further tested by 
DTH assays demonstrated that local administration of the NK1R agonist during sensitization 
favored the generation of Th1 effector immunity, an effect confirmed by the intense cutaneous 
infiltrate of CD8+ T cells and macrophages during the elicitation phase.   
 To our knowledge this is the first study that has tested the ability of an NK1R agonist to 
enhance the generation of Ag-specific humoral and cellular Th1 and Tc1 immune responses 
elicited by GG immunizations of the skin.  The synergistic effect of the NK1R agonist on 
cutaneous GG immunization was mediated, at least in part, by inducing inflammatory changes in 
the skin and sDLNs.  The use of the synthetic NK1Ra such as  SarSP seems to represent a safe 
adjuvant to promote Th1-Tc1 mediated cell immunity  Our results strongly support the concept 
that under the appropriate pro-inflammatory environment, epidermal LCs are capable of eliciting 
potent T cell immune responses, which can be exploited for vaccine development.  
 
 
 
 Figure 1.  Immunization with the GG limits the expression of tg Ag to the epidermis and 
the sDLNs.  (A) Cross-section of skin (ear), obtained immediately after GG treatment, showing 
1μm gold particles located in the epidermis.  Inset: detail of gold particles (arrows) within the 
epidermis.  (B) Cross-sections of skin (ear) showing the expression of tg EGFP (green) by 
epidermal cells (arrows), 24 h after GG delivery of pCMV-EGFP.  Dotted line in B indicates the 
epidermal-dermal junction.  (C and D) Epidermal (C) and dermal (D) sheets obtained 24 h after 
GG delivery of pCMV-EGFP demonstrates the expression of EGFP (green) by epidermal cells.  
(E) Quantification of tg Luc in samples of skin (ear) GG-transfected with pCMV-Luc 24 h 
earlier.  The plasmid pBackbone (encoding no transgene) was used as control.  (F) Assessment 
of tg Luc in epidermal and dermal sheets dissected from skin (ear) 24 h after GG transfection 
with pCMV-Luc.  Means ±1 SD of RLU of triplicates are illustrated.  Data are representative of 
3 independent experiments.  (G and H) Kinetics of tg Luc expression by cells from the 
epidermis (abdomen, G) and sDLNs (H) following GG delivery of pCMV-Luc.  LNs analyzed 
included sDLNs from transfected area (inguinal, black), control sDLNs from non-transfected 
areas (cervical, gray), and control sDLNs from skin areas transfected with pBackbone (white).  
Means ±1 SD of RLU of triplicates are shown.  Data are representative of 5 independent 
experiments.  (A) H&E staining, (B-D) immunofluorescence. Magnification: 200X. Inset: 
1000X. 
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 Figure 2.  Skin DCs constitutively express the NK1R.  Panels (A-C) and (D-F) are cross-
sections of skin (ear) from two independent experiments showing the expression of the NK1R 
(green) by keratinocytes, epidermal LCs (arrowheads), and DDCs (arrows) (the latter two 
identified by their expression of CD11c in red).  In (C and F) the yellow fluorescence is due to 
the overlap of red (CD11c) and green (NK1R).  Cell nuclei were counterstained with DAPI 
(blue).  Immunofluorescence, magnification: 200X.  (G) The green histogram demonstrates the 
expression of NK1R by freshly-isolated LCs gated on CD11c expression.  The grey histogram 
corresponds to negative control cells.  The numbers in the histogram represents the percentage of 
NK1R positive LCs and the mean fluorescent intensity (between parenthesis).  Data are 
representative of 2 independent experiments. 
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 Figure 3.  GG immunizations with the NK1R agonist triggers skin acute inflammation and 
increases the expression of tg Ag.  (A-D) Cross-sections of skin (abdomen) obtained from mice 
untreated (A) and experimental animals 24 h after administration (i.d.) of the NK1R agonist (B), 
immunization with GG (C), or treatment with GG plus NK1R agonist (D).  The arrows indicate 
the localization of the acute cellular infiltrate composed mainly of PMN cells.  The insets detail 
the characteristics of the acute inflammatory infiltrate. H&E staining, magnification: 200X. 
Insets: 1000X.  (E and F) Expression of tg Luc in the skin (E) and sDLNs (F) 24 h following 
GG delivery of pCMV-Luc in the presence (or not, control) of the NK1R agonist or the NK1R 
antagonist.  Data are representative of 4 independent experiments.  (E and F) Results are 
expressed as mean RLU ± 1 SD of the fold-increase compared to background levels obtained 
from non-immunized control mice. N.D.: Non-detected.   
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 Figure 4.  Effects of skin genetic immunizations with the GG and the NK1R agonist on 
migration of epidermal LCs.  (A-D) Distribution of DEC-205+ LCs (in red) in epidermal sheets 
(ear) obtained from non-immunized control mice (A) and from animals treated (24 h prior) with 
the NK1R agonist (i.d.) (B), GG (pCMV-Luc) (C), or GG plus NK1R agonist (D).  The few LCs 
remaining in the epidermis after treatment became round-shaped (arrows), a feature indicative of 
LC migration.  Immunofluorescence, magnification: 200X.  (E) Quantification of the density of 
DEC-205+ LCs in epidermal sheets (ear) 24 h post-treatment.  Data represents the means ±1 SD 
from 3 independent experiments performed.  (F) Comparison of the expression of LYVE-1 (red) 
and the chemokine CCL21/SLC (green) in the sDLNs 24 h following the indicated treatments.  
Immunofluorescence, magnification:  100X.   
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 Figure 5.  The NK1R agonist enhances the abilities of the GG to promote sDLN 
inflammation and homing of activated LCs.  (A-D) Structure of sDLNs (inguinal) excised 
from non-treated control mice (A) and from animals treated (24 h prior) with: the NK1R agonist 
(i.d.) (B), GG (pCMV-Luc) (C), or GG plus NK1R agonist (D).  sDLNs from treated mice show 
sinus hyperplasia characterized by the presence of cells with abundant pale cytoplasm (some 
with morphological features of DCs indicated by arrows and detailed in the insets) located 
mainly within the subcortical and paracortical areas (dotted lines).  Additionally, 1 μm gold 
beads were detected in the cytoplasm of DCs 24h after GG treatments alone or in combination 
with the NK1R agonist (illustrated in insets of C and D, and indicated by asterisks).  H&E stain. 
Magnification: 400X. Insets:1000X.  (E-H) Identification of the population of LCs co-expressing 
langerin [CD207 (green)] and CD11c (red) (arrows) in the paracortical areas of sDLNs (inguinal) 
excised from non-immunized control mice (E) and from animals treated (24 h prior) with NK1R 
agonist (i.d.) (F), GG (pCMV-Luc) (G), or GG plus NK1R agonist (H). Insets show CD11c+ 
langerin+ LCs at higher magnification.  Immunofluorescence; magnification: 200X. 
Insets:1000X.  (I) Quantification by flow cytometry of CD11c+ CD11b+ MHC-II (IAb)high 
langerin+ epidermal LCs and CD11c+ CD11b+ MHC-II (IAb)high langerin- DDCs in the sDLNs 
(inguinal) of non-immunized control mice and animals treated (24 h prior) with NK1R agonist 
(i.d.), GG (pCMV-Luc), or GG plus NK1R agonist.  Data are representative of 2 independent 
experiments.  (J) Comparative analysis of tg Luc expression in sDLNs, 24 h after GG delivery of 
pNFκB-Luc or pCMV-Luc in the presence (or not, control) of the NK1R agonist.  Means± 1SD 
of the fold-increase of RLU compared to background levels are illustrated.  Three independent 
experiments were performed. 
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 Figure 6.  Skin GG immunizations in the presence of NK1R signaling enhances IFN-γ 
secretion by Ag-specific T cells.  (A and B) Detection by ELISA of total OVA-specific serum 
IgG.  (A) O.D.450 at a 1/2,000 serum dilution and (B) OVA-specific serum IgG titer at an O.D.450 
of 0.2.  (C and D)  Detection by ELISPOT assays of IFN-γ and IL-5 secreted by CD4+ (C) and 
CD8+ (D) T cells isolated from spleens of B6 mice left untreated (control) or GG immunized 
with pCMV-OVA-TR in the presence (or not, control) of NK1R agonist.  Results are expressed 
as the means of spot forming cells ±1 SD of triplicates.  Data are representative of 3 experiments.  
Insets are representative images of the IFN-γ ELISPOT wells.  (E) Ag-specific cytotoxic in vivo 
killing assays performed in B6 mice pre-immunized with GG on the abdominal skin with 
pCMV-OVA-TR and one boosting in the presence (or not, control) of the NK1R agonist.  Means 
± 1 SD of the specific cell lysis determined by the percentage of splenic cells, CFSEhi and 
CFSElo, analyzed by flow cytometry.  * indicates a p < 0.05 compared to GG immunizations 
alone. 
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 Figure 7.  Administration of the NK1R agonist increases the ability of the GG to promote T 
cell responses.  (A) Illustrates the ear thickness of mice immunized with the GG in the presence 
or not of the NK1R agonist and analyzed following the elicitation of DTH assays.  Data are 
representative of 3 independent experiments.  * indicates a p < 0.05 compared to the non-
sensitized animals (Naïve).  ** indicates p < 0.05 compared to GG immunizations alone at each 
time point.  (B-E) Analysis of the cellular infiltrate in the skin (right ear) from non-sensitized 
control mice (B), control animals sensitized with the irrelevant pBackbone (C), and mice 
sensitized with the pCMV-OVA-TR alone (D) or GG in the presence of the NK1R agonist (E).  
The skin was analyzed 72 h after sensitization.  The mononuclear cell infiltrate is detailed in the 
insets.  Epidermis is indicated by arrows and dermis by arrowheads.  Red arrows indicate the 
thickening of the skin (excluding the hypodermis).  H&E staining, magnification: 200X. Insets, 
1000X.  (F-K) Cellular infiltrate composed of CD4+ and CD8+ T cells (F-I) and F4/80+ 
macrophages (J-K) in the presence (G, I, K) or absence (F, H, and J) of NK1R agonist.  
Immunofluorescence, magnifications: F, G, J, and K: 200X; H and I: 400X.  (L). Quantification 
of the cellular infiltrate in tissue sections by microscopy is expressed as means ±1 SD of cell 
numbers from at least 20 high power fields (HPF, magnification: 400X).   
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